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Introduction 
 
Paracetamol (APAP), in the USA known as acetaminophen, is widely used 
both in hospital settings and at home for antipyresis and mild 
(postoperative) pain. Although APAP is available over the counter and is 
ranked on the third place, following nystatin and cisapride, when looking at 
the most commonly prescribed drugs in our Pediatric Surgical Intensive 
Care Unit (PSICU),1 it is surprising that there are still little data available 
concerning the pharmacokinetics (i.e. absorption, distribution, metabolism 
and elimination) and pharmacodynamics (i.e. effects) of APAP in children. 
Off label prescription of APAP is common, since prescription is often 
outside the terms of the product license with regards to the age of the 
patient, the indication and the dose and frequency of administration. 
Product license does not account for children < 3 months of age and 
prolonged use in children < 4 years of age for more than 2 days is advised 
against,2 since studies investigating the effects of prolonged use in children 
are lacking. 
Although APAP is considered as a safe drug, when administered within the 
therapeutic dosing range, concern exists about the maximum daily doses 
and the prolonged use of APAP, as overdoses of APAP (> 150 mg/kg in 
children2) might be associated with severe toxic effects, i.e. liver necrosis, 
which might lead to death if not treated adequately or in time with 
acetylcysteine. 
 
 
Pharmacokinetics 
 
Studies have been performed evaluating the pharmacokinetics of APAP 
after oral and rectal administration in children of different ages. These 
studies showed that rectal administration of APAP is associated with a 
delayed and erratic absorption as compared to absorption after oral 
ingestion.3 Furthermore, higher peak plasma concentrations are obtained 
following oral APAP administration as compared to rectal APAP 
administration.4-6 Consequent to this observation, rectal APAP loading 
doses should be high, approximately 40 mg/kg.7 A bioavailability of 80% is 
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reported comparing suppositories to tablets,4 while Anderson et al report a 
relative bioavailabilty of 54%.8  
An alternative route of APAP administration is intravenous administration 
of propacetamol. However data considering APAP pharmacokinetics in 
neonates following intravenous administration of propacetamol are lacking.  
 
Anderson et al report a mean maximum concentration (Cmax) of 17.4 (SD 
7.4) mg/l in children (12 months-17 yrs) after major orthopedic surgery, 
receiving 40 mg/kg APAP rectally.9 Peak plasma concentration (Cmax) 
occurred at 2.3 (SD 1.2) hours (Tmax), while mean plasma concentration 
was 10.6 (SD 4.5) mg/l at six hours.9 In neonates and infants, a total body 
clearance of APAP and a volume of distribution at birth of respectively 
62% and 174% compared to older children have been reported.10 A target 
concentration > 10 mg/l in approximately 50%of the subjects can be 
achieved by a dose of 45 mg/kg/day at birth, up to a dose of 90 mg/kg/day 
in 5-year-old children.10 However a reduced dose of 75 mg/kg/day in an 8-
year-old child is sufficient, as clearance is a nonlinear function of weight.10  
 
Piletta et al reported that APAP-induced analgesia might be centrally 
mediated,11 in which the time-course of APAP in cerebrospinal fluid (CSF) 
may parallel that of analgesic effect.12 The CSF equilibration half time 
suggests that CSF kinetics approximate more closely to the effect 
compartment than plasma.13 Since the effect site concentrations equilibrate 
slowly with plasma, APAP should be given 1-2 h before anticipated pain or 
fever in children.13 
 
 
Pharmacodynamics 
 
Several studies investigated the effect of APAP following oral or rectal 
administration. Plasma concentrations of APAP associated with analgesic 
effects in children are unknown, but antipyretic effects are seen in the range 
of 10.0-19.7mg/l.8 APAP suppositories 40 mg/kg given peroperatively 
achieve effective therapeutic antipyretic plasma concentrations within 1-2 
h.9 An equilibration half-time of an effect compartment of 1.6 hours is 
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reported.9  
Cullen et al compared plasma concentrations and the effect on temperature 
and reported a significant correlation between peak plasma concentrations 
and maximum drop in temperature.14 Hopkins et al showed that there was 
no difference in antipyretic effect between oral and rectal administration.6 
 
The analgesic effect of APAP following (adeno)tonsillectomy has been 
evaluated in a limited number of studies. Anderson et al reported an effect 
compartment concentration of 10 mg/l to achieve analgesia,9 whereas 
Gaudreault et al concluded that the rectal administration of APAP at the 
induction of anesthesia results in incomplete and delayed absorption and 
does not prevent the occurrence of immediate postoperative pain in children 
undergoing adeno-tonsillectomy.15 Diclofenac is suggested as an alternative 
for postoperative analgesia following (adeno)tonsillectomy.16 Rømsing et al 
compared oral diclofenac (1-2 mg/kg) to oral APAP (22.5 mg/kg) the day 
after (adeno)tonsillectomy and reported no difference in analgesic effect 
and no significant reduction in pain scores following diclofenac or APAP 
ingestion.17  
The use of APAP in addition to continuous morphine infusion (CMI) has 
increased in recent years despite the fact that the safety and additional value 
of this combined treatment has never been studied in newborns and young 
infants. In adults, combinations of opioids with APAP or non-steroidal anti-
inflammatory drugs (NSAIDs) have resulted in a reduced morphine and 
fentanyl consumption as well as in reduced postoperative pain, without 
increased adverse effects.18-23 Morton et al demonstrated reduced morphine 
requirements in postoperative children 3 to 15 years of age given diclofenac 
1 mg/kg 8 hourly, but no effect attributable to APAP 15 mg/kg 6 hourly 
was shown.24  
 
 
Metabolism and pharmacogenetics 
 
Considering APAP metabolism, there are four pathways through which 
APAP is metabolized: glucuronidation, sulphation, oxidation and  
Introduction 
 
 
5
 
Figure 1 APAP metabolism 
 
hydroxylation, in which APAP is metabolized into respectively APAP-
glucuronide, APAP-sulphate, N-acetyl-p-benzoquinone- imine (NAPQI ) 
and 3’-hydroxy-APAP (Figure 1).25,26  
In adults APAP is mainly metabolized through glucuronidation, whereas in 
children sulphation is the major pathway.27 This is represented in mean 
(SE) glucuronidation to sulphation ratios increasing from 0.12 (0.09) in 
preterm neonates 28-32 weeks gestational age,28 to 0.28 (0.35) in preterm 
neonates 32-36 weeks gestational age,28 0.34 (0.08) in newborns,27 0.75 
(0.10) in 3-9 year old children,27, 29 and 1.61 (0.21) in 12 year old children,27 
with an adult ratio of 1.80 (0.32) (Figure 2).27 Data considering APAP-
glucuronide to APAP-sulphate ratio in infants are lacking. The oxidation 
pathway is minor in the therapeutic dosing range, but becomes more 
important when plasma concentrations are reaching toxic levels. 
Subsequently more NAPQI is formed at toxic plasma concentrations when 
both the glucuronidation and sulphation pathway are rate limiting, leading 
to liver necrosis if the amount of gluthation available is not sufficient to 
conjugate all NAPQI.25 The enzymes involved in the formation of NAPQI 
are CYP2E1, CYP3A4, CYP1A2 and possibly CYP3A5.25, 30, 31 Genotype 
of these enzymes may alter the expression and/ or the activity of these 
enzymes and may result in an increased or decreased formation of NAPQI 
and thus an increased or decreased propensity to APAP toxicity effects. 
APAP metabolism through hydroxylation into 3’-hydroxy-APAP is 
negligible.25 
APAP 
APAP - 
glucuronide  
APAP - sulphate  3’-hydroxy-APAP NAPQI 
Binding with hepato-cellular 
proteins 
  
Liver cell necrosis 
  
Conjugation by gluthation  
Mercapturine and cysteine metaboli tes  
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Figure 2 *    van Lingen, 1999 
**  Miller, 1976 
 
Toxicity 
 
According to international guidelines APAP can be used safely in doses up 
to 90 mg/kg/day, whereas in the Netherlands a maximum daily dose of 60 
mg/kg is recommended.2,32,33 Doses > 150 mg/kg/day might be associated 
with toxicity, resulting in liver necrosis.2,34-36 However children experience 
less toxicity after high APAP doses compared to adults.35,37,38 APAP plasma 
concentrations > 200 mg/l at 4 hours after ingestion and > 50 mg/l at 12 
hours after ingestion are associated with toxic effects.34,35 In case of the 
occurrence of toxic effects, SGOT becomes elevated and irreversible liver 
damage may be the consequence.34-36 Recently data have been published 
that not only ingestion of toxic APAP doses may impair liver function, but 
also the chronic use of high APAP doses within the therapeutic ranging 
dose may impair liver function.39 
 
Scope of this thesis 
 
Although APAP is available over the counter and has potential toxic 
effects, data concerning the pharmacokinetics and pharmacodynamics of 
APAP in children are limited. To gain a better insight into the 
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pharmacokinetics, the pharmacodynamics and the pharmacogenetics of 
APAP in children, we conducted several studies.  
 
 
Pharmacokinetic studies 
 
A report of age-related changes in the plasma to CSF equilibration half-time 
(Teq) of APAP in neonates to adolescents, undergoing (semi) elective 
surgery for placement or revision of a ventriculo-peritoneal shunt or 
insertion of a temporary external ventricular drain (chapter 2.1). 
A description of the clearances of APAP to glucuronide and sulphate 
metabolites as well as the urinary clearance of unmetabolized APAP in 
infants undergoing major craniofacial surgery, using non-linear mixed 
effects models (chapter 2.2). 
A description of pharmacokinetics and pharmacodynamics after 
administration of a single dose of propacetamol in preterm and term infants 
on the first day of life, undergoing minor, painful procedures or as 
additional treatment in infants on opioids (chapter 2.3). 
A description of diclofenac, 4’-hydroxy-diclofenac (D4OH) and 5’-
hydroxy-diclofenac (D5OH) pharmacokinetics after rectal administration in 
children 2-8 years of age, undergoing (adeno)tonsillectomy (chapter 2.4). 
 
 
Pharmacodynamic studies 
 
A comparison of APAP plasma concentrations and effects between children 
receiving either multiple doses of APAP rectally or equal doses of oral 
APAP after an initial rectal loading dose in infants following elective major 
craniofacial surgery. Furthermore the dose-plasma concentration and the 
plasma concentration-effect relation of both orally and rectally administered 
APAP are evaluated (chapter 3.1). 
A comparison of total postoperative morphine consumption in neonates and 
infants receiving either placebo or APAP in addition to continuous 
morphine infusion, following major abdominal or thoracic surgery  
(chapter 3.2). 
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A comparison of the analgesic effect of rectally administered APAP and 
diclofenac in children 3-8 years of age undergoing (adeno)tonsillectomy 
during ambulatory surgery and assessment of the relation between APAP, 
diclofenac and D4OH plasma concentrations and postoperative pain scores. 
Furthermore the safety of diclofenac by monitoring postoperative bleeding 
is assessed (chapter 3.3). 
 
 
Pharmacogenetic studies 
 
A description of a pilot study evaluating the relation between APAP 
clearance and CYP2E1, CYP3A4 and CYP3A5 genotype in neonates, 
infants and children (chapter 4.1).  
A description of a pilot study evaluating the relation between diclofenac 
clearance and CYP2C9, CYP3A4 and CYP3A5 genotype, between D4OH 
formation clearance and CYP2C9 genotype and between D5OH formation 
clearance and CYP3A4 and CYP3A5 genotype in children 3-8 years of age 
(chapter 4.2).  
 
 
General discussion 
 
The results of the studies described in this thesis and directions for future 
research are discussed (chapter 5). 
 
 
Future directions 
 
Assessment of the value of EEG and SSR registration for postoperative pain 
assessment in neonates and infants during the first 48 hours after major 
abdominal or thoracic surgery (chapter 6).  
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Paracetamol in cerebrospinal fluid in children 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Caroline D van der Marel, Brian J Anderson, Marien AL  Pluim , TH Rob 
de Jong, Antonia Gonzalez, Dick Tibboel. 
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Abstract 
 
Background  
There are few studies describing paracetamol (APAP) cerebrospinal fluid 
(CSF) concentrations in children. This current study was undertaken in 
children from neonates to adolescents in order to investigate age-related 
changes in the plasma to CSF equilibration half-time (Teq) of APAP. 
 
Methods  
Children (n = 41) 1 week-18 years of age undergoing (semi) elective 
surgery for placement or revision of a ventriculo-peritoneal shunt or 
insertion of a temporary external ventricular drain, received a loading dose 
of 30-40 mg/kg APAP 1 hour before scheduled surgery. Blood and CSF 
samples for APAP concentration analysis were collected during surgery. In 
those children with a temporary external drain blood and CSF sampling 
were extended into the postoperative period. APAP and CSF 
pharmacokinetics were estimated using non-linear mixed effects models. 
Size was standardized to a 70 kg person using allometric “¼ power 
models”. 
 
Results  
Median (25-75th percentile) age and weight of the patients included in this 
study were 12 (3-78) months and 9.8 (5.7-20.5) kg. Median (25-75th 
percentile) time between APAP loading dose administration and collection 
of blood samples and median time (25-75th percentile) between APAP 
loading dose and collection of CSF were respectively 125 (95-210) and 133 
(33-202) minutes. The population mean Teq, standardized to a 70 kg 
person, was 1.93 (CV 43%) h, an estimate similar to that described in adults 
(2.1 h). There was no relationship between age and Teq other than that 
predicted by size. APAP plasma concentrations ranged from 0.0-33.0 mg/l, 
APAP CSF concentrations ranged from 0.0-21.0 mg/l. 
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Conclusion 
Size rather than blood-brain-barrier maturation determines Teq changes 
with age in children. We predict a neonate (3.5 kg), 1 year old child (10 kg), 
5 year old child (20 kg), 10 year old child (30 kg) and an adult (70 kg) to 
have a Teq of 0.9, 1, 1.4, 1.6 and 1.93 h respectively. 
 
 
Introduction 
 
The mechanism of action of paracetamol (APAP) analgesia is multi 
factorial. It is known to be a potent inhibitor of prostaglandin synthesis 
within the central nervous system but also acts peripherally by blocking 
impulse generation within the bradykinin-sensitive chemo receptors 
responsible for the generation of nociceptive impulses. APAP is also 
thought to have an analgesic effect by antagonizing N-methyl-D-aspartate 
(NMDA) and substance P in the spinal cord.1,2 Analgesic effect involves an 
inhibitory action on spinal nitric oxide (NO) mechanisms.3 APAP’s 
antipyretic effect is mediated through inhibition of prostaglandin E2 in the 
brain.4 These temporal disequilibriums have been modeled using delayed 
effects with an effect compartment. The equilibration half-time between 
plasma and effect compartment is reported as 53 min (CV 217%) for 
analgesia and 71 min (CV 10%) for anti-pyresis in children [mean (SD): 9.0 
(3.0)].5,6 
 
Reduction of CSF prostaglandin concentrations in animals after APAP 
administration might be responsible for APAP’s analgesic effect.7,8 
Consequently the amount of APAP reaching the central nervous system 
(CNS) and causing inhibition of prostaglandin synthesis may mirror its 
analgesic effect. APAP CSF concentrations are dependent of APAP plasma 
concentrations and the permeability of the blood-brain barrier (BBB) to this 
molecule. Debate exists concerning BBB permeability changes with age.9 
There are few APAP CSF pharmacokinetic studies in adult humans10,11 and 
only one study in children earlier reported by Anderson et al.12 However 
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seven of the nine children studied by Anderson et al,12 suffered of traumatic 
brain injury that may have influenced BBB permeability. 
 
This current study was undertaken in children from neonates to adolescents 
in order to investigate age-related changes. The results were compared to 
the results of the study performed by Anderson et al,12 in order to examine 
the influence of traumatic brain injury and its possible disruption of the 
BBB on the plasma-CSF Teq. 
 
 
Methods 
 
Patients and methods 
After approval of the Medical Ethical Committee of the Erasmus MC 
Rotterdam, informed consent was obtained from the parents of children 
participating in this study. Children aged between 0 to 18 years undergoing 
placement or revision of a ventriculo-peritoneal (VP) shunt or insertion of a 
temporary external ventricular drain were considered for enrolment. 
Exclusion criteria were pre-existent liver- or kidney disorders, known 
allergy to APAP and traumatic brain injury. 
 
All children (n = 41) were given a rectal loading dose of 30-40 mg/kg 
APAP 1 hour before scheduled surgery. Anesthesia was induced using 
thiopentone, propofol, etomidate or sevoflurane. Before tracheal intubation 
children received 2-5 µg/kg fentanyl. Tracheal intubation was facilitated 
with vecuronium or suxamethonium. Breathing was controlled and 
anesthesia was maintained using O2/N2O or O2/air and isoflurane 0.5-1%. 
Before incision children were given a further 2-5 µg/kg fentanyl. Extra 
doses of 2 µg/kg fentanyl were administered if heart rate and/ or mean 
arterial blood pressure were higher than 10% above baseline values 
measured 10 minutes after tracheal intubation. A blood sample for APAP 
plasma concentration analysis was collected directly after induction. A CSF 
sample for APAP CSF concentration analysis was collected during shunt 
insertion or revision.  
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Postoperatively patients received APAP suppositories according to hospital 
standard dosing schedules. CSF sampling was extended to the postoperative 
period in patients undergoing insertion of a temporary external ventricular 
drain (n = 5). The sampling schedule in these patients was adjusted to the 
clinical circumstances of the individual patients and based on pain scores 
validated for this population.13 
APAP suppositories contained 60 mg, 120 mg, 240 mg, 500 mg or 1000 mg 
APAP in a triglyceride base (Pharmachemie, Haarlem, The Netherlands). 
Loading dose (30-40 mg/kg) was dependent on available suppository size. 
 
CSF sampling 
In patients with VP shunts it was only possible to collect a single CSF and 
blood sample, taken during surgery. Further CSF sampling was possible in 
5 patients with external ventricular drains. These patients were given 45.5-
108.0 mg/kg/24h APAP rectally in divided doses, including the pre-
operatively administered rectal loading dose. Plasma and CSF sampling 
was intermittent and varied from 0.5 hourly for 4 h to 2-5 hourly for 68 
hours. 
 
Paracetamol assay 
Plasma and CSF samples were stored at 4 °C until analysis. APAP plasma 
and CSF concentrations were determined using fluorescence polarization 
immunoassay (ADX systems, Abbott Laboratories, North Chicago, IL) 
(Erasmus MC Rotterdam). The APAP plasma determination limit was 1.0 
mg/l, which was defined as the lowest measurable concentration which can 
be distinguished from zero with 95% confidence. Precision was measured at 
APAP plasma concentrations of 15, 35 and 150 mg/l; 55 samples of each 
concentration were assayed to determine coefficients of variation at these 
concentrations (CV = SD/mean; RSD = CV*100%). RSD was at these 
concentrations were 7.22%, 3.37% and 3.11% respectively. The APAP 
plasma concentration range in which accuracy was measured was 10-150 
mg/l. 
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Modeling 
 
Population parameter estimates were obtained using a non-linear mixed 
effects model (NONMEM).14 This model accounts for population parameter 
variability (between and within subjects) and residual variability (random 
effects) as well as parameter differences predicted by covariates (fixed 
effects). The population parameter variability in model parameters was 
modeled by a proportional variance model. Additive terms characterized the 
residual unknown variability for plasma and CSF concentrations. This error 
model assumes that the residual variability is of the same order of 
magnitude over the whole range of measurements. The population mean 
parameters, between subject variance and residual variance were estimated 
using NONMEM version V release 1.1. Estimation used the first order 
conditional estimate method with the interaction option and ADVAN 6 with 
Tol = 5. Convergence criterion was 3 significant digits. A FORTRAN F77 
compiler (Watcom version 10.6) was used with an Intel Celeron 333 MHz 
CPU under MS Windows 98.  
A first order input, first order elimination, two compartment link model was 
used to describe the time course of plasma and CSF drug concentrations. 
The model is shown schematically in Figure 1.  
 
The relevant differential equations were: 
 
 dAgut/dt = -Ka x Agut 
 dC/dt = (Agut x Ka - C x CL) / V 
 dCcsf/dt = ln(2)/Teq x (C x PC - Ccsf) 
 
Agut is the amount of drug in the gut at any one time. This amount is 
assumed equal to the dose at time zero. Ka is the absorption rate constant 
(h-1); V is the central compartment volume (l); C is the plasma 
concentration (mg/l); CL is the clearance from the central compartment 
(l/h); Ccsf is the cerebrospinal fluid concentration (mg/l);  
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Figure 1  Diagram of CSF Pharmacokinetic Model. Ka, absorption rate constant 
(h-1); V/F, central compartment volume (l); C, plasma concentration 
(mg/l); CL/F clearance from central compartment (l/h); Ccsf, 
cerebrospinal fluid concentration (mg/l); PC, csf/plasma partition 
coefficient; Keq, equilibration rate constant (/h).  The Keq can be 
expressed as Ln2/Teq  
 
APAP is not bound to plasma proteins. Concentrations were measured in 
serum (containing protein that contributes to total volume) and CSF 
(without protein). Consequently a partition coefficient was required to 
model the data. The partition coefficient estimate is similar to the alcohol 
partition coefficient between csf and serum measured in rats15 and would be 
predicted for drugs that distribute in plasma water but which do not bind to 
plasma proteins16 because plasma water occupies 90% of plasma by 
volume. PC is the CSF/ plasma partition coefficient and accounts for 
protein concentration differences between plasma and CSF;  
Teq is the equilibration half time (h) between plasma and CSF. 
 
APAP was administered as an extra vascular dose and both clearance and 
distribution volume is confounded by bioavailability. Frectal/oral is used to 
refer to the relative bioavailability of the suppository compared to the oral 
formulation.  
 
 
 Dose
Ka
PC * Keq Keq
CL/F
  V/F
  C
Ccsf
Agutgut
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Children with traumatic brain injury 
Plasma and CSF time-concentration data from 9 children with external 
ventricular shunts, originating from the study published by Anderson et al,12 
were included in the analysis of the data from this study in order to examine 
the influence of traumatic brain injury and its possible disruption of the 
BBB on the plasma-CSF Teq. Seven of these 9 children suffered traumatic 
brain injury. All 9 children were ventilator dependent and required external 
ventricular drains for the management of raised intracranial pressure. These 
children were given APAP elixir (40 mg/kg, 250 mg/5ml, SmithKline 
Beecham (NZ) Ltd, Auckland, NZ), instilled down a nasogastric feeding 
tube and both arterial blood and cerebrospinal fluid sampled at hourly 
intervals for the first four hours and then two hourly for the subsequent six 
hours. 
A separate additive term was used to characterize the residual unknown 
variability for plasma and CSF concentrations from each study. 
 
Quality of fit 
The quality of fit of the pharmacokinetic model to the data was assessed by 
visual examination of plots of observed versus predicted concentrations. 
Models were nested and an improvement in the objective function was 
referred to the Chi-squared distribution to assess significance e.g. an 
objective function change (∆OBJ) of 3.84 is significant at α = 0.05.  
 
Covariate Analysis 
The parameter values were standardized for a body weight of 70-kg using 
an allometric model,17 
 
 Pi = Pstd x (Wi / Wstd) PWR 
 
where Pi is the parameter in the ith individual, Wi is the weight in the ith 
individual and Pstd is the parameter in an individual with a weight Wstd of 70 
kg. The PWR exponent was 0.75 for clearance, 1 for distribution volumes 
and 0.25 for time related indices.18-21  
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Interpreting sparse pharmacokinetic data 
It was not possible to collect data to obtain time-concentration profiles on 
current study patients - often only a single plasma APAP sample was 
collected from each patient. Consequently a larger data set from a previous 
study reported by Anderson et al investigating age-related APAP 
pharmacokinetics (n = 221)22 was included to perform the population 
analysis.  
 
 
Results 
 
Population demographics 
Forty-one children participated in this current study, 21 boys and 20 girls. 
The eligible number of patients was 47. Six children were excluded because 
informed consent was not obtained due to either language difficulties  
(n = 1) or to parental belief that there was no advantage gained for their 
child to participate in this study (n = 5). Median age (25-75th percentile) 
and weight of the children participating were 14 (3-74) months and 10.0 
(5.7-20.4) kg. Median (25-75th percentile) APAP loading dose was 32.3 
(25.3-42.5) mg/kg. Median (25-75th percentile) time between APAP 
loading dose administration and collection of blood samples and median 
time (25-75th percentile) between APAP loading dose and collection of 
CSF samples were respectively 125 (95-210) and 133 (33-202) minutes. 
Twenty-three children underwent VP shunt insertion, 13 children had a VP 
shunt revision and 5 children underwent insertion of a temporary external 
ventricular drain.  
 
There were 114 observations. APAP plasma concentrations ranged from 
0.0-33.0 mg/l, APAP CSF concentrations ranged from 0.0-21.0 mg/l.  
 
Parameter estimates 
Parameter estimates with covariate analyses are shown in Table 1a & 1b. 
Pharmacokinetic estimates and maturational half-lives of V/Foral and 
CL/Foral were similar to those reported previously.23 The population mean 
Teq, standardized to a 70 kg person, was 1.35 (CV 108%) h. Figure 2 
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shows individual Bayesian Teq predictions and their relationship to age for 
the complete pooled data set. These predictions are based on maximum a 
posteriori Bayesian estimates of the parameters for each specific individual 
using their observed data. No relationship between age and Teq was 
determined. The mean Teq from the earlier data from Anderson et al,12 was 
lower (Teq 0.71 h, CV 105%) than that from the current study population 
(Teq 1.93 h, CV 43%). Two children from the earlier study by Anderson et 
al,12 had a Teq greater than 2.5 h (Figure 2). These two children both had 
posterior fossa pathology, as opposed to the remaining children whom 
suffered traumatic brain injury. 
 
The type of surgery (VP shunt vs. external ventricular drain) had no effect 
on individual Bayesian Teq predictions. The covariance of the 
pharmacokinetic parameters, expressed as the correlation of population 
parameter variability was low (Table 2).   
 
 
Table 1a  Standardized Population Pharmacokinetic Parameter Estimates  
 
Parameter Estimate  %CV 
Vstd  l/ 70kg 75.7 26 
CLstd  l/h/70kg 14.2 49 
Felixir 1 fixed  - 
Tabs elixir h  0.426 151 
Tlag elixir h 0.21 68 
Frectal/oral suppository 0.838  
Tabs  suppository h 1.42 65 
Tlag  triglyceride base h 0.075 68 
Teq  h 1.35 108 
PC 1.11  
 
CLstd = population estimate for CL/Foral (clearance after oral administration l/h/70kg), 
Vstd = population estimate for V/Foral (volume of distribution l/70kg),  
Tabs = absorption half-life after nasogastric (elixir) or suppository administration (h), 
Tlag = absorption lag time after nasogastric (elixir) or suppository administration (h), 
Frectal/oral = relative bioavailability of the rectal compared to the oral formulation, 
Teq is the serum to CSF equilibration half-time,  
PC is the partition coefficient between serum and CSF. 
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Table 1b Covariate Models and Estimates for Pooled Population Parameters 
a) Volume of distribution V/Foral = (Vstd x (Wt/70)) x (1 + βvol x EXP(-AGE in months 
* Ln(2)/Tvol))  l  
b) Clearance CL/Foral = (CLstd x (Wt/70)0.75) x (1 + βcl x EXP(-AGE in months * 
Ln(2)/Tcl))  l/ h 
 
Parameter Estimate 
βvol 0.781 
Tvol 0.0556 months 
βcl -0.597 
Tcl 3.11 months 
 
βvol and βcl are parameters estimating the fraction above or below V/Foral and CL/Foral 
respectively at birth; Tvol and Tcl describe the maturation half-lives of the age-related 
changes of V/Foral and CL/Foral. 
 
Table 2  Correlation of population pharmacokinetic parameter variability  
 
  CL V Tabs elixir Tabs suppository Teq 
CL 1     
V 0.42 1    
Tabs elixir 0.09 -0.134 1   
Tabs suppository 0.131 -0.172 0.064 1  
Teq 0.043 -0.031 -0.065 0.039 1 
 
 
 
 
 
 
 
 
 
 
 
Figure 2  Individual Bayesian Teq (plasma to CSF equilibration half-time) 
predictions (standardized to a 70 kg person) and their relationship to age 
for the complete pooled data set. Predictions from the current data set 
are shown as x. Predictions from data from Anderson et al are shown as 
∆. Standardized Teq does not change with age. 
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The individual Bayesian predictions for plasma and CSF concentration are 
compared to those observed in Figure 3a & 3b. These predictions are based 
on maximum a posteriori Bayesian estimates of the parameters for each 
specific individual using their observed data. Figure 4a & 4b demonstrate 
the quality of fit for pharmacokinetic data over the study time period – each 
subject’s data is connected by a line.  
 
 
Figure 3a 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3b 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 The individual Bayesian predictions for plasma (Figure 3a) and CSF 
concentration (Figure 3b) are compared to those observed. The line x = y 
is the line of identity 
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The residual errors (mg/l) for the plasma concentration data were 3.4 and 
3.2 for the current data and that from Anderson et al,12 respectively. The 
residual errors (mg/l) for the CSF concentration data were 4.3 and 2.0 for 
the current data and that from Anderson et al,12 respectively. 
 
Figure 4a 
 
Figure 4b 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4  The quality of fit for pharmacokinetic data over the study time period – 
each subject’s data is connected by a line. Plasma data are shown in 
Figure 4a. CSF data are shown in Figure 4b. 
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Discussion 
 
This study estimates a population plasma to CSF equilibration half-time 
(Teq) of 1.93 h (standardized to a 70 kg person) for APAP in children of all 
ages – an estimate similar to the Teq of 2.1 h determined from naïve pooled 
adult data collected by Bannwarth et al.10 Patients in that study were adults 
(n = 43) with rheumatic and nerve root compression pain. They were given 
an intravenous prodrug of APAP (propacetamol) and a single CSF APAP 
concentration was measured. Data were modeled with the MKMODEL 
program23 using the same equations as in this current study and in the study 
performed by Anderson et al.12 Our current data do not support the concept 
of an increased permeability BBB in early infancy. We have recently 
expanded this view in relation to opioids.24 Children with traumatic brain 
injury, however, did have a lower Teq – consistent with disruption of the 
BBB.  
 
Size was the first covariate used in our current analysis. This deliberate 
choice was based on known biological principles. A lot of physiological, 
structural and time related variables can be predicted within and between 
species with weight exponents of 0.75, 1 and 0.25 respectively.20 We have 
used physiological time, rather than chronological time, to define 
standardized Teq. The concept of physiological time was developed as a 
consequence of allometry.25 For example, most mammals have the same 
number of heartbeats and breaths in their life span. The difference between 
small and large animals is that smaller animals have faster physiologic 
processes and consequently a shorter life span. West et al,18,19 have used 
fractional geometry to mathematically explain the allometric power 
exponents. The “¼ power laws” were derived from a general model that 
describes how essential materials are transported through space-filled 
fractional networks of branching tubes.18 These design principles are 
independent of detailed dynamics and explicit models and should apply to 
virtually all organisms.19 Consequently we might expect a neonate (3.5 kg), 
1 year old child (10 kg), 5 year old child (20 kg), 10 year old child (30 kg) 
and an adult (70 kg) to have a chronological Teq of 0.9, 1, 1.4, 1.6 and 1.93 
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h respectively (Figure 5), which would result in a more rapid onset of effect 
in younger children. This is consistent with the speed of onset of other 
drugs due to distribution to an effect compartment.26 This covariate should 
be factored into investigations of APAP effect. We might, for example, 
expect maximum fever reduction after APAP elixir to occur earlier in 1 
year olds than 10 year olds. 
 
The plasma to CSF Teq is longer than the effect compartment Teq 
estimated for analgesia (53 min, CV 217%)5 and for anti-pyresis (71 min, 
CV 10%)6 in children. These data suggest that the CSF compartment is not 
the effect compartment responsible for these actions. Anti-pyresis is 
mediated through prostaglandins in the hypothalamus and analgesia through 
both prostaglandin synthesis and by antagonizing N-methyl-D-aspartate 
(NMDA) and substance P in the spinal cord. Our data suggests that 
analgesic and anti-pyretic effects occur earlier than APAP concentration 
changes in the CSF. 
 
Figure 5 Teq expected for a neonate (3.5 kg), 1 year old child (10 kg), 5 year old 
child (20 kg), 10 year old child (30 kg) and an adult (70 kg). 
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Abstract 
 
Background 
Data concerning metabolism of paracetamol (APAP) in infants are scant. 
Previous studies have examined urinary metabolite recovery rates after a 
single dose of APAP in either neonates (< 6 weeks) or in children (3-9 
years). There are no studies investigating infants. 
 
Methods 
Infants (n = 47) undergoing major craniofacial surgery were given APAP 
19-45 mg/kg 6-, 8-, or 12 hourly as either elixir or suppository formulation 
for postoperative analgesia, after a loading dose of 33-59 mg/kg rectally 
during the operation. Serum was assayed for APAP concentration in 40 of 
these infants at 5, 8, 11, 14, 17 and 20 h postoperatively. Urine samples 
were collected every 3 h for 24 h in 15 of these infants. The clearances of 
APAP to glucuronide and sulphate metabolites as well as the urinary 
clearance of unmetabolized APAP were estimated using non-linear mixed 
effects models. 
 
Results 
Mean (± SD) age and weight of the patients were 11.8 ± 2.5 months and 9.1 
± 1.9 kg. Clearance of APAP to APAP-glucuronide (%CV) and to APAP-
sulphate were 6.6 (11.5) l/h and 7.5 (11.5) l/h respectively, standardized to a 
70-kg person using allometric ‘¼ power’ models. Glucuronide formation 
clearance, but not sulphate formation, was related to age and increased with 
age from a predicted value in a neonate of 2.73 l/h/70 kg to a mature value 
of 6.6 l/h/70kg with a maturation half-life of 8.09 months. Urine clearance 
of APAP-glucuronide, APAP-sulphate and unchanged APAP (%CV) were, 
respectively 2.65, 3.03 and 0.55 (28) l/h/70 kg. The urine clearance of 
unchanged APAP and metabolites was related to urine volume flow rate. 
Clearance attributable to pathways other than these measured in urine was 
not identifiable. The glucuronide/sulphate formation clearance ratio was 
0.69 at 12 months age. Sulphate metabolism contributed 50% towards 
APAP clearance. 
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Conclusion 
Glucuronide formation clearance increases with age in the infant age range 
but sulphate formation does not. Renal clearance of APAP and its 
metabolites increases with urine flow rate. This and other studies show that 
APAP metabolism to glucuronide appears to be similar in infants and 
children, but in adults is increased in comparison with children. Oxidative 
pathways were undetectable in this infant study and may explain, in part, 
the reduced incidence of hepatotoxicity in infants. 
 
 
Introduction 
 
Paracetamol (APAP) is a popular analgesic for mild postoperative pain in 
children. The five most commonly prescribed drugs in our Pediatric 
Surgical Intensive Care Unit (PSICU) are nystatin, cisapride, APAP, 
cefotaxime and furosemide.1 Although APAP is one of the most prescribed 
drugs, there are few data concerning metabolite formation in infants. 
Prescott has reviewed APAP metabolism in adults; APAP is conjugated to 
APAP-glucuronide (50-60%) and APAP-sulphate (25-35%).2 A small part 
is metabolized through oxidation (2-10%) to the toxic metabolite N-acetyl-
p-benzoquinone-imine (NAPQI) and into 3-hydroxy-APAP.2 Oxidation 
involves the cytochrome P450 system, of which CYP2E1 is the most 
important.3 NAPQI is conjugated by glutathione into cysteine and 
mercapturic acid metabolites.3 APAP-glucuronide, APAP-sulphate, 3-
hydroxy-APAP, cysteine and mercapturic acid metabolites and a small 
amount of unchanged APAP (2-5%) are excreted in urine.2  
 
Hepatotoxicity occurs as a consequence of APAP overdose when an 
increased amount of APAP is metabolized through oxidation with a 
consequent increase of NAPQI.4 Glutathione, required to conjugate NAPQI 
into the non-toxic cysteine and mercapturic acid metabolites, becomes 
depleted and NAPQI conjugation with hepatocellular proteins occurs, 
eventually leading to liver cell necrosis.4  
APAP developmental pharmacokinetics were studied in premature neonates 
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and infants by Anderson et al., showing a exponentially decreasing volume 
of distribution with a maturation half-life of 11.5 weeks and an increasing 
APAP clearance with a maturation half-life of 11.3 weeks reaching, 
respectively 72.9 l/70 kg and 10.8 l/h/70 kg at the age of 60 weeks post-
conception.5  
 
An understanding of the contribution of glucuronide and sulphate 
metabolite formation is important in order to appreciate the factors that 
determine the extent of formation of NAPQI. If affinity and capacity of 
glucuronide and/or sulphate formation is limited in relation to oxidative 
pathways, then NAPQI formation may increase and with it the risk of 
hepatotoxicity. 
 
 
Methods  
 
Patients and methods 
The medical ethical committee of the Erasmus MC Rotterdam approved the 
study, and written informed consent was obtained from the parents of all 
infants participating in the study. Data were collected from 47 children, of 
whom 40 participated in a study published previously6 (see Figure 1) in 
which we described longitudinal data on plasma APAP levels. 
 
The Erasmus MC-Sophia serves as a level-III referral centre for all pediatric 
surgical subspecialties. As such, it is the only designated pediatric 
craniofacial centre in the Netherlands. Around 100 major craniofacial 
corrections are performed annually. Infants aged between 3 months and 3 
years presenting for elective craniosynostosis correction were considered 
for enrolment. Exclusion criteria were craniotomy for tumors, 
hydrocephalus or trauma, pre-existent liver or kidney disorders as reflected 
by abnormal values of liver enzymes, bilirubin, urea and creatinine, severe 
mental retardation, Glasgow Coma Score < 8, postoperative mechanical 
ventilation, and known allergy for APAP.  
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Figure 1  Flowchart of patients included in this study  
  
All infants (n = 47) were given a rectal APAP loading dose of 
approximately 40 mg/kg during craniosynostosis surgery, approximately 2 
h before anticipated extubation. At this time, major blood loss had been 
adequately compensated for and patients were hemodynamically stable. 
After the operation, patients were admitted to the PSICU for a minimum of 
24 hours.  
 
Group A (n = 40) consisted of patients participating in a study comparing 
the analgesic efficacy of rectal versus oral APAP after craniofacial surgery.6 
Two hours after arrival in the PSICU, patients had a gastric lavage until 
gastric fluid was clear and patients were then given approximately 20 
mg/kg APAP study medication 6-hourly, either orally or rectally. APAP 
elixir was given through a nasogastric tube. Blood samples were drawn 
from an indwelling arterial catheter at 30, 60 and 90 min after 
administration of the rectal loading dose and 1 h before and 2 h after APAP 
maintenance dose administration. An extra dose of APAP was given if the 
VAS pain score7 was more than 4 cm. Blood samples were taken just prior 
to administration of the extra dose and two h thereafter. The next dose of 
the study medication was then administered according to the protocol 
schedule, which has been described previously.6 From 8 of these 40 
patients, urinary samples were also collected for analysis. 
Blood 
samples 
Urinary 
samples 
n=47 
Group A 
n=40 
Group B 
n=7 
n=0 n=40 
n=7 n=8 
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Group B (n = 7) consisted of patients meeting the same inclusion criteria as 
the patients in group A. They received APAP suppositories for maintenance 
doses, 21-45 mg/kg 6-, 8- or 12-hourly after arrival in the PSICU. From 
these seven patients urinary samples were also available for analysis. 
As a consequence, the total study population for the urinary analysis was 15 
(8 from group A and 7 from group B). Urine was collected from the urinary 
catheter at 3-h intervals starting at 3 h after the arrival in the ICU and 
finishing at 24 h. After each 3-h collection period, the total amount of urine 
produced in the previous 3 h was registered and two samples of 3 ml were 
taken from the urine collected in this 3-h period for APAP, glucuronide and 
sulphate metabolite analysis. After collection samples were stored at 4°C 
until the end of the 24-h study period. Samples were then stored at -20°C 
until analysis.  
 
The formulation for the rectal loading dose and the maintenance doses in 
the seven children from group B were 60, 120, 240 or 500 mg APAP 
suppositories contained in a triglyceride base (Pharmachemie, Haarlem, 
The Netherlands). The loading dose given (32-59 mg/kg) was dependent on 
available suppository size. Subsequent study medication, both elixir (APAP 
24 mg/ml, glycerol 85%, sodium lactate, raspberry essence and sorbitol 
solution) and APAP suppositories (APAP and Witepsol H15, synthetic 
saturated triglycerides with a chain length of C12 - C18, as the base), were 
manufactured in the department of pharmacy. The deviation of the APAP 
doses in the suppositories was less than 10%. APAP for the study 
medication was supplied by Bufa b.v., Uitgeest, the Netherlands. The 
suppositories, the elixir, and all ingredients met with the requirements in the 
European Pharmacopoeia. APAP suppositories and elixir were 
manufactured according to the Dutch Pharmacists Formulary. Stability of 
these preparations is tested by the laboratory of the Royal Dutch 
Association of Pharmacists. 
 
APAP assay 
APAP plasma concentrations were determined using fluorescence 
polarization immunoassay (Adx system, Abbott Laboratories, North 
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Chicago IL) (Erasmus MC Rotterdam). The detection limit of this method 
was 1.0 mg/l. Precision was measured at APAP concentrations of 15, 35 
and 150 mg/l. To determine coefficients of variation at these 
concentrations, 55 samples of each concentration were assayed [CV = 
(SD/mean); RSD = CVx100%]. RSD was 7.22%, 3.37% and 3.11% at 15, 
35 and 150 mg/l, respectively. The APAP concentration range in which the 
accuracy was determined, is 10-150 mg/l. 
 
APAP-glucuronide, APAP-sulphate and unchanged APAP concentrations 
in urine were determined using high-performance liquid chromatography 
(HPLC) (Isala Klinieken, Zwolle). The HPLC system consisted of a pump 
(ThermoFinnigan, SpectraSYSTEM P2000, flow 1.8 ml/min), an injector 
(ThermoFinnigan, SpectraSYSTEM AS3000), a Kolomoven 
(ThermoFinnigan, IGLOO-CIL, 21°C), a detector (ThermoFinnigan, 
Spectra Focus, 240 nm) and an integrator (ThermoFinnigan, ChromQuest 
2.51). The column used was a LiChroCART 125-4, LiChrospher 100 RP-18 
(Merck 1.50943). Reagents used were potassium dihydrogen phosphate 
(Merck 1.04873), formic acid (Merck 1.00264) and isopropanol (Merck 
1.01040). The mobile phase of the column consisted of formic acid: 
isopropanol: 0.1 M potassium dihydrogen phosphate in water (0.1:1.7:98.2, 
v/v/v). The flow rate was 1.8 ml/min. 
 
Calibration curves were prepared of APAP, APAP-glucuronide and APAP-
sulphate by adding standard solutions of APAP, APAP-glucuronide and 
APAP-sulphate in water to a pooled sample of ‘blank’ urine of infants, so 
that the final concentrations of APAP in urine were 5-10-20-40 µg/ml, of 
APAP-glucuronide 5-50-100-200 µg/ml, and of APAP-sulphate 10-100-
500-1000 µg/ml. In a pilot study, APAP-mercapturate and APAP-cysteine 
were not detected in urine samples of infants; therefore no calibration 
curves were prepared for APAP-mercapturate and APAP-cysteine. 
Duplicate urine samples (100µl) were diluted with 900 µl water and mixed, 
and 20 µl was injected onto the column. 
The precision of this method was determined by six replicate assays at two 
concentrations (of the calibration curve) for APAP, APAP-glucuronide and 
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APAP-sulphate. The specificity of the method was determined by assay of 
six independent urine samples of patients who received other drugs 
(caffeine, gentamicine, carbamazepine, vancomycine, and digoxine). 
Detection limits (signal/noise ratio: 3) were 0.3 mg/l, 2.3 mg/l and 6.3 mg/l 
for APAP, APAP-glucuronide, and APAP-sulphate, respectively. Detection 
limits (signal/noise ratio: 5) were 1.0 mg/l, 3.2 mg/l and 10.1 mg/l for 
APAP, APAP-glucuronide, and APAP-sulphate, respectively. Precision was 
7% for APAP, 3% for APAP-glucuronide and 3% for APAP-sulphate. 
 
 
Modeling 
 
Population parameter estimates 
Urine metabolite data were converted to APAP mg equivalents using a 
molecular weight of 151.2 mg/mmol for APAP, 328.3 mg/mmol for APAP-
glucuronide and 230.2 for APAP-sulphate. Population parameter estimates 
were obtained using a non-linear, mixed effects model.8 This model 
accounts for population parameter variability (between and within subjects) 
and residual variability (random effects) as well as parameter differences 
predicted by covariates (fixed effects). The population parameter variability 
in model parameters was modeled by a proportional variance model. 
Additive terms characterized the residual unknown variability for serum 
concentration and the amount of glucuronide, sulphate and unmetabolized 
APAP in the urine. This error model assumes that the residual variability is 
of the same order of magnitude over the whole range of measurements. The 
population mean parameters, between subject variance and residual 
variance, were estimated using NONMEM version V release 1.1. 
Estimation used the first-order conditional estimate method with the 
interaction option and ADVAN 6 with Tol = 5. Convergence criterion was 
three significant digits. A Compaq Digital Fortran Version 6.5 compiler 
with Intel Pentium III 1 GHz CPU under Windows 2000 was used. 
Differential equations were used to describe the pharmacokinetics of APAP 
and its metabolites. 
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dAgut/dt = -Ka x Agut  
 
Agut is the amount of drug in the gut at any one time.  
  
CLT  =  CLNRP + CLMG + CLMS + CLUP 
 dCP/dt   =  (Agut x Ka - CP x CLT) / VP 
 dCLMG/dt =  (CLMG x CP-CLUG x CG) / VMG  
 dCLMS/dt  =  (CLMS x CP-CLUS x CS) / VMS 
 dCLUP/dt  =  (CLUP x CP) / VP 
 dCLUS/dt =  (CLUS x CS) / VMS 
 dCLUG/dt  =  (CLUG x CG) / VMG 
 
 
The model is shown in Figure 2. VP is the volume of distribution for 
APAP, CP is APAP serum concentration, CLMP is clearance to metabolites 
of APAP, CLMG is clearance to APAP-glucuronide, CLMS is clearance to 
APAP-sulphate, VMS is the volume of distribution of sulphate metabolite, 
VMG is the volume of distribution of glucuronide metabolite, CS is APAP-
sulphate serum concentration, CG is APAP-glucuronide serum 
concentration, CLUG is urine clearance of glucuronide, CLUS is urine 
clearance of sulphate, CLUP is urine clearance of unmetabolized APAP, 
CLNRP is clearance attributable to pathways other than these measured in 
urine in this current analysis and Tabs is the absorption half-life (Ln(2)/Ka).  
The ratio for the formation of the glucuronide (CLMG) and sulphate 
(CLMS) metabolites was set the same as the urine clearance ratio for these 
metabolites i.e.  
 
CLMG  =  CLMP x (CLUG/(CLUG+CLUS)) 
CLMS  =  CLMP x (1-CLUG/(CLUG + CLUS)) 
 
CLMP is the total non-renal clearance through the two metabolites (CLUG 
+ CLUS). The metabolite volumes of distribution (VMS and VMG) cannot 
be identified using the current study design and were fixed at 17 l/70kg, 
based on the study by Lowenthal et al.9 For patients who did not have any 
urine data, the total clearance of APAP was estimated as a single parameter 
(CLT) with its own variability. 
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A model for size and age changes in pharmacokinetics of APAP 
Initial models confirmed the previous conclusion by van der Marel et al.6 
that the bioavailability of elixir was low compared to suppository 
formulation in the 47 infants given APAP for analgesia after craniofacial 
surgery. In order to gain a better understanding of the elixir bioavailability, 
data from the 47 craniofacial patients were included with those from a 
previous study investigating age-related pharmacokinetics (n = 221).10 A 
separate additive term was used to characterize the residual unknown 
variability for serum concentration from each study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 VP volume of distribution for APAP, CP APAP serum concentration, 
CLMP the total non-renal clearance through the two metabolites (CLUG 
+ CLUS), CLMG clearance to APAP-glucuronide, CLMS clearance to 
sulphate, VMS volume of distribution of sulphate metabolite, VMG 
volume of distribution of glucuronide metabolite, CS APAP-sulphate 
serum concentration, CG APAP-glucuronide serum concentration, 
CLUG urine clearance of glucuronide, CLUS urine clearance of 
sulphate, CLUP urine clearance of unmetabolized APAP, CLNRP non-
renal clearance of APAP, Tabs absorption half-life (Ln(2)/Ka), Tlag Lag 
time  
VP
CP
Dose, F
Tabs
Tlag CLUG
CLUS
CLUP
CLMG
CLMS
VS
CS
CLNRP
VG
CG
CLMP
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Covariate Analysis 
The parameter values were standardized for a body weight of 70 kg using 
an allometric model.11 
   
 Pi  =  Pstd x (Wi / Wstd) PWR 
 
where Pi is the parameter in the ith individual, Wi is the weight in the ith 
individual and Pstd is the parameter in an individual with a weight Wstd of 70 
kg. The PWR exponent was 0.75 for clearance and 1 for distribution 
volumes.12-16  
Exponential functions were applied to allow for age-related changes of 
CLT, CLMG, CLMS, CLUP and VP,9 e.g.: 
 
V/Foral = (VPstd x (Wt/70)) x (1 + βvol x EXP(-AGE in months x Ln(2)/Tvol)) l  
 
CLT/Foral = (CLTstd x (Wt/70)0.75) x (1 + βcl x EXP(-AGE in months x Ln(2)/Tcl)) l/h 
 
CLMG = (CLMGstd x (Wt/70)0.75) x (1 + βcl x EXP(-AGE in months x Ln(2)/Tcl)) l/h 
 
 
βvol and βcl are parameters estimating the fraction above or below 
VP/Foral and CLT/Foral respectively, at birth; Tvol and Tcl describe the 
maturation half-lives of the age-related changes of VP/Foral and 
CLT/Foral.  
 
The influence of urine flow rate (URATE, l/3h) on CLMG, CLMS and 
CLUP was modeled with an exponential function with a scaling constant 
(USCALE) e.g. 
 
  CLUP  = CLUPstd x EXP(USCALE x URATE)  
 
Scaling factors were applied to Foral (elixir bioavailability) for infants who 
vomited (Fvom) or suffered nasogastric loss (F nasogastric) after oral elixir 
APAP administration.  
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The quality of fit of the pharmacokinetic model to the data was assessed by 
visual examination of plots of observed versus predicted concentrations. 
Models were nested and an improvement in the objective function was 
referred to the Chi-squared distribution to assess significance, e.g. an 
objective function change (∆OBJ) of 3.84 is significant at α = 0.05.  
 
 
Results 
 
Population Demographics 
Mean (±SD) age and weight of the 47 infants undergoing craniofacial 
surgery were 11.5 ± 2.5 months and 9.2 ± 1.4 kg. There were 32 boys and 
15 girls. APAP elixir was used as maintenance medication in 20 infants and 
suppositories were used in the other 27. The 15 patients from whom urine 
data were collected consisted of 8 boys and 7 girls with a mean age of 11.8 
± 2.5 months and a mean weight of 9.1 ± 1.9 kg . There were no significant 
differences between patients receiving oral APAP and patients receiving 
rectal APAP with respect to age, weight, sex, extent of operation procedure, 
blood loss, duration of operation and underlying diagnosis. The total APAP 
dose over the 24-h study period was 114 ± 18 mg/kg.  
Urine recovery of APAP at steady state (18- to 24-h dose interval) was 70% 
(CV 38%) of the given dose. This is comparable to the estimated relative 
bioavailability of the triglyceride suppository (0.72, CV 42%) and suggests 
almost complete recovery. 
 
Parameter estimates 
Formation clearance of APAP-glucuronide (%CV) and APAP-sulphate 
were 6.5 (11.5) l/h/70 kg and 7.5 (11.5) l/h/70kg, respectively. Final 
parameter estimates with covariate analyses are shown in Table 1 & Table 
2. Pharmacokinetic estimates and maturational half-lives of VP/F and 
CLT/F were similar to those reported previously.10 Figure 3 shows 
clearance changes with age for the complete pooled data set. The clearance 
estimates for infants undergoing craniofacial surgery (symbol x) enrich the 
data set and are consistent with the other data used in the pooled analysis.  
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Table 1 Pharmacokinetic parameter estimates. These estimates are 
standardized to a 70-kg person using an allometric size model; 
%CV is the coefficient of variation for the population parameter 
estimate; S.E. is the standard error of the structural parameter 
estimate. SE% is the S.E. expressed as a percentage of the 
population parameter estimate. CLT  population estimate for 
CL/Foral (clearance after oral administration l/h/70kg) in infants 
with no urine data, VPstd population estimate for V/Foral (volume 
of distribution l/70kg), CLUG, CLUS, CLUP std are urinary 
clearances of glucuronide, sulphate and unmetabolized APAP 
before effect of urine flow , Tabs absorption half-life after 
nasogastric (elixir) in infants out of the neonatal period, 
triglyceride base suppository and capsule suppository 
administration (h), Tlag absorption lag time after nasogastric 
(elixir), triglyceride base suppository and capsule suppository 
administration (h), Frectal/oral relative bioavailability of the rectal 
compared to the oral formulation. 
  
Parameter Estimate CV % S.E. % 
CLTstd 
No urine data 
14.1 l/h/70kg 35.8 6.6 
VPstd 78.7 l/70kg 10.3 4.4 
CLMGstd 6.6 l/h/70kg 11.5 10.6 
VMG 17 l/70kg FIX   
CLMSstd 7.5 l/h/70kg 11.5 10.6 
VMS 17 l/70kg FIX   
CLUG std 2.65 l/h/70kg  26.6 
CLUS std 3.03 l/h/70kg  15.9 
CLUP std 0.55 l/h/70kg 28.0 12.5 
F elixir 1 FIX 30.2  
Tabs elixir 0.138 h 140 13.7 
Tlag elixir 0.383 h 29.4 6.0 
F triglyceride/oral 0.718 42.4 7.1 
Tabs triglyceride 2.7 h 64.4 13.9 
Tlag triglyceride 0.201 h 29.4 28.3 
F capsule/oral 0.727 34.9 6.3 
Tabs capsule 0.724 h 64.4 10.1 
Tlag capsule 0.513 h 29.4 6.1 
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Table 2 Covariate models and estimates for pooled population parameters. βvol 
and βcl are parameters estimating the fraction above or below VP/Foral 
and CLT/Foral respectively at birth; Tvol and Tcl describe the maturation 
half-lives of the age-related changes of VP/Foral and CLT/Foral. Fvom is 
the proportion of drug lost from vomiting after elixir administration; F 
nasogastric is that proportion lost from nasogastric drainage. 
 
Parameter Estimate S.E. % 
USCALEc 5.5 3.7 
Fvom 0.65 31.0 
F nasogastric 0.425 14.8 
βvola 0.615 48.0 
Tvola 1.7 days 30.5 
βclb -0.587 7.1 
Tclb 8.09 months 49.1 
 
a Volume of distribution 
V/Foral = (VPstd x (Wt/70)) x (1 + βvol x EXP(-AGE in months x 
Ln(2)/Tvol)) l  
b Clearance 
CLT/Foral = (CLTstd x (Wt/70)0.75) x (1 + βcl x EXP(-AGE in months x 
Ln(2)/Tcl)) l h-1 
CLMG = (CLMGstd x (Wt/70)0.75) x (1 + βcl x EXP(-AGE in months x 
Ln(2)/Tcl)) l h-1 
c Relationship of unmetabolized APAP clearance to 3-hourly urine 
volume (URATE, l/3h) 
CLUS = CLUS baseline x EXP(USCALE x URATE) 
CLUG = CLUG baseline x EXP(USCALE x URATE)  
CLUP = CLUP baseline x EXP(USCALE x URATE)  
 
Clearance attributable to pathways other than these measured in urine was 
not identifiable in this study (i.e. CLNRP = 0). The urinary clearance ratio 
APAP-glucuronide to APAP-sulphate was 0.87. The exponential function 
applied to allow for age-related changes of CLT was also applied to 
glucuronide metabolite formation. Consequently, the formation clearance 
ratio of APAP-glucuronide to APAP-sulphate varied with age and was 0.69 
at 12 months age and 0.81 at 2 years. Sulphate and glucuronide conjugation 
contributed equally towards APAP metabolism. The individual Bayesian 
predictions for serum concentration, 3-hourly urine APAP, glucuronide and 
sulphate excretion are compared with those observed in Figure 4a, 4b, 4c & 
4d, respectively. These predictions are based on maximum a posteriori 
Bayesian estimates of the parameters for each specific individual using their 
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observed data.  
Glucuronide formation clearance, but not sulphate formation, was related to 
age and increased with age from a predicted value in a neonate of 2.73 
l/h/70kg to a mature value of 6.6 l/h/70kg with a maturation half-life of 8.09 
months. The objective function did not improve when clearance of 
unmetabolized APAP and sulphate conjugation was assumed to be age 
related. These metabolite age relationships are shown graphically in  
Figure 5. 
 
The clearance of unmetabolized APAP, glucuronide and sulphate 
metabolites were all related to the volume collected in the 3-hourly urine 
(i.e. the urine flow rate measured over 3 h) using an exponential function 
(Figure 6). The objective function was significantly worse (∆OBJ 35.8) 
when urine flow rate was only used to account for differences in unchanged 
urinary APAP clearance. The mean urine clearance of unchanged APAP 
was 0.55 l/h/70kg (CV 28%). 
The residual errors for 3-hourly urine glucuronide, sulphate and APAP were 
15.6 , 24.2 and 3.2 mg, respectively. The residual errors for serum 
concentrations from infants undergoing craniofacial surgery was 3.1 mg/l 
and from Anderson et al.10 was 1.8 mg/l. 
Figure 3 Individual predicted clearances, standardized to a 70-kg person, from 
NONMEMs post-hoc step are plotted against Log age. The solid line 
demonstrates the non-linear relationship between clearance and age. 
Infants (n = 47) studied after craniofacial surgery are shown as open 
circles. Infants from the reference data set (n = 221) are shown as closed 
circles 
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a       b  
c      d 
Figure 4 Quality of fit of pharmacokinetic data. Individual Bayesian concentration 
predictions based on values of the parameters for the specific individual 
are compared with observed. The line x = y is the line of identity. a 
Serum concentration data from craniofacial infants (n = 47) and from 
the reference data set (n = 221) b urine APAP-glucuronide metabolite 
data (n = 15) c urine APAP-sulphate metabolite data (n = 15) d urine 
unmetabolized APAP data (n = 15). 
 
Discussion 
 
The mean (±SEM)  glucuronide to sulphate ratio increases from 0.12 ± 0.09 
in preterm neonates 28-32 weeks gestational age,17 to 0.28 ± 0.35 in 
preterm neonates 32-36 weeks gestational age,17 0.34 ± 0.08 in newborns,18 
0.75 ± 0.10 in 3- to 9-year-old children18,19 and 1.61 ± 0.21 in 12- year-old 
children,18 with an adult ratio of 1.80 ± 0.32.18 As Miller et al. studied only 
seven children,18 and since there are no studies in infants out of the neonatal 
age group reported in the literature, we evaluated 15 patients of 6-16 
months of age (mean ±SD; 11.8 ± 2.5 months) following major craniofacial 
surgery. 
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Figure 5 Individual predicted metabolite clearances of children with urine data  
  (n = 15), standardized to a 70-kg person, from NONMEMs post-hoc step 
are plotted against age. The total body clearance and clearance to the 
glucuronide metabolite increase with age, while clearance to the 
sulphate metabolite was not age-related in the studied infants. 
CLT total metabolite formation clearance, CLMG glucuronide formation 
clearance, CLMS sulphate formation clearance 
 
 
Figure 6 The relationship between urine clearance of unmetabolised APAP and 3-
hourly urine volume collection (URATE) in children with urine data (n = 
15) 
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In this current study, we have demonstrated a glucuronide to sulphate 
metabolite ratio increase in infancy. Clearance was to glucuronide and 
sulphate metabolites as well as renal elimination of unmetabolised APAP. 
Other routes of elimination were not detectable. Size was the first covariate 
used in our analysis. By choosing weight as the primary covariate and 
applying allometric size models, the secondary effects of age could be 
investigated and parameter estimates at different ages standardized to a 70-
kg person. The sulphate metabolite clearance of 7.5 l/h/kg is similar to 
those described in adults (mean ± SD 6.8 ± 1.2 l/h/70kg) (Table 3) and 
there was no age-related change detected in this cohort of infants. The 
objective function (∆OBJ) improved by only 2, when age related sulphate 
clearance was added. Urine glucuronide/sulphate ratios of 0.34 in neonates 
rising to 0.75 in children 3-9 years have been reported.17,18 Our current data 
suggests that the ratio reported reaches a constant value by 3 years 
(glucuronide maturation half-life of 8.09 months). Several studies have 
shown that the rate constant for APAP-glucuronide formation in neonates is 
considerably smaller than in adults but the rate constant.5,17,20 The increase 
relative to adults may be an artefact of a non-biological based size model 
and has been observed when applied to clearance.21 
 
Our estimate for glucuronide formation clearance 6.6 l/h/70kg (CV 11.5%)  
is approximately half that of adult estimates (11.8 ± 3.7 l/h/70kg) (Table 3). 
We estimated a total APAP clearance of 14.6 l/h/70kg in infants who had 
urine data and 14.1 l/h/70kg in the other infants. These estimates are lower 
than that reported in adults; the mean total clearance in adults from Table 3, 
for example, is 21.6 ± 4.3 l/h/70kg. Miller et al.17 report a 
glucuronide/sulphate ratio in urine of 1.61 ± 0.21 in 12-year-old children 
and 1.8 ± 0.32 in adults. These data are suggestive of a further increase in 
glucuronide metabolism during the teenage years. But this increase might 
be due to other age-related factors, e.g hormone changes, rather than 
exclusively to maturation of the enzymes involved in glucuronidation. 
APAP is metabolized principally by the UGT1A6 enzyme. Although the 
UGT1A6 enzyme for APAP has been identified, little about its maturation 
profile is known. In vivo studies reveal that glucuronidation during fetal life 
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is 1-10% of adult levels. There is an increase slowly after birth and at 6 
months it is 50% of adult activity, findings similar to those reported in this 
current study where we estimate a maturation half-life of 8.09 months. 
Enzyme activity is not only determined by postnatal age, but might also be 
regulated by both ontogenic and genetic processes and these have not yet 
been elucidated.22  
 
Table 3 Metabolite clearance (S.D. or range) (l/h/70kg) in adults given a single 
dose APAP. Estimates are based on urine metabolite analyses po oral, iv 
intravenous administration  
Reference CL glucuronide CL sulphate CL total  
Mitchell31 9.76 (0.38) 5.64 (0.25) 18.2 (0.82) n = 7, po 
Sonne32 9.83 (3.17) 4.93 (1.84) 18.9 (3.2) n = 9, po 
Mitchell33 15.9 (2.34) 7.62 (1.32) 26.5 (3.7) n = 9, po 
Miners34 14.5 (3.2) 7.9 (1.6) 26.1 (4.7) n = 8, po 
Wynne35 10.5 (0.42) 7.56 (0.42) 19.7 (0.84) n = 19, iv 
Hoffman36 15.6 (1.7) 7.79 (2.59) 22.9 (6.9) n = 7, po 
Baraka37 14.8 (5.6) 5.6 (1.2) 22.3 (5.6) n = 10, po 
Rumble38 5.4 (1.8) 6.3 (2.4) 21 (5.9) n = 8, po 
Miners39 10.7 (1.8) 5.1 (0.73) 18.5 (2.73) n = 8, po 
Miners40 14.4 (0.68) 6.2 (0.47) 24.4 (0.85) n = 12, po 
Ismail41 6.6 (1.6) 3.7 (1.2) 16.07 (5.3) n = 8, po 
Kamali42 7.42 (1.19) 6.02 (1.19) 14.9 (1.47) n = 9, iv 
Haderslev43 13.46 (10.95-15.13) 5.51 (5.37-7.06) 22.72 (19.61-24.79) n = 10, po 
Manyike3 16.18 (5.18) 8.02 (2.34) 30.54 (7.39) n = 8, po 
Average 11.8 (3.7) 6.8 (1.2) 21.6 (4.3)  
 
The clearance of unmetabolized APAP normally contributes 2-5% of total 
urine clearance.2,3 We estimate the renal clearance of unchanged drug to be 
3.7% of total APAP clearance. There was almost complete recovery of 
administered APAP in the urine at steady state. The metabolites of APAP 
are thought to be stable in urine. The clearance of APAP and its metabolites 
in the urine was related to 3-hourly urine volume (i.e. flow) using an 
exponential function. Miners et al.23 have shown a 2.5-fold increase in the 
renal clearance of unchanged APAP in adults as urine flow increased from 
0.81 ml/min to 6.00 ml/min (0.7-5.2 ml/h/kg). We were able to define a 
relationship between urine flow rate and clearance in infants with urine 
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flows of 0.46-13.6 ml/h/kg. As APAP is a weak acid, with a pKa value of 
9.5, it is essentially unionized at all urine pH values, and pH is unlikely to 
have an effect on urine clearance. APAP is passively reabsorbed throughout 
the entire nephron, and clearance is expected to increase with increasing 
urine flow.24 There was no effect of age on unchanged APAP clearance 
because glomerular filtration rate and renal blood flow, corrected for body 
size, are mature by 6 months of age.25 
 
Clearance of glucuronide and sulphate conjugates in dogs is similar to 
clearance of inulin but there is active tubular transport probably localized to 
the distal nephron; clearance of these metabolites is reported to be 
independent of urine flow.26 We observed an improved fit to the urine 
excretion data when we assumed that clearance of these two metabolites 
changed similarly to APAP with increased urine flow. This has not been 
previously reported in humans. 
 
Pharmacokinetic estimates were similar to those previously published. Data 
from the previous pediatric analysis10 performed by Anderson et al. were 
included in this current analysis in order to estimate that portion of dose lost 
to nasogastric drainage (42.6%) and vomiting (65%) in infants undergoing 
craniofacial surgery. Gastric emptying after major surgery is delayed and 
the reduced bioavailability of the oral formulation was noted but not 
quantified in the previous paper investigating pharmacodynamics in infants 
undergoing craniofacial surgery.19 The earlier pooled analysis10 had fewer 
infants about the 12-month age bracket and inclusion of these children who 
had craniofacial surgery in this analysis revealed a longer clearance 
maturation half-life of 8.09 months (S.E. % 49.1), as opposed to an earlier 
estimate of 3.25 months (S.E.% 43). However, both of these covariate 
models predict that total APAP clearance is 94% that of older children by 1 
year of age.  
 
We were surprised to be unable to detect oxidative metabolites (cysteine 
and mercapturic acid conjugates) in our pharmacokinetic analysis (i.e. 
CLRNP, clearance attributable to pathways other than those measured in 
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the urine in this current analysis). Hepatotoxicity has been reported in 
neonates given APAP, but NAPQI was not measured. There is a relatively 
low level of activity of the cytochrome P450 CYP2E1 enzyme system27,28 in 
infants and this may contribute to the wider margin of safety reported in 
infants. However, the contribution of this metabolic pathway, even in 
adults, can be low (2%) and may be missed if urine collection after APAP 
administration is incomplete. Although Al-Obaidy et al.29 report that these 
metabolites contribute 12.6% of drug excreted in children with chronic liver 
disease, there are no data available concerning these urinary metabolites in 
either healthy or sick infants, except for neonates after maternal overdose.30 
The lack of urinary metabolites derived from NAPQI formation may mean 
that NAPQI formation is negligible in infants and thus explain the apparent 
lack of APAP hepatotoxicity in this age group. 
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Abstract 
 
Aim 
To investigate pharmacokinetics and –dynamics after single dose 
administration of propacetamol in preterm and term infants on the first day 
of life. 
 
Methods 
Neonates were stratified by gestational age (GA). Preterm (< 37 weeks) and 
term (37-41 weeks) infants received a single dose of propacetamol in the 
first 24 hours of life when they underwent minor, painful procedures or as 
additional treatment in infants on opioids. Blood samples were taken from 
an arterial line and pain was evaluated by a multidimensional pain scale. 
Results were reported by mean and standard deviation (SD). Student t and 
Wilcoxon test were used to compare both groups. 
 
Results 
Thirty neonates were included, of which 10 were term infants. Mean serum 
half life (t ½) in preterm infants was 277 (SD 143) minutes and was 172 
(SD 59) minutes in term infants (P < 0.05) while clearance (CL) was 0.116 
(SD 0.08) l/kg/h in preterm and 0.170 (SD 0.06) in term infants (P < 0.05). 
A correlation of GA with t ½ was found (r = -0.46). An effect of gender or 
administration of prenatal steroids on pharmacokinetics of paracetamol 
could not be documented. In neonates who only received propacetamol (n = 
15), the level of analgesia seems to be associated with a therapeutic (> 5 
mg/l) level.  
 
Conclusions 
A correlation between GA and T ½ for propacetamol was documented. The 
maturational trend of CL and T ½ in preterm and term neonates is in line 
with data on pharmacokinetics of propacetamol beyond the newborn period. 
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Abbreviations 
  
T ½   serum half life 
GA  gestational age 
Vd  distribution volume 
CL  total body clearance 
SD  standard deviation 
CV  conventional ventilation 
HFO  high frequency oscillation 
CPAP  continuous positive airway pressure 
HELLP hemolysis, elevated liver functions, low platelets 
 
 
Introduction 
 
Adequate management of pain in neonates is a major issue in neonatal care 
since Anand demonstrated the positive effect of opioids on mortality and 
morbidity in neonates who underwent cardiac surgery.1 Although the 
NOPAIN preliminary trial only documented a non-significant trend in 
reduction of poor neurologic outcome in preterms on morphine during 
ventilation, pre-emptive analgesia in ventilated infants is considered 
standard of care in most neonatal units.2-5  
 
Pharmacokinetics and –dynamics of most drugs prescribed in contemporary 
neonatal intensive care are still rare or even lacking, leading to frequent 
unlicensed and off-label use of drugs.6 To a certain extent, this also is true 
for paracetamol (APAP).  
APAP, N-acetyl-p-aminophenol, is a readily available antipyretic and 
analgesic agent. Although less potent, this drug might have fewer side 
effects when compared with opioids. It is the most often prescribed drug for 
treatment of mild to moderate pain in infants, including neonates. This drug 
can be administered by oral, rectal but also by intravenous route. 
 
The intravenous prodrug administration might improve prediction of 
concentration and consequent effect compared to rectal and/or oral 
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formulations by elimination of plasma variability due to absorption kinetics 
and relative bioavailibity.7-13 The combined use of opioids and APAP might 
reduce the need for opioids and reduce the side-effects, especially 
hypoventilation, in neonates. Although some believe that APAP itself is 
harmless in neonates, there is potential hepatotoxity.14 Propacetamol is a 
pro-drug of APAP and is hydrolysed by plasma esterases after intravenous 
administration in which one gram of propacetamol liberates 0.5 g of APAP, 
assuming adequate esterase activity in neonates, in line with documented 
cholinesterase activity.10,15 To document pharmacokinetics and 
pharmacodynamics of propacetamol in neonates of different gestational age 
(GA), a single dose study in the first 24 hours of life was performed. 
 
 
Patients and methods 
 
All neonates admitted within the first 24 hours of life in the neonatal 
intensive care unit and with an arterial line in place were considered for 
inclusion if propacetamol was administered. The decision to prescribe 
propacetamol or any other analgesic was made by the attending 
neonatologist. Propacetamol was administered when infants underwent 
minor, painful procedures (i.e. insertion of peripheral arterial or venous 
line, insertion of central venous line or placement of a chest tube) or as 
additional therapy in infants on opioids. Exclusion criteria were major 
congenital malformations or severe birth asphyxia (Apgar < 4 at 5 minutes) 
in line with other studies performed in neonates. The initial dose, i.e. 20 mg 
(10 mg APAP)/kg dose was based on literature data, with the intention to 
change this dose if interim analysis of the APAP levels in the first 15 
infants was inadequate (plasma levels < 5mg/l within 8-10 hours after 
administration).10-13 Maternal use of analgesics (besides APAP) were no 
reason for exclusion in this single dose pharmacokinetic study. 
 
As part of standard nursing care within the neonatal intensive care unit, a 
multi-dimensional pain scale was used to document pain/comfort in these 
neonates. With this pain scale (Leuven neonatal pain scale), three different 
levels (level 1: < 4/14, no pain; level 2: 4-6/14 mild discomfort; level 3: > 
Pharmacokinetics of single dose i.v. propacetamol in neonates: effect of gestational age 
 
63
6/14 pain) can be discriminated.16 An algorithm is used within the unit to 
administer and to adapt analgesics based on this pain scale.17 
 
The number and dose of other analgesics or sedatives prescribed in the first 
day of life were recorded. Birth weight was documented on admission in 
the unit. Gestational age (GA) was estimated by routine ultrasound 
examination before 20 weeks of gestation if available, or was based on the 
mother last month’s period and postnatal physical characteristics. 
Propacetamol was administered as a 15-minutes infusion to avoid local 
discomfort.18 Blood samples (0,2 ml) were taken from an arterial line 30, 
60, 90, 120, 180, 240 and 600 minutes after initiation of intravenous 
administration. The maximal total allowed amount of blood collected in a 
single neonate was 1 ml/kg. After centrifugation, samples were stored at  
–20°C until analysis. APAP plasma concentrations were determined using 
fluorescence polarization immunoassay (Adx system, Abbott Laboratories, 
North Chicago IL). Determination limit was 1 mg/l and precision was 7%. 
 
Pharmacokinetics were calculated assuming a linear one-compartment 
model with instantaneous input and first-order output. For every single 
patient a logarithmic trend line (y = a ln(x) + b) was calculated, based on at 
least three plasma samples. Relative distribution volume (l/kg) (Vd) and 
concentration at t = 0 (C max 0) were calculated. The slope of the curve 
{slope = (log Cp2 – log Cp1) (t2-t1)} was used to calculate the time 
constant K (slope x 2.303), elimination half life (0,693/K) (T ½) and total 
clearance (K x Vd) (CL). Results are expressed by mean, standard deviation 
(SD) and range.  
 
Student t test (normal distribution) or Wilcoxon test were used to compare 
clinical and pharmacokinetic findings in preterm (< 37 weeks GA) and term 
(≥ 37 weeks GA) infants. Linear regression analysis of GA and birth weight 
on T ½ were calculated (MedCalc®). The protocol was approved by the 
local ethics committee (Gasthuisberg, Leuven, Belgium) and infants were 
only included after informed consent of the parents. 
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Results 
 
Thirty neonates of variable GA were included in this single dose study. 
Fifteen infants received the 20 mg (10mg APAP)/kg dose and 15 infants 
received a 40 mg (20 mg APAP)/kg dose. Clinical characteristics are 
summarised in Table 1. 
 
Table 1 Clinical characteristics of the population. Results are reported by 
mean, standard deviation and range or by absolute numbers in term (37-
41 weeks) and in preterm (< 37 weeks) infants. (HELLP: hemolysis, 
elevated liver enzymes, low platelets, CV: conventional ventilation, HFO: 
high frequency oscillation, CPAP: continuous positive airway pressure). 
Three infants received surgery on the first day of life (esophageal atresia)  
  Term Preterm 
Number of infants   10 20 
Birth weight (g) mean 3323 (538) 1456 (592) 
 range 1980-4000 505-2440 
GA (wk) mean 38.5 (1.2) 31.4 (2.5) 
 range 37-40 27-35 
Maternal disease Preeclampsia/HELLP 3 4 
 Solutio placentae 1 2 
 Other medical conditions 0 2 
Delivery Caesarean 2 12 
Diagnosis Respiratory distress -- 9 
 Wet Lung Disease 5 -- 
 Meconium aspiration 2 -- 
 Pneumothorax 1 -- 
 Congenital heart disease 1 -- 
 Surgical conditions 1 2 
 Prematurity -- 9 
Ventilation  CV/HFO 8 8 
 Nasal CPAP -- 10 
Prenatal betamethasone  -- 13 
 
Overall mean birth weight was 2111g (SD 1094g) and mean GA at 
inclusion was 33.8 (SD 3.9 weeks). Mean postnatal age (hours) at inclusion 
was 12.7 (SD 6.4). Ten infants had a GA ≥ 37 weeks. Twenty infants were 
preterm (< 37 weeks GA), of whom 10 were younger then 32 weeks GA. 
Twenty-six infants received respiratory support, of whom 16 (53%) infants 
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were ventilated. Fifteen (50%) received other analgesics in the first 24 
hours of life.  
In total 213 blood samples were collected and analyzed. Results of all 
plasma samples are available in Figure 1a & 1b.  
 
Figure 1a 
 
Figure 1b 
 
Figure 1 a-b Plasma levels of APAP (n = 213) (mg/l) in all infants following single 
intravenous administration of 20 mg/kg (Figure 1a) or 40 mg/kg (Figure 
1b) of propacetamol (X-axis: time in minutes), hereby illustrating major 
variability. 
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Table 2 Pharmacokinetics of propacetamol in preterm (< 37 weeks) and 
term (37-41 weeks) infants.  
 
  Preterm Term 
Number of infants 
 
 20 10 
Relative Vd (l/kg) mean 0.61 (0.15) 0.64 (0.25) 
 range 0.44-1 0.46-1.3 
T ½ (min) mean 277 (143) 172 (59) 
 range 87-680 100-269 
Clearance (l/kg/h) mean 0.116 (0.08) 0.170 (0.06) 
 range 0.004-0.24 0.08–0.29 
 
Pharmacokinetic characteristics are summarized in Table 2. No significant 
difference in relative Vd (l/kg) between preterm and term infants could be 
documented. T ½ and CL are significantly different (both P < 0.05) between 
preterm and term infants (both P < 0.05). Mean T ½ in preterm infants was 
277 minutes. In term infants mean T ½ was 172 minutes. Mean CL was 
significantly lower in preterm infants when compared with term (0.116 
versus 0.170 l/kg/h) infants. In < 32 weeks GA infants, mean T ½ was 290 
while in more mature infants (32-36 weeks GA), mean T ½ was 265 
minutes. Correlation of GA with T ½ (r = - 0.46) was stronger than (birth) 
weight with T ½ (r = - 0.39). Linear regression analysis of GA on T ½ with 
95% confidence intervals is available in Figure 2. We could not document a 
significant difference in T ½ nor in other clinical characteristics (birth 
weight, GA) between preterms (< 35 weeks GA) who received (n = 13) and 
preterms (n = 6) who did not receive prenatal steroids (betamethasone) for 
lung maturation. Neither could we document any gender-related differences 
in pharmacokinetics in this study.  
 
Pharmacodynamics: since this is a single dose study, other analgesics were 
allowed. 15/30 infants received at least one other analgesic [(fentanyl (11), 
tramadol (6), ibuprofen-lysine (1)] during the first 24 hours based on the 
standardized evaluation by pain score (Leuven neonatal pain scale). In the 
hours before APAP was administered, stage 1 (pain scale < 4) was 
documented in 26/30 infants, during the period when a therapeutic level (> 
5 mg/l) was reached, it was 30/30 and thereafter it was 24/30. If we 
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consider only infants (n = 15) who did not receive any analgesic besides 
APAP in the first 24 hours, level 1 of analgesia was documented in 14/15 
infants before administration, in 15/15 infants in the period when a 
therapeutic level (> 5 mg/l) was reached and in 12/15 infants after this 
period.  
Figure 2 Linear regression analysis with 95% confidence intervals of gestational 
age (GA) on serum half life (T ½) (r= -0.46). 
 
 
Discussion 
 
Mean serum half life (T ½) in preterm infants was 277 (SD 143) and was 
172 (SD 59) in term infants (P < 0.05) while clearance (CL) was 0.116 (SD 
0.08) l/kg/h in preterm and 0.170 (SD 0.06) in term infants (P < 0.05) in 
this single dose study. Pharmacokinetics and –dynamics of propacetamol 
are documented in adults and children but there is only one single study on 
pharmacokinetics in infants younger than 1 year (n = 12, of which 5 infants 
< 10 postnatal days) and there are no data of propacetamol in preterm 
neonates. Pharmacokinetics of propacetamol in this study were compared 
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with pharmacokinetics of APAP and propacetamol in other cohorts 
described in literature.  
 
Term neonates 
Findings in term infants are in line with the single study on intravenous 
propacetamol.10 Autret documented pharmacokinetics in 12 infants, of 
whom 5 neonates younger than 10 days. Serum half life in these 5 neonates 
was 210 (SD 30) minutes, CL was 0,149 (SD 0,067) l/kg/h while Vd was 
0,7 (SD 0,2).10 (Table 3) Pharmacokinetics after rectal administration of 
APAP in term neonates were studied by Van Lingen and Hopkins.11,18 Van 
Lingen (n = 10) documented a mean T ½ of 162 (SD 84) minutes and the 
mean T ½ in neonates studied by Hopkins (n = 9) was 228 minutes. There 
are no studies available on pharmacokinetics of APAP after nasogastric 
administration in the first day of life. Studies in neonates by Hopkins (n = 
3) and Anderson (n = 16) after nasogastric administration documented 
serum T ½ of 168 minutes and 576 minutes.9,19 Co-administration of 
opioids and its effect on gastric motility might at least partially explain 
these differences. There is a recent report on unintentional intramuscular 
administration of propacetamol in one term neonate.  
In that single case, calculated serum half life (T ½) was 210 minutes.20 
 
Table 3 Maturational trend (mean) of serum half life (T ½) and relative 
distribution volume (relative Vd) in the first year of life after intravenous 
administration of propacetamol, based on this population# and on the 
study of Autret10. (GA: gestational age).  
 
 Preterm# Preterm# Term# Term10 < 1 year10 
 < 32 GA 32-36 GA day1 < 10days 10-365 days 
 
Number infants 10 10 10 5 7 
T ½ (min) 290 265 172 210 126 
Relative Vd (l/kg) 0.66 0.56 0.61 0.7 0.9 
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Preterm infants 
Mean T ½ (< 37 GA) (n = 20) and CL after single dose administration were 
277 minutes and 0,116 l/kg/h in preterm infants while mean relative Vd was 
0.61 l/kg in this study. In < 32 weeks GA infants, mean T ½ was 290 (SD 
161), while in more mature infants (32-36 weeks GA) mean T ½ was 265 
(SD 121). Data on pharmacokinetics of APAP in preterm neonates are only 
available after rectal administration. Van Lingen studied pharmacokinetics 
after rectal administration of APAP in 28 preterm neonates in the first day 
of life (28-36 weeks GA).11 T ½ in the 28-32 weeks GA group was 660 (SD 
342) minutes and was 450 (SD 240) minutes in 32-36 weeks GA group. 
Mean maximal concentration was 12.5 and 7.5 mg/l and mean time to reach 
maximal concentration was 234 and 306 minutes (28-32 and 32-36 
weeks).11 Lin documented a maximal concentration of 8,38 (SD 3,9) mg/l 
and a time to reach maximal concentration of 78 (SD 40) minutes after 
rectal administration of 20 mg/kg in 5 preterm neonates.12 
 
These findings (T max and C max) are formulation specific but might be 
relevant in clinical care since therapeutic drug concentration after 
intravenous administration will be reached sooner.  
Combining pharmacokinetic data in term and preterm neonates in our 
population with the findings of Autret in neonates and infants, a 
maturational trend during the first year of life is documented (Table 3). This 
is in line with the developmental pharmacokinetics described after oral or 
rectal administration of APAP.7,9,10 
 
Although we could document a maturational trend in the pharmacokinetics 
of APAP after intravenous administration, overall correlation (r = -0.46) 
between GA and T ½ is still weak. In contrast to rectal and oral 
administration, differences in bio-availability (venous rectal drainage, 
gastro-intestinal motility) can not explain this variability. Further study is 
needed to document other variables potentially involved in this variability. 
Prenatal administration of betamethasone for lung maturation had no 
maturational effect on T ½ in this study. We could not document any 
gender-related differences in this study, in contrast to the findings reported 
in infants after rectal administration.11 
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Pharmacodynamic data suggest an analgesic effect of intravenous APAP in 
this population. The design (not blinded, other analgesics accepted) of this 
study does not allow to draw conclusions other than that multiple dose 
administration of intravenous APAP should be adjusted for GA. Based on 
the longer T ½ in preterm infants, either the interval should be longer or the 
dose should be lower, in line with reported regimens on rectal or oral 
administration.7,9,11  
 
Based on the major interindividual variability of PK in preterm infants, we 
believe it is too early to make any multiple dose recommendations in 
preterm infants. In term infants, a loading dose of 30 mg/kg propacetamol 
(i.e. 15 mg APAP), followed by 20 mg/kg every 6 hours might be 
considered. Since accumulation might still occur in the individual neonate, 
it is safe and feasible to determine plasma concentrations until additional 
data are available.  
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Abstract 
 
Background 
Data concerning metabolism of diclofenac in children are limited to 
intravenous and enteric coated oral formulations. There are no data 
examining diclofenac or its hydroxyl metabolite pharmacokinetics after 
rectal administration in children. 
 
Methods 
Infants (n = 26) undergoing tonsillectomy were given diclofenac 2 mg/kg 
followed by 1 mg/kg 8-hourly as suppository formulation for postoperative 
analgesia. Serum was assayed for diclofenac, 4’-hyroxy-diclofenac (D4OH) 
and 5’-hydroxy-diclofenac (D5OH) concentrations during the procedure 
and 1, 2 and 3 h postoperatively. The formation clearances of diclofenac to 
hydroxyl metabolites were estimated using non-linear mixed effects 
models. A single compartment, first order absorption and first order 
elimination model was used to describe diclofenac pharmacokinetics. 
 
Results 
Mean (SD) age and weight of the patients were 4.5 (1.5) years and 20.5 
(4.1) kg. The formation clearance to D4OH (% CV) and to D5OH were 
8.41 (8.1) and 3.41 (113) l/h respectively, standardized to a 70 kg person 
using allometric ‘¼ power’ models. Clearance by other routes contributed 
33.0 (64) l/h/70kg. Elimination clearance of hydroxyl metabolites was fixed 
at 27.5 l/h/70kg. The volumes of distribution of parent diclofenac and its 
hydroxyl metabolite were 22.8 (19.0) and 45.3 l/70kg. The suppository 
formulation had an absorption half-life of 0.613 (33.2) h with a lag time of 
0.188 (24.9) h. Inter-occasion variability of formation clearance to D4OH, 
diclofenac volume of distribution, absorption half-time and lag time for the 
suppository was 36%, 55%, 14% and 119% respectively. The relative 
bioavailability of the suppository compared to an enteric-coated tablet was 
1.26. 
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Conclusion 
The formation clearance of the active metabolite D4OH contributed 19% of 
total clearance (44.82 l/h/70kg). The rectum is a suitable route for 
administration of diclofenac in children 2-8 years of age and was associated 
with a higher relative bioavailabilty than enteric-coated tablets and an 
earlier maximum concentration (50 vs. 108 min). This pharmacokinetic 
profile renders diclofenac suppositories a suitable formulation for short 
duration surgery. 
 
 
Introduction 
 
Diclofenac, 2-[(2,6-dichlorophenyl) amino] benzene acetic acid, is a non-
steroidal anti-inflammatory drug with an approximate relative COX-
1/COX-2 specificity ratio of one.1 Diclofenac has reversible anti-platelet 
effects that are attributable to the inhibition of thromboxane synthesis. It 
has been used after tonsillectomy2-4 and is believed to be associated with a 
decreased propensity to postoperative bleeding than ketorolac.5-10 
Formulations may be administered orally, topically, intraocularly, intra-
articular, intravenously, intramuscularly and rectally. Diclofenac 
pharmacokinetic parameters have been estimated after intravenous11 and 
oral formulations3 in children, but there are no estimates after rectal 
administration and metabolite data in children are scant.12,13 Diclofenac is 
metabolized by P450 (CYP2C9, CYP3A4 and possibly CYP3A5) phase I 
hydroxylation and phase II conjugation.14-16 The principal metabolite in 
humans is the 4’-hydroxyl derivative of diclofenac (D4OH), metabolized by 
CYP2C9. D4OH has 30% of the anti-inflammatory and antipyretic activity 
of diclofenac in animal models.17 
 
We had the opportunity to examine diclofenac and metabolite serum 
concentrations in children 2-8 years old given diclofenac for management 
of tonsillectomy pain. Data from these patients were combined with those 
from a published study of children given diclofenac enteric-coated tablets 
after tonsillectomy.3 These pooled data were investigated using a 
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population-based approach that included size as the primary covariate. A 
concentration-response relationship for diclofenac has not been described 
and this current study investigates pharmacokinetics only. 
 
 
Methods  
 
Patients and methods 
The study was approved by the Medical Ethical Committee of the Erasmus 
MC, Rotterdam and written informed consent was obtained from parents. 
Children (ASA 1 and 2, 2-8 years) undergoing elective tonsillectomy with 
or without adenoidectomy were enrolled into the study. Exclusion criteria 
were a known coagulation defects, diclofenac administration within 24 
hours of surgery, diclofenac allergy, hepatic disease or abnormal renal 
function. 
Children were given diclofenac suppository 2 mg/kg 30 minutes before 
scheduled surgery. Blood samples (1 ml) for diclofenac, D4OH and 5’-
hydroxydiclofenac (D5OH) concentration assays were obtained through a 
peripheral venous catheter directly after induction, at the end of the 
procedure and 1, 2 and 3 hours after awakening.  
 
Suppository formulation 
The diclofenac sodium suppositories (with witepsol H15, synthetic 
saturated triglycerides with a chain length of C12-C18, as base) were 
manufactured in the hospital pharmacy. The diclofenac dose in the 
suppository never deviated more than 10%. The ingredients were obtained 
through regular commercial suppliers. Suppositories and ingredients 
conformed to the quality requirements in the European Pharmacopoeia. 
 
Diclofenac assay 
Diclofenac sodium was purchased from Sigma Aldrich (Saint Quentin 
Falavier, France), D4OH and D5OH were obtained from Novartis (Novartis 
International AG, Basel, Switzerland). All the solvents used were analytical 
grade.  
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The HPLC system consisted of a P quaternary P 1000 XR pump 
(ThermoQuest- TQ, Florida, USA), a TQ autosampler, a TQ UV 6000 
detector (280 nm) linked to TQ Spectranet for recording and storing 
throughout the analysis. A LC8 5µm particle size Supelcosil column (150 x 
4.6 mm, Supelco Bellafonte, USA) was used. The mobile phase was a 
mixture of acetonitrile /sodium acetate 50 mM (70/30, v/v) adjusted to pH 5 
by phosphoric acid and the flow rate 1.2 ml/min.  
Stock solutions of diclofenac (1 mg/ml), 4- and 5-hydroxymetabolites (500 
µg/ml) were prepared in methanol and stored at –20°C. Calibration 
standards (10-1000 ng/ml) and plasma controls (40, 200, 750 ng/ml) were 
prepared by appropriate dilutions of the stock solutions in drug-free plasma. 
Briefly, 500 µl of plasma sample, 100 µl of internal standard and 1500 µl 
H3PO4 (1M) were extracted in 8 ml of diethylether. After centrifugation, 
the organic layer was evaporated to dryness at 40°C under nitrogen. The 
residue is dissolved in a mixture of 50 mM sodium acetate and-methanol 
(v/v 50/50). 
 
Under the chromatographic conditions used, the retention times were 6.1, 
6.9, and 18.5 min for D5OH, D4OH, and diclofenac respectively. Recovery 
from extraction was over 90% for the three compounds. Calibration curves 
were linear over the range of 10 to 1000 ng/ml and coefficients of variation 
of the slope were between 2.8 and 5.8% (n = 5). The limit of quantification 
was 5 ng/ml for the three compounds. The intra and inter-assay coefficients 
of variation, determined from three quality controls (40, 200 and 750 ng/ml) 
were lower than 7%.  
  
 
Modeling 
 
Population parameter estimates 
Diclofenac metabolite data were converted to diclofenac mg equivalents 
using a molecular weight of 318 for diclofenac sodium and 312.7 for the 
D4OH and D5OH. Population parameter estimates were obtained using a 
non-linear mixed effects model. This model accounts for random between 
subject parameter variability and residual variability (random effects) as 
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well as between subject parameter differences predicted by covariates 
(fixed effects). The population parameter variability in model parameters 
was modeled by an exponential variance model. The covariance between 
clearance, distribution volume, lag time and absorption half-life was 
incorporated into the model. An additive and a proportional term 
characterized the residual unknown variability for diclofenac and the 
hydroxyl metabolite concentrations. Estimation used the first order 
conditional estimate method with the interaction option and ADVAN 6 with 
Tol = 5. Convergence criterion was 3 significant digits. A Compaq Digital 
Fortran Version 6.6A compiler with Intel Celeron 333 MHz CPU (Intel 
Corp., Santa Clara, CA) under MS Windows XP (Microsoft Corp., Seattle, 
WA) was used to compile NONMEM. 
Differential equations were used to describe the pharmacokinetics of 
diclofenac and its metabolites. 
 
 CLT   = CL2D4OH + CL2D5OH + CLEX 
 dCS/dt  = (Ka x dose  - CS x CLT) / V 
 dD4OH/dt  = (CL2D4OH x CS-CLDOH x CD4OH) / VOH 
 dD5OH/dt  = (CL2D5OH x CS-CLDOH x CD5OH) / VOH 
 
This model is shown in Figure 1. CLT is total diclofenac clearance, V is the 
volume of distribution for diclofenac, CS is diclofenac serum concentration, 
CD4OH is D4OH concentration, CD5OH is D5OH concentration, 
CL2D4OH is formation clearance to D4OH, CL2D5OH is formation 
clearance to D5OH, CLDOH is the elimination clearance of the hydroxyl 
metabolite, VOH is the volume of distribution of the hydroxyl metabolites, 
CLEX is diclofenac clearance by other routes, Ka is the absorption rate 
constant (= Ln(2)/Tabs), Tabs is the absorption half-life.  
 
The elimination clearance of the hydroxyl metabolites (CLDOH) can not be 
identified with the current study design, but a value of 27.5 l/h in adults has 
been reported by Landsorp et al.18  
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Figure 1  V = volume of distribution for diclofenac, VOH = volume of distribution 
for hydroxyl metabolites, CS = diclofenac serum concentration, 
CL2D4OH = formation clearance to D4OH, CL2D5OH = formation 
clearance to D5OH, CLDOH = elimination clearance of hydroxyl 
metabolites, CD4OH = D4OH serum concentration, CD5OH = D5OH 
serum concentration CLEX = clearance attributable to other pathways, 
Tabs = absorption half-life (Ln(2)/Ka), Tlag = Lag time 
 
Diclofenac was administered as an extravascular dose and both clearance 
and distribution volumes are confounded by bioavailability.  Frectal is used 
to refer to the relative bioavailability of the suppository compared to the 
oral formulation.  
The quality of fit of the pharmacokinetic model to the data was assessed by 
visual examination of plots of observed versus predicted concentrations. 
Models were nested and an improvement in the objective function was 
referred to the Chi-squared distribution to assess significance e.g. an 
objective function change (∆OBJ) of 3.84 is significant at α = 0.05.  
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Figure 2a 
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Figure 2b 
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Figure 2c 
 
Figure 2  Quality of fit of pharmacokinetic data. Individual Bayesian concentration 
predictions based on values of the parameters for the specific individual 
are compared to observed. The line x = y is the line of identity. 2a) serum 
diclofenac concentration data 2b) serum D4OH data 2c) serum D5OH 
data. 
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Covariate Analysis 
The parameter values were standardized for a body weight of 70-kg using 
an allometric model19 
 
Pi = Pstd x (Wi / Wstd) PWR 
 
where Pi is the parameter in the ith individual, Wi is the weight in the ith 
individual and Pstd is the parameter in an individual with a weight Wstd of 70 
kg.  The PWR exponent was 0.75 for clearance and 1 for distribution 
volumes.20-23 
  
Inter-occasion variability 
The between subject variability in NONMEM is modeled in terms of ETA 
(η) variables. Each of these variables is assumed to have mean 0 and a 
variance denoted by ω2, which is estimated. A covariance between two 
elements in η (e.g. CL and V) is a measure of statistical association 
between these two variables. Their covariance is related to their correlation 
(R) i.e.  
 
 R = covariance/√ (ωCL x ωV ) 
 
Between occasion variability for the structural parameters of clearance, 
apparent volume, rectal absorption half-life and lag time were added to the 
model because some children were given diclofenac on two different 
occasions. The between occasion covariance for clearance of D4OH, 
volume, absorption and lag time was also estimated. This covariance is 
effected by factors that affect these parameters together (e.g. protein 
binding, total body water), but variability of Frectal is the major contributor 
to this estimate.   
 
Determining relative rectal bioavailability 
In order to gain a better understanding of the suppository bioavailability 
relative to oral (Frectal), time-concentration profiles from 11 children 
(mean 11 y, range 5-15 y; mean 50 kg, range 22-67 kg) given enteric-coated 
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diclofenac tablets 25 or 50 mg (Diclon®, DuraScan Medical Products AS, 
Odense S, Denmark) after tonsillectomy from a published study were 
included in the analysis.3 These children were given diclofenac 1-2 mg/kg 
the morning after surgery. Blood samples for diclofenac assays were drawn 
at 0.5, 1, 1.5, 2, 2.5, 3, 3.5 and 4 h after administration. Blood was 
centrifuged and serum stored at –20oC until assay.  
 
Diclofenac concentrations in that study were measured using HPLC. The 
calibration curve was linear in the range up to 6 mg/l, with a minimal 
quantifiable concentration (MQC) of 0.06 mg/l. Intra-assay variations were 
2.9% for concentration of 0.6 mg/l and 1.8% for a concentration of 4.5 
mg/l. The inter-assay variation was 4.6% at both these concentrations. 
A first order process was initially used to estimate enteric-coated diclofenac 
absorption. However, a zero order model proved superior (∆OBJ 88.535) 
and the final model estimated a zero order absorption time (TK0) rather 
than an absorption half-life (Tabs). The variability between this published 
study by Rømsing et al3 and the current study was accounted for by giving 
each study separate residual errors. 
 
 
Results 
 
Population Demographics 
Mean (SD) age and weight of the patients were 4.5 (1.5) years and 20.5 
(4.1) kg. There were 14 boys and 12 girls. 
 
Parameter estimates 
The total analysis used 314 concentration observations from 37 subjects. 
Parameter estimates, standardized to a 70-kg person are shown in Table 1. 
The covariance of the pharmacokinetic parameters, expressed as the 
correlation of population parameter variability was low, except that 
between clearance and absorption (Table 2). Figure 2a, 2b & 2c show 
pharmacokinetic data analysis fits. 
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Table 1 Pharmacokinetic parameter estimates.   
These estimates are standardized to a 70-kg person using an allometric 
size model (%CV is the coefficient of variation for the population 
parameter estimate, except for V, CL2D4OH, Tabs and Tlag where 
between subject (BSV) and between occasion variability (BOV) were 
estimated. 
 
Parameter Estimate CV % 
CLT 44.82 l/h/70kg  
V 22.8 l/70kg BSV 19.0 
BOV 54.9 
CL2D4OH 8.41 l/h/70kg BSV 8.1 
BOV 35.8 
CL2D5OH 3.41 l/h/70kg 113.1 
CLEX 33.0 l/h/70kg 64.0 
CLDOH 27.5 l/h/70kg FIXED  
Tabs rectal 0.613 h BSV 33.2 
BOV 13.9 
Tlag rectal  0.188 h BSV 24.9 
BOV 119.2 
TK0 oral 0.563 h - 
Tlag oral 1.5 h 24.9 
F rectal 1.26  - 
 
CLT = population estimate for CL/Foral (clearance after oral 
administration L/h/70kg), V = volume of distribution for diclofenac and 
hydroxy metabolites, CL2D4OH = formation clearance to D4OH, 
CL2D5OH = formation clearance to D5OH, CLDOH = elimination 
clearance of hydroxy metabolites, CLEX = clearance attributable to other 
pathways, Tabs = absorption half-life (Ln(2)/Ka), TK0 = zero order 
infusion time, Tlag = Lag time, Frectal is the relative bioavailability of 
the rectal compared to the oral formulation. 
 
 
Table 2.  The covariance of the pharmacokinetic parameters, expressed as the 
   correlation of population parameter variability 
 
  CL2D4OH Tabs Tlag V 
CL2D4OH 1    
Tabs 0.875 1   
Tlag -0.014 0.021 1  
V -0.054 -0.149 -0.50 1 
 
Chapter 2.4 
 
84
The formation clearance to D4OH (CL2D4OH) and to D5OH (CL2D5OH) 
were 8.41 (8.1) and 3.41 (CV, 113%) l/h respectively, standardized to a 70 
kg person using allometric ‘¼ power’ models. Clearance by other routes 
(CLEX) contributed 33.0 (64) l/h/70kg. Elimination clearance of hydroxyl 
metabolites (CLDOH) was fixed at 27.5 l/h/70kg. The volumes of 
distribution of parent diclofenac (V) and its hydroxyl metabolite (VOH) 
were 22.8 (19.0) and 45.3 l/70kg. The suppository formulation had an 
absorption half-life (Tabs) of 0.613 (33.2) h with a lag time (Tlag) of 0.188 
(24.9) h. Enteric-coated tablets had a TK0 of 0.563 and a Tlag of 1.5 (24.9). 
Inter-occasion variabilities of formation clearance to D4OH, diclofenac 
volume of distribution, absorption half-time and lag time for the 
suppository were 36%, 55%, 14% and 119% respectively (Table 1). The ω2 
estimates for the different components contributing to variability are shown 
in Table 3. The relative bioavailability of the suppository compared to an 
enteric-coated tablet was 1.26. Figure 3 shows typical time-concentration 
profiles for diclofenac and the hydroxyl metabolites for an individual. 
 
Residual errors for diclofenac concentrations were similar for both data 
sets. The current data additive and proportional errors were 0.009 mg/l and 
0.349%, while those from Rømsing et al’s data were 0.053 mg/l and 
0.204%. The additive and proportional errors for 4’-hyroxydiclofenac were 
0.023 mg/l and 0.273%. An additive error for 5’-hyroxydiclofenac was 
0.063 mg/l. 
 
Table 3.  The between-occasion covariance for clearance of D4OH, volume, 
absorption and lag time. 
 
  CL2D4OH Tabs Tlag V 
CL2D4OH 1    
Tabs 0.999 1   
Tlag 0.122 0.071 1  
V -0.110 -0.124 -0.011 1 
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Figure 3 Diclofenac and hydroxyl metabolite time-concentration profiles for a 4 
year old, 19 kg boy given diclofenac suppository 37.5 mg. 
 
 
Discussion 
 
We report a clearance, standardized to a 70-kg person using allometric size 
models, of 44.82 l/h/70kg and volume of distribution of 22.8 l/70kg in 
children given oral diclofenac tablets. Allometric size models23 are based on 
fractal geometry21,22 and have been used to estimate pediatric 
pharmacokinetics of other NSAIDs e.g. ibuprofen in children 4-16 year.24 
These models disentangle age-related factors from those related to size. The 
clearance of ketorolac in children, for example, is reported to be similar to 
adult values when data from different age groups are pooled.25 However, a 
child 1-3 y has a higher clearance than a child 12-16 y and this difference is 
attributable to size (Table 4a). Similar age-related clearance changes 
(l/h/kg), predicted using the current data for diclofenac are shown in Table 
4b.  
Rømsing et al3 reported a standardized clearance of 48.5 l/h/70kg (assuming 
a mean weight of 50 kg). A clearance of 0.462 (SD 90) l/kg/h, however, 
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was reported in children 4.3-6.8 years given 0.5 mg/kg of intravenous 
diclofenac using a standard two-stage population approach.11 This 
standardized clearance of 23.6 l/h/70kg (assuming a mean weight of 20 kg) 
is less to our current estimate. The standard two-stage approach used in 
these earlier studies is incapable of investigating covariates such as weight, 
does not account for the imprecision of individual estimates and may 
require weighting if estimates are skewed. It is also possible to have strong 
correlation between parameter variability, so that both clearance and 
volume estimates are affected by each other. 
The volume of distribution of diclofenac in adults is 7-14 l/70kg.12 This 
small volume is due to high plasma protein binding (>99.7%) and minimal 
tissue binding. Although reduced protein binding has been reported for 
some NSAIDs in children,26 the magnitude of protein binding differences is 
small and is unable to explain reported volumes of distribution of 50-63 
l/70kg for diclofenac in children.3,11 Our current estimate of 22.8 in children 
2-15 y is reasonable.  
 
Table 4a  Ketorolac age related pharmacokinetic changes. 
Data from Dsida et al. Anesth Analg 2002;94: 266-70 (n = 36)25  
 
Age 
years 
Weight 
kg 
Vss (S.D.) 
 l/kg 
CL (S.D.) 
l/min/kg 
CLstd (S.D.) 
l/min/70kg 
1-3  12  0.111 (0.0 25) 0.6 (0.2) 27.0 (9.0) 
4-7  20  0.128 (0.047) 0.61 (0.22) 31.2 (11.3) 
8-12  30  0.099 (0.014) 0.54 (0.15) 30.6 (8.5) 
12-16  50  0.116 (0.040) 0.51 (0.12) 32.8 (7.7) 
Adult38 70  0.11 0.3-0.55 21-38.5 
 
CLstd is total body clearance standardized to a 70 kg person using an 
allometric ¾ power model. Weight is estimated 
 
Table 4b  Predicted diclofenac age related pharmacokinetic changes 
  (based on current study) 
 
Age years Weight kg CL l/h/kg CLstd l/h/70kg 
1-3  12  1.00 44.82 
4-7  20  0.88 44.82 
8-12  30  0.79 44.82 
12-16  50  0.70 44.82 
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Suppositories have a reduced relative bioavailability compared to the oral 
formulations for most drugs.27,28 attributable to erratic absorption and loss 
through the anal sphincter. Diclofenac suppository in this study had a 
relative bioavailability of 1.26. Diclofenac is rapidly and well absorbed by 
the intestinal tract from suppositories18 and we report an absorption half-life 
of 0.613 with a lag time of 0.188 h. The relative bioavailability from the 
colon in adults was 0.78 (range 0.54-1.09).29 The absolute bioavailability is 
90% (SD 11.6%) after oral administration in adults30,31 but there are reports 
that diclofenac may undergo first pass metabolism with 60% of the drug 
reaching the systemic circulation as intact diclofenac.32,33 The rectal route 
may be better than oral for drugs destroyed by gastric acidity or by enzymes 
in the intestinal wall and microflora. Venous drainage from the rectum 
through the inferior and middle haemorrhoidal veins may bypass the 
hepatic portal circulation and result in a rectal relative bioavailabilty 
(Frectal) greater than 1. Other NSAIDs have also reported high relative 
rectal bioavailability. The relative bioavailability of suppository compared 
to oral flurbiprofen was 0.998 in children 6-12 years of age.34 
 
Diclofenac metabolites in man have been described in urine and plasma 
after single dose administration.16,18,35. These comprise of D4OH, D5OH, 
3’-hydroxy, 4’,5’-hydroxy and 3’-hydroxy-4’-hydroxy-methoxy diclofenac 
in adult volunteers. The amount of D4OH excreted in urine accounts for 
30% of the dose and 10-20% of the dose in bile in adults.14,15,30 The 
metabolite proportions are unknown in children and we were unable to 
estimate these from the current study design. Landsdorp et al18 estimate an 
apparent total body clearance for D4OH of 27.5 (SD 10.9) l/h in adult 
volunteers and we assumed this value for the current study. The volume of 
distribution of this metabolite is unknown. We estimate an hydroxyl 
metabolite volume of 45.3 l/70kg. The greater volume of the hydroxyl 
metabolites, compared to the parent diclofenac, could be due to decreased 
protein binding, but this is currently unknown. D4OH contained in serum 
samples may be further oxidized to 4’,5-dihydroxydiclofenac, increasing 
the error of the estimate.18  
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Figure 4 Simulated time-concentration profiles for a typical 20-kg individual 
given diclofenac suppository 2mg/kg, diclofenac enteric-coated tablet 2 
mg/kg, APAP suppository 40 mg/kg and APAP elixir 40 mg/kg. APAP 
parameter estimates are from Anderson et al.39 Diclofenac parameter 
estimates are from current study. 
 
The analysis of the 5’-hydroxyl metabolite was less satisfying. Most serum 
sample concentrations were below the MQC (0.05 mg/l) and only three 
children had complete time-concentration profiles above MQC. 
Consequently we have less confidence in the elimination clearance of this 
metabolite. 
Figure 4 shows simulated time-concentration profiles for a diclofenac 
suppository and enteric-coated tablet in a 20-kg child compared to profiles 
for paracetamol (APAP) suppository and elixir. Peak concentrations are 
reached earlier after diclofenac suppository than APAP elixir. Diclofenac 
absorption is rapid by the rectal route. The effect compartment equilibration 
half-time (Teq) of diclofenac analgesia is unknown, but that for analgesia in 
adults with bone pain given ketorolac (25 min)36 is less than that for 
children suffering tonsillectomy given APAP (52 min).37 We might predict 
that the Teq for diclofenac analgesia is also less than that for APAP 
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analgesia and that the diclofenac suppository is a suitable formulation for 
short duration surgery because effect onset is quicker than APAP.  
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Abstract 
 
Background 
Analgesic paracetamol (APAP) plasma concentrations after major surgery 
in neonates and infants have not yet been established in the literature. We 
therefore conducted a study in our intensive care unit. 
 
Methods 
Forty children, mean (SD) age, 10.3 (2.3) months, received 20 mg/kg 
APAP either orally (n = 20) or rectally (n = 20) 6-hourly after a rectal 
loading dose (40 mg/kg) during elective craniofacial correction. Blood 
samples were taken 1 hour before and 2 hours after administration of APAP 
maintenance doses; pain scores were obtained every 3 hours. 
 
Results 
APAP plasma concentrations were higher in patients receiving rectal APAP 
(mean area under the concentration-time curve [AUC], 171.2 mg.h/l) than 
in patients receiving oral APAP (mean AUC, 111.9 mg.h/l). Pain scores 
were higher in patients receiving oral APAP. However, after exclusion of 
the patients who vomited from the patients receiving oral APAP, APAP 
plasma concentrations and pain scores did not differ between the groups. 
There was no relation between APAP plasma concentrations and pain 
scores. Although 9 of all 40 patients (22.5%) did not reach the expected 
analgesic APAP plasma concentrations of 10 to 20 mg/l, < 7.5% of the 
VAS pain scores exceeded 4 cm, which was considered as a cut off point. 
 
Conclusion 
These are the first data showing that the analgesic APAP plasma 
concentration after major surgery in this age group, does not always reach 
the 10 to 20 mg/l level. These data also show that, after a rectal loading 
dose of 40 mg/kg has been given during surgery, the best way of 
administering APAP after craniofacial surgery is the rectal route. (Clin 
Pharmacol Ther 2001;70:82-90.) 
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Introduction 
 
Paracetamol (APAP) is widely used for postoperative analgesia in patients 
who experience moderate pain. Dose-effect relationships,1 dose-
concentration relationships,2 and effects of APAP on body temperature3 in 
children have been reported in the literature. Findings in newborns 
receiving APAP after vacuum extraction have been published recently by 
our group.4 However, there are no data on the analgesic APAP plasma 
concentrations in neonates and infants after major surgery.  
 
In children aged from 2 to 15 years undergoing tonsillectomy, an APAP 
plasma concentration of 10 mg/l is considered necessary to achieve 
satisfactory pain relief.5 The optimal plasma concentration to obtain 
analgesia is usually considered to be 10 to 20 mg/l,6,7 a level that is 
extrapolated from findings in adults. 
 
Because the absorption rate and bioavailability of orally administered 
APAP differ from those in rectally administered APAP 6,8,9 and oral 
medication may cause nausea and vomiting, it is important to obtain 
information about both routes of administration.  
 
The delayed and erratic absorption after rectal administration leads to 
unpredictable APAP plasma concentrations and does not consistently 
produce rapid onset of analgesia.10 An APAP rectal loading dose of at least 
30 to 40 mg/kg is therefore recommended to achieve satisfactory pain 
relief.11 The advised maximum daily dose of APAP is 90 to 100 mg/kg, 
which then allows for 3 doses of 20 mg/kg after an initial loading dose of 
40 mg/kg. 
In a randomized controlled trial we compared the efficacy of both oral and 
rectal APAP administration in young children undergoing major 
craniofacial surgery by comparing APAP plasma concentrations with 
changes in scores for two validated pain measurement instruments for this 
age group.12  
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We primarily aimed at determining the differences in APAP plasma 
concentrations and effects between children receiving either multiple doses 
of APAP rectally or equal doses of oral APAP after an initial rectal loading 
dose. The secondary aim of the study was to determine a dose-plasma 
concentration and a plasma concentration-effect relation of both orally and 
rectally administered APAP in children aged 3 months to 3 years after 
elective major craniofacial surgery. 
 
 
Methods  
 
Patients and methods 
The Sophia Children’s Hospital serves as a level III referral centre for all 
pediatric surgical subspecialties. As such, it is the only designated pediatric 
craniofacial center in the Netherlands. Approximately 100 major 
craniofacial corrections are performed annually. 
 
After approval of the study by the Medical Ethical Committee of the 
University Hospital Rotterdam and after written informed consent was 
obtained from the parents, 45 children were enrolled consecutively during 
the period from March 1999 through March 2000. Inclusion criteria were 
age between 3 months and 3 years and elective craniofacial correction for 
different forms of craniosynostosis. Exclusion criteria were craniotomy of 
tumors, hydrocephalus, or trauma, pre-existent liver or kidney disorders as 
reflected by abnormal values of liver enzymes, bilirubine, urea, and 
creatinin, severe mental retardation, Glasgow Coma Score < 8, 
postoperative mechanical ventilation, and known allergy for APAP.  
 
Participant flow and follow-up 
The eligible number of patients was 54. Because the parents of 9 children 
did not give informed consent, 45 of them were included in this study. Five 
of the 45 included patients were later excluded from analysis for various 
reasons as follows: logistic problems with the delivery of the study 
medication (2 patients), returning from the operating room with mechanical 
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ventilation (1 patient), and withdrawal of the parental informed consent 
during the study (2 patients). These 5 patients were found not to differ from 
the 40 included patients with regards to operation procedure, blood loss, 
and pain scores. 
Hence the data of 40 patients were analyzed for this study, 20 receiving oral 
APAP and 20 receiving rectal APAP. 
 
Procedure 
By protocol, anesthesia was induced with the patients under either 
sevoflurane or intravenous thiopental. After administration of vecuronium 
and 3 µg/kg fentanyl intravenously, the patients were intubated and 
ventilated with air, oxygen, and isoflurane. An arterial catheter, central 
venous line, nasogastric tube, and urinary catheter were inserted while the 
patients were under anesthesia. The scalp was infiltrated with bupivacaine 
0.25% and epinephrine 1:200,000 up to a maximum of 1 ml/kg. Before the 
skin incision was made, fentanyl 15 to 25 µg/ kg was administered 
intravenously. Approximately 2 hours before anticipated extubation, a 
loading dose of APAP (40 mg/kg) was administered rectally. Usually at this 
time major blood loss had been adequately compensated and the patient was 
hemodynamically stable. After the operation patients were admitted to the 
Pediatric Surgical Intensive Care Unit (PSICU) for a minimum of 24 hours, 
depending on the clinical condition. 
 
Two hours (t = 2) after arrival in the PSICU, patients underwent a gastric 
lavage until the gastric fluid was clear on aspiration. The 20-mg/kg APAP 
maintenance doses were given at t = 6, t = 12 and t = 18 hours. Oral 
medication was given via the nasogastric tube. If the nasogastric tube had 
been accidentally removed, the medication was given by mouth. 
 
Blood samples were taken from the arterial catheter at 30, 60 and 90 
minutes after the rectal loading dose of APAP and at t = 5, t = 8, t = 11, t = 
14, t = 17, and t = 20 hours. Samples were taken 1 hour before (minimum 
APAP plasma concentration) and 2 hours after (maximum APAP plasma 
concentration) the administration of an APAP maintenance dose.13 
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Trained intensive care nurses obtained pain scores every 3 hours (t = 3, t = 
6, t = 9, t = 12, t = 15, t = 18, t = 21 and t = 24 hours), using the visual 
analogue scale (VAS) and the COMFORT score.12,14,15 From the original 
COMFORT score the behavioral items were summed as published 
recently.12 With regard to the VAS used as an observational instrument, 
there is evidence that, first the interrater reliability is good between nurses 
or between nurses and physicians in judging postoperative pain in pediatric 
samples.16-21 Second, the concurrent validity with other observational pain 
instruments has also been established by different authors.12,16 22 
 
An extra dose of the study medication was given if the VAS score was ≥ 4 
cm. Blood samples were taken just before administration of the extra dose 
and 2 hours thereafter. The next dose of the study medication was then 
administered according to the protocol schedule. APAP plasma 
concentrations were determined using fluorescence polarization 
immunoassay (Adx system; Abbott Laboratories, North Chicago Ill).11 
The study design is represented schematically in Figure 1a & 1b. 
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Figure 1a 
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The study protocol was stopped if the parents withdrew their informed 
consent during the study or if the patient returned from the operating room 
with mechanical ventilation. In the former case all data of the patient 
involved were excluded from further analysis and the randomization 
number was not used again. 
 
Statistical methods 
The area under the concentration-time curve (AUC) of the APAP plasma 
concentrations and of the pain scores of patients receiving either oral APAP 
or rectal APAP were compared per group using the Mann-Whitney U test 
(both the pain scores and the APAP plasma concentrations had nonnormal 
distributions; P = 0.05).23  
After logarithmic transformation of the mean APAP plasma concentrations 
and of the mean pain scores, multiple regression analysis was performed to 
establish the relation between APAP plasma concentrations and pain scores. 
Corrections were made for receiving oral or rectal APAP, for receiving an 
extra dose of APAP, and for vomiting in patients receiving oral APAP. 
 
Assignment 
The randomization schedule for oral or rectal administration had been made 
before the study by computer block randomization. After inclusion of a 
patient, the hospital’s pharmacist prepared the study medication according 
to the randomization schedule. The schedule was kept solely by the 
pharmacist to ensure blinding until the end of the study. 
 
Masking (blinding) 
The study medication of patients receiving rectal APAP consisted of APAP 
suppositories and placebo elixir, that of patients receiving oral APAP 
consisted of APAP elixir and placebo suppositories. Since all children 
received both an elixir and a suppository and since APAP suppositories 
(with APAP and witepsol H15, synthetic saturated triglycerides with a 
chain length of carbon 12 to 18 as the basis), elixir (with APAP 24 mg/ml, 
glycerol 85%, sodium lactate, raspberry essence and sorbitol solution), and 
placebos were all manufactured in the department of the hospital pharmacy, 
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patients, nurses and investigators were blinded for the route of the actual 
APAP administration.  
 
The composition of the placebo suppositories and placebo elixir was equal, 
except for the APAP. The APAP doses in the suppositories never deviated 
more than 10% (18-20 mg/kg). APAP was supplied by Bufa bv (Uitgeest, 
the Netherlands). The suppositories, the elixir, and all ingredients met the 
requirements in the European Pharmacopoeia. APAP suppositories and 
elixir were manufactured according to the Dutch Pharmacists Formulary. 
Stability of these preparations is tested by the laboratory of the Royal Dutch 
Association of Pharmacists. 
 
 
Results 
 
Analysis 
The mean (standard deviation [SD]) age of the patients receiving oral 
APAP was 10.0 (2.7) months, and their mean (SD) weight was 9.2 (1.1) kg. 
Patients receiving rectal APAP had a mean (SD) age of 10.6 (1.9) months 
and a mean (SD) weight of 9.4 (1.5) kg.  
There were no significant differences between patients receiving oral APAP 
and patients receiving rectal APAP with respect to age, weight, gender, 
baseline heart rate, baseline mean arterial pressure, duration of the 
operation, amount of blood loss during the operation, and the operative 
procedures (Table 1). 
 
Confounders 
In both groups 3 patients required an extra dose of APAP (rectal APAP: t = 
5, t = 14, and t = 4 hours; oral APAP: t = 3, t = 4 and t = 9 hours). 
Eleven patients receiving rectal APAP and 12 patients receiving oral APAP 
vomited once or twice. Of the latter, 5 required metoclopramide and 1 
required domperidon; of the former, 3 required metoclopramide and 2 
required ondansetron.  
Because of restlessness or presumed fear, midazolam was given to 3 
patients receiving oral APAP and to 2 patients receiving rectal APAP. 
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Table 1 Characteristics of patients  
 Rectal group (n = 20) Oral group (n = 20)
Age (mo)  
 Mean (SD) 
 Range 
 
10.6 (1.9) 
8-15 
 
10.0 (2.7) 
6-20 
Weight (kg) 
 Mean (SD) 
 Range 
 
9.4 (1.6) 
5.4-12.2 
 
9.2 (1.1) 
6.7-11.0 
Sex 
 Male 
 Female 
 
15 
5 
 
14 
6 
Condition requiring operative correction 
 Scaphocephaly 
 Trigonocephaly 
 Plagiocephaly 
 Brachycephaly 
 
10 
6 
2 
2 
 
10 
1 
7 
2 
Duration of operation( min)  
 Mean (SD) 
 Range 
 
221 (40) 
175-315 
 
214 (26) 
170-270 
Amount of blood loss (ml) 
 Mean (SD) 
 Range 
 
983 (560) 
400-2800 
 
741 (448) 
300-2000 
Baseline heart rate (beats/min) 
 Mean (SD) 
 Range  
 
141 (26) 
75-195 
 
148 (23) 
105-195 
Baseline mean arterial pressure (mm Hg) 
 Mean (SD) 
 Range  
 
78 (15) 
53-106 
 
73 (12) 
48-93 
 
APAP plasma levels 
The rectal loading dose of 40 mg/kg resulted in widely varying APAP 
plasma concentrations (mean values [SD] at 30, 60 and 90 minutes after the 
rectal loading dose: 2.0 [2.8] mg/l, 4.2 [5.4] mg/l, and 6.3 [7.4] mg/l 
respectively) (Figure 2a). There was no difference between the rectal and 
the oral group in mean APAP plasma concentrations after the rectal loading 
dose. The AUC of the APAP plasma concentrations (t = 5 to t = 20 hours) 
was significantly higher in patients receiving rectal APAP (mean AUC, 
171.2 mg.h/l) than in the patients receiving oral APAP (mean AUC, 111.9 
mg.h/l) (P = 0.004) (individual values of APAP plasma concentrations are 
depicted in Figure 2b). After exclusion of those patients who vomited in the 
oral group, there was no longer a significant difference anymore between 
the AUCs in the two groups (mean AUC rectal group: 171.2 mg.h/l and 
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mean AUC oral group after exclusion of patients who vomited: 144.3 
mg.h/l) (P = 0.3).  
 
The APAP plasma concentrations at the time of the extra APAP 
administration were 5.5, 13.5 and 0.9 mg/l in the patients receiving rectal 
APAP and 15.8, 7.5 and 4.9 mg/l in the patients receiving oral APAP. 
 
In all patients, both in the oral and in the rectal group, APAP plasma 
concentrations ≥ 5 mg/l were reached at least at one sampling point. Among 
all patients 22.5% showed APAP plasma concentrations of 5 to 10 mg/l 
(oral group, 35%, rectal group 10%). APAP plasma concentrations of 10 to 
15 mg/l were reached by 27.5% of all patients (oral group 20%; rectal 
group, 35%); 20% reached APAP plasma concentrations of 15 to 20 mg/l 
(both in the oral and in the rectal group, 20%); APAP plasma 
concentrations ≥ 20 mg/l were reached in 30% of all patients (oral group, 
25%, rectal group, 35%).  
 
Pain scores 
The AUC of the COMFORT scores (mean AUC rectal group: 265.4; mean 
AUC oral group: 286.2) and the AUC of the VAS scores (mean AUC rectal 
group: 16.1 cm.h; mean AUC oral group: 22.5 cm.h) were significantly 
higher in patients receiving oral APAP (P = 0.02 and P = 0.04 respectively) 
(individual VAS and COMFORT scores and means are depicted in Figure 
3a & 3b). However, there was no significant difference after exclusion of 
the patients who vomited in the oral group (mean AUC COMFORT scores 
and mean AUC VAS scores oral group after exclusion of the patients who 
vomited: 279.9 and 22.5 cm.h, respectively) (P = 0.2 and P = 0.2 
respectively). 
 
Multiple regression analysis with corrections for receiving oral or rectal 
APAP, for receiving an extra dose of APAP, and for vomiting in patients 
receiving oral APAP showed no significant relation between the APAP 
plasma concentrations and the pain scores (ie, the VAS score and the 
COMFORT score [P = 0.2 and P = 0.2 respectively]). 
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Figure 2a Mean APAP plasma concentration 
 
Figure 2b Solid line: Mean APAP plasma concentration rectal group;  
dashed line: Mean APAP plasma concentration oral group;  
dotted line: Mean APAP plasma concentration in oral group after 
exclusion of patients who vomited;  
triangles: patient receiving oral APAP;  
squares: patient receiving rectal APAP 
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Figure 3a Solid line: Mean VAS score in rectal group; 
Dashed line: Mean VAS score oral group; 
Dotted line: Mean VAS score oral group after exclusion of patients who 
vomited; 
Triangles: patient receiving oral APAP; 
Squares: patient receiving rectal APAP 
   
Figure 3b Solid line: Mean COMFORT score in rectal group; 
Dashed line: Mean COMFORT score oral group; 
Dotted line: Mean COMFORT score oral group after exclusion of 
patients who vomited; 
Triangles: patient receiving oral APAP; 
Squares: patient receiving rectal APAP 
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The percentage of VAS scores < 4 cm was 93.6% at APAP plasma 
concentrations of 0 to 5 mg/l, 97,8% at 5 to 10 mg/l, 100%, at 10 to 15 
mg/l, 92.5% at 15 to 20 mg/l, and 100% at concentrations > 20 mg/l. 
Although the VAS scores decreased slightly over time, with an increase at t 
= 18 hours, the COMFORT scores increased slightly over time. 
 
The percentage of VAS scores ≥ 4 cm declined over time. The median 
APAP plasma concentration at VAS scores ≥ 4 cm was 5.6 mg/l (25th 
percentile, 2.3 mg/l; 75th percentile, 9.0 mg/l). 
 
 
Discussion 
 
The APAP plasma concentrations in patients receiving rectal APAP were 
significantly higher than those in patients receiving oral APAP. This is 
surprising, since previous studies showed lower concentrations after rectal 
administration compared with oral administration at the same doses.7,9 A 
possible explanation for the lower concentrations after oral administration is 
that patients in the oral group who vomited, received little or no APAP at 
all at a given time point. After exclusion of these patients, there was indeed 
no significant difference in APAP plasma concentrations, although the 
rectal concentrations were still higher than the oral concentrations. Another 
explanation is that the peak APAP plasma concentration after oral 
administration was missed as a result of sampling 2 hours after the 
maintenance dose was administered. Normally, the peak plasma 
concentration after oral APAP administration is expected within 30 to 60 
minutes.24 However the slower gastric emptying in patients after general 
anesthesia results in a peak plasma concentration after 90 to 120 minutes,24 
which makes it less probable that the peak plasma concentration is missed. 
Also normal adult rate of gastric emptying may not be reached until the age 
of 6 to 8 months.9 Before normal adult rates are reached, gastric emptying is 
slow and erratic,9,25 and gastric emptying and drug absorption is inhibited 
by narcotic analgesics.26 
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Pain scores were significantly higher in those patients receiving oral APAP 
and thus inversely related to the lower APAP plasma concentrations in 
these patients.  
However, a significant relation between APAP plasma concentrations and 
pain scores could not be established. Other studies in infants delivered by 
vacuum extraction at term also report absence of such a relation.4 
 
Since ondansetron has no psychoactive properties and domperidon and 
metoclopramide have only weak psychoactive properties, it is very unlikely 
that a single dose of these antiemetics had influence on the pain scores. On 
the other hand, midazolam, which does not have significant analgesic 
properties, might have had influence on the pain scores, especially on the 
COMFORT score, because this rating scale is a measurement instrument for 
distress. However, the VAS score should not be influenced by midazolam. 
 
The required analgesic APAP plasma concentrations of 10 to 20 mg/l6,7 
were not reached by 22.5% of all patients during the 24-hour observation 
period. However, still more than 92.5% of the VAS scores in these patients 
did not exceed 4 cm. Studies in adults showed that APAP plasma 
concentrations of 6 to 24 mg/l, after intravenous administration, produce 
adequate analgesia.27,28 Since APAP plasma concentrations ≥ 5 mg/l were 
reached in all the children in our study and more than 92.5% of VAS scores 
in all children were under 4 cm, the analgesic range for this age group could 
well be < 10 to 20 mg/l.  
 
The slight decrease in VAS scores over time is explained by the fact that 
the most intense pain usually occurs in the first hours after the operation 
and then slowly decreases. At t = 18 hours there was a sudden increase in 
VAS scores preceded by a low APAP plasma concentration at t = 17 hours. 
Taking into account this low value and the absence of a relation between 
APAP plasma concentrations and pain scores are, the low plasma 
concentrations at t = 17 hours cannot (fully) explain the sudden increase in 
VAS scores at t = 18 hours. A possible explanation is that t = 18 hours is 
approximately the time the children wake up the morning after the 
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operation and find themselves in a stressful environment. Also, in view of 
the low mean age of the study population, fear and anxiety could partly be 
responsible for this phenomenon. This would also explain the increase in 
Comfort scores at t = 18 hours. 
The fact that after the operation the faces of the children become swollen 
and that they are scarcely able to open their eyes after several hours, 
provides an argument for distress.  
Another factor to explain the widely varying APAP plasma concentrations 
are differences in the activities of the enzymes involved in the APAP 
metabolism. These differences mainly result from differences in the 
patients’ genetic background.29 Since all our patients were approximately 
the same age, age-related maturation29 of enzyme activity cannot be held 
responsible for the differences in activity. 
 
Further research should aim at detecting differences in enzyme activity and 
at correlating the widely varying APAP plasma concentrations with the 
genetic background. 
We conclude that these are the first data showing that the analgesic APAP 
plasma concentration after major surgery in this age group does not always 
reach the 10 to 20-mg/l level. However, a relation between APAP plasma 
concentrations and pain scores was absent. These data also show that, after 
a rectal loading dose of 40 mg/kg has been given during surgery, the best 
way of administering APAP after craniofacial surgery is the rectal route. As 
a result of this study rectal administration of APAP after craniofacial 
surgery is now standard policy in our PSICU. 
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Abstract 
 
Background 
Paracetamol (APAP) is commonly prescribed for pain relief after 
(adeno)tonsillectomy [(A)TE], but reports of effectiveness are inconsistent. 
Diclofenac has been suggested as an alternative, although concerns about 
possible postoperative bleeding have tempered the use of diclofenac 
following (A)TE. We designed and conducted this study to compare the 
analgesic effect of rectally administered APAP and diclofenac in children 
undergoing (A)TE during ambulatory surgery and to assess the relation 
between APAP, diclofenac and 4’hydroxy-diclofenac plasma 
concentrations and postoperative pain scores. Furthermore we assessed the 
safety of diclofenac by monitoring postoperative bleeding and by 
registering the use of bipolar diathermy at the end of the procedure to arrest 
further bleeding. 
 
Methods 
A randomized controlled trial was performed in 65 children given either 
APAP (40 mg/kg loading dose, 30 mg/kg 8-hourly maintenance dose) or 
diclofenac (2 mg/kg loading dose, 1 mg/kg 8-hourly maintenance dose) 
rectally. APAP loading dose was administered 90 minutes before surgery, 
diclofenac loading dose was administered 30 minutes before surgery. 
Analgesic effect was assessed every 15 minutes during the first hour 
postoperatively, using validated pain scores (VAS and POCIS). After the 
first hour, analgesic affect was assessed 1-hourly until discharge. Morphine 
(5 µg/kg) was administered intravenously if VAS ≥ 4 cm or POCIS ≥ 4. 
Blood samples were collected at the start and at the end of surgery and 1, 2 
and 3 hours postoperatively Furthermore we registered whether children 
had primary or secondary bleeding following the procedure and whether 
bipolar diathermy was performed at the end of the procedure to arrest 
further bleeding. Following discharge, parents of the children performed a 
daily VAS score for the first postoperative week.  
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Results 
Data of 60 patients were analyzed. Median (25th-75th percentile) age was 4 
(3-5) years. Both the APAP and the diclofenac group consisted of 30 
patients. There was no difference in analgesic effect between APAP and 
diclofenac and there was no relationship between plasma concentrations 
and pain scores. Two children had primary bleeding, both given APAP. 
Bipolar diathermy was performed in 14 patients, 8 versus 6 in respectively 
the APAP and the diclofenac group. 
 
Conclusion 
Rectal diclofenac (2 mg/kg loading dose, 1 mg/kg 8 hourly) does not 
provide better pain relief than rectal APAP (40 mg/kg loading dose, 30 
mg/kg 8-hourly) following (A)TE. Our data showed no relationship 
between plasma concentrations and pain scores and no increase in incidence 
of primary or secondary bleeding due to the administration of diclofenac 
was shown, despite its effect on platelet aggregation.  
 
 
Introduction 
 
(Adeno)tonsillectomy [(A)TE] is generally considered as a very traumatic 
and painful procedure. Adequate treatment to reduce this traumatic and 
painful experience is important, since insufficient analgesia might lead to 
behavioral changes postoperatively.1 Rectal paracetamol (APAP) 15-20 
mg/kg 6-8-hourly is used frequently, but this often does not provide 
adequate postoperative analgesia.2,3 For adequate analgesia a rectal loading 
dose of 40 mg/kg approximately 2 hours before the procedure has been 
suggested.4,5 However, with a recommended daily dose of 75 mg/kg and a 
loading dose of 40 mg/kg, the ability to give extra doses of APAP if pain 
persists, is reduced.6 Despite dosing equivalence, APAP plasma 
concentrations are widely varying and unpredictable,7,8 due to triglyceride 
base suppository absorption, relative bioavailability and clearance 
parameters, which are associated with considerable variability (CV 90%, 
30%, 41% respectively.9 Considering the dose-effect relationship, Anderson 
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et al. reported that a target effect compartment concentration of 10 mg/l was 
associated with a mean pain score (VAS 0-10) reduction of 2.6 following 
(adeno)tonsillectomy.10 But this reduction may be inadequate if pain scores 
are high directly following the procedure. The large pharmacodynamic 
variability (EC50 CV 107%) also means that pain may be poorly controlled 
in some individuals and might explain why other studies in neonates and 
infants have been unable to establish a relationship between APAP plasma 
concentrations and analgesic effect.8,10,11 
 
Rectal diclofenac 1-2 mg/kg approximately 1 hour prior to the procedure is 
considered as an alternative for APAP for postoperative analgesia following 
(A)TE,12 but the concerns about possible postoperative bleeding have 
tempered the use of diclofenac following (A)TE.13 A retrospective 
evaluation of the incidence of postoperative bleeding following (A)TE did 
not seem to confirm the increased risk of postoperative bleeding.14 In 
contrast to APAP, there are few pharmacokinetic-pharmacodynamic data 
for diclofenac in children. Rømsing et al. were unable to establish a 
relationship between diclofenac dose and effect.15 However, diclofenac has 
an active metabolite, 4’-hydroxy-diclofenac (D4OH), and this metabolite 
may contribute to the analgesia observed after diclofenac dosing. 
 
We designed and conducted a double blind, randomized study, to compare 
the analgesic effect of rectally administered APAP and diclofenac in 
children undergoing (A)TE during ambulatory surgery and to assess the 
relation between APAP, diclofenac and D4OH plasma concentrations and 
postoperative pain scores. Furthermore we assessed the safety of diclofenac 
for this procedure by monitoring postoperative bleeding.  
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Patients and methods  
 
Patients and methods 
Following approval of the study by the Medical Ethical Committee of the 
Erasmus MC Rotterdam and after written informed consent was obtained 
from the parents, 65 children, undergoing elective (A)TE during ambulatory 
surgery, were included consecutively during the period from July 2000 till 
November 2001.  
Inclusion criteria were: age between 3 and 12 years, elective (A)TE, ASA 
status 1 or 2 and the presence of at least one Dutch speaking parent at the 
day of surgery. Exclusion criteria were: coagulopathy, diclofenac or APAP 
< 24 hours prior to surgery, known allergy for diclofenac or APAP, hepatic 
diseases interfering with drug metabolism and abnormal renal function. 
 
Procedure 
Patients were randomly assigned to receive a rectal loading dose of either 
40 mg/kg APAP 90 minutes before scheduled surgery or 2 mg/kg 
diclofenac 30 minutes before scheduled surgery.4,5,12 Patients receiving 
APAP 90 minutes before scheduled surgery received a placebo suppository 
30 minutes before scheduled surgery, while patients receiving diclofenac 30 
minutes before scheduled surgery received a placebo suppository 90 
minutes before scheduled surgery (Figure 1a). 
Anesthesia was performed according to standardized protocols. Anesthesia 
was induced using intravenously propofol 3-4 mg/kg, sufentanyl 0.2 µg/kg 
and mivacurium 0.2 µg/kg or by inhalation, with sevoflurane 8%. After 
tracheal intubation anesthesia was maintained with isoflurane 0.5 MAC. 
 
During the procedure when heart rate was 10% or more above baseline 
value, as described in our earlier randomized controlled trial,8 10 µg/kg 
alfentanyl was administered. If heart rate was still 10% or more above 
baseline value, 10 minutes after the administration of 10 µg/kg alfentanyl, 
another dose of 10 µg/kg alfentanyl was administered. Heart rate baseline 
value was obtained 10 minutes after intubation.  
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(A)TE was performed using blunt dissection. Bleeding was stopped with 
packing. If bleeding persisted, bipolar diathermy was used to arrest further 
bleeding.  
Postoperatively analgesic effect was assessed using validated pain scores, 
performed by trained investigators. POCIS (consisting of face, crying, 
breathing, body, arms, legs and agitation), and Visual Analogue Scale 
(VAS) scores were obtained every 15 minutes during the first hour 
postoperatively and then every hour until discharge of the child at the end 
of the day.16,17 In addition we asked the parents of the children to score the 
VAS 1-hourly postoperatively until discharge (Figure 1b).  
Depending on the POCIS and VAS scores extra pain medication could be 
administered. 
 
When POCIS ≥ 4 or VAS ≥ 4 cm, 5 µg/kg morphine was administered 
intravenously until the child was in minimal pain as indicated by POCIS < 
4 or VAS score < 4 cm. Ten minutes after the administration of morphine, 
pain was reassessed. If the child was still in pain, a second dose of 5 µg/kg 
morphine was administered. 
Blood samples (1.0 ml) for APAP or diclofenac and D4OH plasma 
concentration analysis were taken through a peripheral intravenous canule 
at the start and at the end of surgery and 1, 2 and 3 hours postoperatively 
(Figure 1b).  
We documented whether children had experienced primary or secondary 
bleeding and whether bipolar diathermy had been performed at the end of 
the procedure. Primary bleeding was defined as postoperative bleeding, 
which made re-operating necessary.18,19 Secondary bleeding was defined as 
postoperative bleeding on day 2-day 7 following surgery, which made re-
operating necessary.18,19 
Before discharge parents received 10 blinded suppositories, each consisting 
of either 30 mg/kg APAP or 1 mg/kg diclofenac, to take home as 
maintenance doses. Parents were advised to administer them at 8-hourly 
intervals, starting 8 hours after administration of the first suppository of 
study medication before surgery, which was usually before discharge. 
Parents were advised to administer APAP suppositories if their child was 
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still in pain after finishing the blinded suppositories supplied by the 
hospital. We asked parents to fill in a pain diary at home, consisting of a 
daily VAS score, during the first week after the procedure and to return this 
by mail. We also asked them to record the number of blinded suppositories 
their child used in this diary and extra APAP required after finishing the 10 
blinded suppositories (Figure 1c). 
 
APAP assay 
APAP plasma concentrations were determined using fluorescence 
polarization immunoassay (Adx system, Abbott Laboratories, North 
Chicago IL) (ErasmusMC, Rotterdam).8 Detection limit of this method is 
1.0 mg/l. Precision was measured at APAP concentrations of 15, 35 and 
150 mg/l. To determine coefficients of variation at these concentrations 55 
samples of each concentration were assayed [CV = (SD/mean); RSD = 
CV*100%]. RSD was 7.22%, 3.37% and 3.11% at 15, 35 and 150 mg/l 
respectively. The APAP concentration range, in which the accuracy was 
determined, is 10-150 mg/l. 
 
Diclofenac and D4OH assay  
Diclofenac sodium and naproxen were purchased from SIGMA ALDRICH 
(Saint Quentin Falavier, France), D4OH was provided by Novartis, USA. 
All solvants used were analytical grade. 
The HPLC system consisted of a Quatemary P 1000 XR pump 
(ThermoQuest-TQ, Florida, USA), a TQ autosampler, a TQ UV 6000 
detector (280nm) linked to TQ Spectranet for recording and storing 
throughout analysis. We used a LC8 5 µm particle size Supelcosil column 
(150x4.6 nm, Supelco Bellafonte, USA). The mobile phase was a mixture 
of acetonitrile/ sodium acetate 50 mV (70/30, v/v) adjusted to pH 5 by 
phosphoric acid and the flow rate 1.2 ml/min. 
Stock solutions of diclofenac (1000 mg/l) , D4OH (500 mg/l) and naproxen 
(1000 mg/l) were prepared in methanol and stored at –20°C. Calibration 
standards (0.01-1 mg/l) and plasma controls (0.04, 0.2, 0.750 mg/l) were 
prepared by appropriate dilutions of the stock solutions in drug-free plasma. 
Naproxen (10 mg/l) was used as internal standard.  
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Under the chromatographic conditions used, the retention times were 18.5, 
6.9 and 7.9 min for diclofenac, D4OH and naproxen respectively. Recovery 
from extraction was over 90% for the two compounds. Calibration curves 
were linear over the range of 0.01 to 1 mg/l and coefficients of variation of 
the slope were between 2.8 and 5.8% (n = 5). The limit of quantification 
was 5 µg/l for the two compounds. The intra and inter-assay coefficients of 
variation, determined from three quality controls (0.04, 0.2, 0.750 mg/l) 
were lower than 7%. 
 
Data analysis 
The Mann Whitney U-test was used to assess whether APAP and diclofenac 
differed in analgesic effect. For this purpose the summary measurement 
approach was performed;20 all pain scores (i.e. VAS observer, VAS parents, 
and POCIS scores) were averaged into one single pain score. Chi-square 
tests were used to assess differences in prevalence in primary- and 
secondary bleeding, and bipolar diathermy.  
 
Power analysis 
It was expected that 40% of the patients in the APAP group would need 
extra morphine,21,22 versus 16 % in the diclofenac group.23-25 For a power of 
0.80 and α = 0.05, 50 patients were required in each group.24 Interim 
analysis was performed after inclusion of 60 patients. 
 
Assignment and blinding 
A block randomization schedule was used to allocate APAP or diclofenac. 
The schedule was kept solely by the pharmacist to ensure blinding until the 
end of the study. 
The APAP and diclofenac sodium suppositories (with witepsol H15, 
synthetic saturated triglycerides with a chain length of C12-C18, as the 
base) were manufactured in the hospital pharmacy. As all children received 
suppositories (either APAP and placebo or diclofenac and placebo) 
manufactured in the department of the hospital pharmacy, patients and 
parents, nurses and investigators were blinded for the actual content of the 
suppositories.  
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The composition of the placebo suppositories was equal to the composition 
of the APAP and diclofenac suppositories, except for the APAP and the 
diclofenac. The APAP and diclofenac doses in the suppositories never 
deviated more than 10%. The ingredients were obtained via regular 
commercial suppliers. Suppositories and ingredients conformed with the 
quality requirements in the European Pharmacopoeia. 
 
 
Results 
 
Participant flow and follow up 
The eligible number of patients was 113. The parents of 48 patients refused 
informed consent for varying reasons: to much extra handling of their child 
(8), language difficulties (6), not familiar with diclofenac (5), child has 
suffered enough (4), no reason for not participating (25). As a result we 
included 65 patients in this study, of which 5 patients were excluded for 
analysis because they did not receive standard intervention as allocated (4) 
or due to withdrawal of parental informed consent during the study(1). 
Characteristics of these 5 patients did not differ from the characteristics of 
the 60 patients used for analysis. Both the APAP and the diclofenac group 
consisted of 30 patients.  
Participants’ flow is represented graphically in Figure 2. 
 
Analysis 
Median (25th-75th percentile) age and weight of patients receiving APAP 
(11 boys, 18 girls) and diclofenac (16 boys, 13 girls) were respectively: 4.0 
(3.0-5.5) years, 19 (16.0-22.0) kg and 4.0 (3.5-5.0) years, 20.0 (17.3-23.5) 
kg. 
Age, weight, gender, operative procedure, duration of the operative 
procedure, postoperative bleeding, bipolar diathermy, extra anesthesia, 
extra morphine, postoperative administration of metoclopramide of the 
APAP and diclofenac group are shown in Table 1. 
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Eligible  
N=113 
Included in study 
N=65 
Data analysis 
N=60 
Excluded for data analysis 
N=5 2 
No informed consent 
N=48 1 
 
Figure 2 Patients’ flowchart 
1. reasons: to much extra handling of their child (8), language difficulties 
(6), not familiar with diclofenac (5), child has suffered enough (4), no 
reason for not participating (25) 
2. reasons: not receiving standard intervention as allocated (4), 
withdrawal of parental informed consent during the study (1) 
 
 
Pain scores 
VAS scores obtained by the investigator were highest directly after the 
procedure and then decreased. Approximately 3-4 hours after the procedure, 
which was respectively 5-6 hours after loading dose for the APAP group 
and 4-5 hours after loading dose for the diclofenac group, VAS scores were 
slightly increasing. However these VAS scores stayed below 4 cm (Figure 
3). There was no significant difference in VAS scores between children 
receiving APAP and children receiving diclofenac (Figure 3). The number 
of children receiving extra morphine was not significantly different between 
both groups. Two children in the APAP group and three children in the 
diclofenac group had a VAS ≥ 4 cm during the first hour postoperatively 
and received extra morphine (5 µg/kg).  
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Table 1  Patients’ characteristics  
 APAP (n = 29) Diclofenac (n = 29)
Age (years)    Mean (SD) 
    Range 
4.2 (1.4) 
2-7 
4.5 (1.4) 
2-8 
Weight (kg)    Mean (SD) 
    Range 
19.4 (5.0) 
14-33 
20.4 (4.5) 
13-30 
Gender    boys 
    girls 
11 
18 
16 
13 
Operative procedure   ATE 
    TE 
28 
1 
26 
3 
Duration of procedure (min)  Mean (SD) 
    Range 
52 (17) 
30-110 
47 (13) 
30-80 
Bipolar diathermy 8 6 
Postoperative bleeding 2 0 
Extra fentanyl during anesthesia 14 13 
Extra morphine frequency  0 
    1 
    2 
27 
2 
0 
25 
3 
1 
Postoperative metoclopramide 5 2 
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Figure 3 VAS scores obtained by investigator 
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VAS scores obtained by the parents of the children were significantly 
higher (p = 0.045) and more varying compared to the VAS scores obtained 
by the investigator. There was no significant difference in VAS scores 
obtained by the parents between the APAP group and the diclofenac group 
(Figure 4) and postoperative course of the VAS scores obtained by the 
parents was comparable to the postoperative course of VAS scores obtained 
by the investigator, being highest directly after the procedure and then 
decreasing (Figure 4).  
POCIS scores were highest directly following the procedure and decreasing 
during the first hours postoperatively. There was no significant difference in 
POCIS scores between both groups (Figure 5).  
 
APAP plasma levels 
Patients were sampled at the start and at the end of the procedure and 1, 2 
and 3 hours postoperatively, resulting in a total of 95 samples collected 
from 25 patients assayed for APAP plasma concentrations. APAP plasma 
concentrations varied widely and ranged from 4.8-27.0 mg/l. 
Concentrations were highest at the start of surgery, which was 
approximately 90 minutes after loading dose, and decreased slowly 
postoperatively (Figure 6).  
 
Diclofenac and D4OH  
Patients were sampled at the start and at the end of the procedure and 1, 2 
and 3 hours postoperatively, resulting in a total of 97 samples collected 
from 25 patients assayed for diclofenac and D4OH. Diclofenac plasma 
concentrations varied, ranging from 0-2.6 µg/ml and being highest at the 
start of surgery, approximately 30 minutes after loading dose, and 
decreasing slowly postoperatively (Figure 7a). D4OH concentrations varied 
from 0-.5 µg/ml. Highest plasma concentrations were measured at the start 
of surgery, but there was only a slight decrease during the postoperative 
period (Figure 7b).  
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Figure 4  VAS scores obtained by parents 
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Figure 5  POCIS scores 
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Pain scores and plasma concentrations 
All children receiving APAP had APAP plasma concentrations > 10 mg/l at 
least at two or three sampling points and analgesia was assessed adequate.10 
Two children receiving APAP had a VAS > 4 cm during the first hour 
postoperatively, but APAP plasma concentrations were > 10 mg/l in both 
children. Diclofenac and D4OH plasma concentrations in the 3 children 
with VAS ≥ 4 during the first hour postoperatively were comparable to the 
diclofenac and D4OH plasma concentrations in children with VAS < 4 as 
well. 
 
Safety of diclofenac 
Primary bleeding was experienced in only 2 patients both receiving APAP, 
respectively 65 and 110 minutes postoperatively. There were no children 
experiencing secondary bleeding. 
Bipolar diathermy was performed at the end of the procedure to arrest 
further bleeding in 14 patients, respectively 8 versus 6 in the APAP group 
and in the diclofenac group, which was not significantly different.  
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Figure 6  APAP plasma concentrations 
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Figure 7a  Diclofenac plasma concentrations 
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Postoperative course at home 
72% (n = 42: APAP n = 20, diclofenac n = 22) of the parents returned the 
pain diary with VAS scores obtained daily at home during the first week 
postoperatively. VAS scores varied widely, with a slight decrease in VAS 
scores during the week. There was no significant difference in VAS scores 
between children receiving APAP and children receiving diclofenac (Figure 
8). 
Parents of 7 children explicitly reported in the pain diary how many 
suppositories of the supplied study medication they had administered to 
their children: 1 child (diclofenac) did not receive any study medication 
after leaving the hospital, 2 children (both diclofenac) received study 
medication during the first 2 days postoperatively and 2 children (both 
diclofenac) received study medication during the first 3 days 
postoperatively. The parents of 2 children (1 diclofenac, 1 APAP) reported 
their child needed extra APAP until 6 days postoperatively after the 
supplied study medication was administered. 
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Figure 8  VAS scores obtained by parents at home     
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Discussion 
  
The results of our study comparing the analgesic effect of rectally 
administered APAP and diclofenac in children undergoing (A)TE during 
ambulatory surgery, showed no significant difference in analgesic effect 
between APAP 40 mg/kg 90 minutes before surgery and diclofenac 2 
mg/kg 30 minutes before surgery. Both VAS scores and POCIS scores did 
not differ significantly between APAP and diclofenac group. Since 
analgesia was adequate in both groups and we could not find a difference in 
analgesic effect between both groups after data of 60 patients were analyzed 
in the interim analysis, we decided not to perform further inclusion of 
patients. 
 
We chose time of loading doses respectively 90 minutes prior to the 
procedure for APAP,4,5 and 30 minutes prior to the procedure for 
diclofenac.7 Drugs were given prior to the surgical procedure in the 
expectation that we would achieve maximal effect compartment 
concentrations at the conclusion of surgery. Both time of loading dose and 
amount of loading dose are of direct importance for the analgesic effect 
postoperatively and therefore have a direct influence on the postoperative 
course. If children experience less pain, i.e. if postoperative analgesia is 
adequate, children will be more motivated to increase their fluid intake, 
which has a beneficial effect on their postoperative course.1,27 
 
As expected, pain scores were highest directly after the procedure, 
decreasing slowly during the first hours postoperatively. There was a slight 
increase in pain scores approximately 4 hours postoperatively, respectively 
6 and 5 hours after APAP and diclofenac loading dose. This increase 
approximately 4 hours postoperatively has also been noted by Anderson et 
al. and can be attributable to both placebo effect and decreasing effect 
compartment concentrations.10 Maintenance doses according to the protocol 
were administered 8 hours after administration of the first suppository of 
study medication, respectively 8 and 7 hours after APAP and diclofenac 
loading dose, which was approximately 6 hours postoperatively. Although 
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VAS scores stayed below 4 cm, postoperative course, as reflected in the 
pain scores, might suggest that the first maintenance dose should be 
administered at 4 hours instead of 6 hours postoperatively. This way an 
increase in pain scores can be prevented, resulting in a better overall 
analgesia. Next maintenance doses should then be administered according 
to protocol at 8-hourly intervals. 
 
Pain scores were obtained by investigators and by the parents of the 
children, resulting in a comparable postoperative course. Although there 
was no significant difference in VAS scores obtained by the parents 
between APAP and diclofenac group, parents scored significantly higher 
compared to the investigator.  
 
As a result of adequate analgesia there was little variability in pain scores, 
which makes assessment of the relationship between pain scores and 
plasma concentrations difficult. Furthermore postoperative natural pain 
resolution, behavioral coping mechanisms and residual effects of anesthesia 
have an effect on postoperative pain scores and might have obscured our 
assessment of the analgesic effect of both APAP and diclofenac.14,22 Lavy 
reported that the postoperative pain resolution was faster in children < 10 
years of age compared to children > 10 years of age.28 According to 
Anderson, size is an important contributor in this: smaller children have a 
higher metabolism, resulting in a higher healing speed.10 This higher 
healing speed in smaller children might have contributed to the 
postoperative pain resolution course and therefore to the assessment of the 
analgesic effect of APAP and diclofenac 
APAP plasma concentrations varied widely, which has been reported 
previously in other age groups.8,29,30  
 
Diclofenac concentrations were comparable to the concentrations measured 
by Rømsing et al. and by Haaspasaari et al. Rømsing et al. measured 
diclofenac plasma concentrations in children 5-15 years of age following 
(A)TE after administration of a single dose of 1-2 mg/kg diclofenac 
orally.14 Haaspasaari et al. measured diclofenac concentrations in children 
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2-7 years of age with rheumatoid arthritis after administration of 1.5 mg/kg 
diclofenac orally.31 
 
Anderson reported that 84% of the children included in his study had 
adequate analgesia with APAP plasma concentrations > 10 mg/l.10 In our 
study all children receiving APAP had APAP plasma concentrations > 10 
mg/l at least two or three sampling points. Analgesia was assessed 
inadequate in 2 children receiving APAP, which had a VAS > 4 cm during 
the first hour postoperatively. However APAP plasma concentrations were 
> 10 mg/l in both children. This supports the lack of a relationship between 
APAP plasma concentrations and pain scores, as has been previously 
described in other age groups.8,10,11 Arendt-Nielsen et al. and Nielsen et al. 
reported a delay of 1 hour in maximum analgesia and peak APAP plasma 
concentrations in adults,32,33 supporting the absence of a direct relationship 
between APAP plasma concentrations in this age group as well.  
 
Also diclofenac and D4OH plasma concentrations in the 3 children with 
VAS ≥ 4 during the first hour postoperatively were comparable to the 
diclofenac and D4OH plasma concentrations in children with VAS < 4. The 
absence of a relationship between diclofenac plasma concentrations and 
pain scores has previously been reported by Rømsing et al.14 
 
To evaluate the alleged increased risk on postoperative bleeding associated 
with diclofenac,13 we monitored the incidence of primary and secondary 
bleeding. Although the number of patients receiving diclofenac in this study 
was low, no primary or secondary bleeding in children receiving diclofenac 
was observed in our study. Furthermore the number of children, in whom 
bipolar diathermy was performed at the end of the procedure to arrest 
further bleeding, was comparable in both groups, indicating there was no 
increased peroperative bleeding in children receiving diclofenac.  
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Conclusion 
 
Rectal diclofenac (2 mg/kg loading dose, 1 mg/kg 8-hourly) does not 
provide better pain relief than rectal APAP (40 mg/kg loading dose, 30 
mg/kg 8-hourly) following (A)TE. Our data showed no relationship 
between plasma concentrations and pain scores and no increase in incidence 
of primary or secondary bleeding due to the administration of diclofenac 
was shown, despite its effect on platelet aggregation.  
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Abstract 
 
Background 
The use of paracetamol (APAP) in addition to continuous morphine 
infusion (CMI) has increased in recent years despite the fact that the safety 
and additional value of this combined treatment has never been studied in 
newborns and young infants. We therefore investigated if addition of APAP 
decreased morphine consumption in postoperative newborns and infants 
after major thoracic or abdominal surgery. 
 
Methods 
A randomized controlled trial (RCT) was performed in 71 patients given 
either APAP 90-100 mg/kg/day or placebo rectally. Children received a 
morphine loading dose of 100 µg/kg and then 5 µg/kg/h CMI if < 45 weeks 
post conceptional age (PCA) or 10 µg/kg/h if ≥ 45 weeks PCA. Analgesic 
effect was assessed 2-3-hourly during the first 48 hours using VAS and 
COMFORT pain scores, validated for this age group. Extra morphine was 
administered or CMI was increased if the VAS was ≥ 4. The infusion rate 
was decreased in the second 24 hours if the VAS was < 4. Blood samples 
were collected for APAP plasma concentration analysis. Data were 
analyzed using Mann Whitney U test, ordinal regression, and multivariate 
logistic regression. 
 
Results 
We were able to analyze the data of 54 patients; 17 patients were excluded. 
Median (25th -75th percentile) age was 0 (0-2) months. APAP was 
administered to 29 patients and 25 received placebo. Additional morphine 
bolus requirements and increases in CMI were similar in both groups. 
Furthermore there was no significant difference in total morphine 
consumption. COMFORT and VAS sores did not differ between APAP and 
placebo group. Postoperative total morphine consumption was not related to 
age, although children < 45 weeks PCA needed less additional morphine 
boluses (p < 0.01) and needed less increases in CMI (p < 0.01). Mean 
APAP plasma concentrations ranged from 9.5 to 27.6 mg/l. 
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Conclusion 
APAP as adjuvant to CMI does not have an additional analgesic effect and 
should not be considered as standard of care in young infants, 0-2 months 
of age, following major thoracic or abdominal surgery. 
 
 
Introduction 
 
In many hospitals around the world continuous morphine infusion (CMI) is 
considered as standard for postoperative analgesia after major surgical 
procedures in young infants.1 Neonates and infants have an increased risk 
of respiratory depression with CMI because clearance is both reduced and 
associated with large inter-individual variability, resulting in higher plasma 
concentrations than older children given similar doses.2,3 The additional use 
of paracetamol (APAP) has become more and more popular, since it may be 
associated with less morphine use, reduction of stress responses and a lower 
incidence of side effects.4 In adults, combinations of opioids with APAP or 
non-steroidal anti-inflammatory drugs (NSAIDs) have resulted in a reduced 
morphine and fentanyl consumption as well as in reduced postoperative 
pain, without increased adverse effects.5-10 Morton has demonstrated 
reduced morphine requirements in postoperative children 3 to 15 years of 
age given diclofenac 1 mg/kg 8 hourly, but no effect attributable to APAP 
15 mg/kg 6-hourly was shown.11 
We conducted a randomized controlled trial to test the hypothesis that 
morphine consumption is reduced in postoperative patients receiving the 
combination of morphine and APAP compared to patients receiving 
morphine alone.  
 
 
Methods 
 
Patients and methods 
Approval for the study was granted by the Medical Ethical Committee of 
the Erasmus MC Rotterdam and written informed consent was obtained 
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from parents. Children were enrolled consecutively during the period from 
January 2001 till May 2002.  
Inclusion criteria were: neonates and infants aged 0-1 year, ≥ 36 weeks post 
conceptional age (PCA), weight ≥ 1500 grams and abdominal, including 
urological, or thoracic surgery. Exclusion criteria were: received opioids, 
APAP, or other analgesics, sedative drugs or muscle relaxants < 12 hours 
prior to surgery, hepatic diseases interfering with drug metabolism, 
abnormal renal function (creatinine > 2 SD for age), neurological damage 
(posthypoxic encephalopathy or major congenital anomalies of the central 
nervous system) and severe spasticity or hypotonia. 
 
Procedure 
Patients were randomly assigned to receive rectal APAP (30 mg/kg loading 
dose for children < 4 kg and 40 mg/kg loading dose for children > 4 kg, 
followed by 20 mg/kg 6-hourly) in group A or placebo as adjuvant to 
continuous morphine infusion (CMI) in group B.12 
Anesthesia was induced using intravenous thiopentone 3-5 mg/kg or by 
inhalation with sevoflurane in a nitrous oxide/ oxygen mixture. Fentanyl 5 
µg/kg was given intravenously before tracheal intubation to all children. 
Tracheal intubation was facilitated with atracurium 0.5-1 mg/kg or 
suxamethonium 2 mg/kg. Ventilation was controlled and anesthesia was 
maintained with oxygen/nitrous oxide or oxygen/air, isoflurane 0.5-1 MAC, 
dose corrected for age.13,14 
 
Monitoring consisted of ECG, non-invasive blood pressure (NIBP), oxy-
haemoglobin saturation (SpO2), end-tidal carbon dioxide levels (PetCO2) 
and temperature. The obtained NIBP and heart rate (HR) at 10 minutes after 
intubation were used as peroperative baseline values as described 
earlier.13,14 
Before incision a dose of 5 µg/kg of fentanyl was given. Extra doses of 
fentanyl (2 µg/kg) were given when the HR and/ or the mean arterial blood 
pressure were 10 % or more above baseline values. 
Peroperative fluids were given in a standardized way, to maintain a glucose 
infusion rate between 4-6 mg/kg/min. Body temperature was kept within 
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normal ranges. At the end of surgery the neuromuscular block was 
antagonized and the patients were extubated, unless the anesthesiologist and 
surgeon decided to continue mechanical ventilation. 
 
The rectal loading dose (APAP or placebo) was administered directly after 
induction of anesthesia. At the end of surgery all patients received an 
intravenous loading dose of morphine HCL 100 µg/kg. After surgery all 
children received CMI with a background of 5 µg/kg/h for children < 45 
weeks post conceptional age (PCA) and 10 µg/kg/h for children ≥ 45 weeks 
PCA.  
Pain assessment was performed by Intensive Care Unit (ICU) nurses and 
investigators, using pain scores validated for this age group and these 
circumstances. Visual Analogue Scale (VAS, 0-10) and COMFORT (0-30) 
scores were obtained every 2 hours during the first 24 hours postoperatively 
and every 3 hours during the second 24 hours after surgery, as part of the 
routine nursing observations during handling of the child.15-17 
CMI was routinely decreased in the second 24 hours depending on the VAS 
score. 
 
When VAS ≥ 4, extra amounts of morphine 5 µg/kg were administered 
until the child was in minimal pain as indicated by a VAS score < 4. Ten 
minutes after each extra dose of morphine, pain was reassessed. When the 
child needed an extra morphine bolus ≥ 3 times / hour, CMI was increased 
with 5 µg/kg/h, which could be increased if the child still needed extra 
doses of morphine > 3 times/hour (the maximum morphine background for 
children < 45 weeks PCA was 15 µg/kg/h and 30 µg/kg/h for children ≥ 45 
weeks PCA).  
Distress other than that originating from pain was assessed by COMFORT 
scores ≥17 and VAS < 4. Children then received midazolam for extra 
sedation (Figure 1). 
Blood samples (0.2 ml) for APAP plasma concentrations analysis were 
taken through the arterial catheter, which was inserted after induction, at 30 
and 90 minutes after loading dose, at the end of surgery and 5, 8, 11, 14, 17, 
20, 23, 26, 29, 32, 35, 38, 41, 44, 47 hours after the arrival in the ICU.  
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Participant flow and follow up 
The eligible number of patients was 110. The parents of 39 patients refused 
informed consent for varying reasons: too much extra handling of their 
child (n = 30), dislike of clinical trials (n = 6), no direct advantage to their 
child (n = 2) and language difficulties (n = 1). As a result we included 71 
patients in this study, of which 17 patients were excluded from analysis. 
Reasons for exclusion for data analysis were: not receiving standard 
intervention as allocated (n = 10), withdrawal of parental informed consent 
during the study (n = 1), logistical problems (n = 3) and canceling or 
rescheduling of the procedure after inclusion (n = 3). 29 of these 54 patients 
received APAP, 25 received placebo as adjuvant to intravenous morphine 
(Figure 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2  Patients’ flowchart 
 
1. Reasons for not obtaining informed consent: to much extra handling  
(n = 30), dislike of clinical trials (n = 6), no direct advantage (n = 2), 
language problems (n = 1) 
2. Reasons for exclusion for data analysis: not receiving standard 
intervention as allocated (n = 10), withdrawal of parental informed 
consent during the study (n = 1), logistical problems (n = 3), OK 
canceling or rescheduling of the procedure after inclusion (n = 3) 
Eligible  
N=110 
Included in study 
N=71 
Data analysis 
N=54 
Excluded for data analysis 
N=172 
No informed consent 
N=39 1 
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Data analysis 
Differences in morphine requirements were analyzed using the summary 
measurement approach.18 Since data were too skewed and could not be 
transformed to normality, ordinal regression analysis was performed. For 
this purpose we calculated the average morphine requirements during the 
first 48 hours, followed by discretizing the average morphine requirements 
into four categories, using the 25th, 50th, and 75th percentile as cut off 
scores. Age of the infants, loading dose of morphine at the end of surgery 
and number of postoperative rescue doses of morphine were added as 
covariates. Differences in number of children needing postoperative rescue 
doses of morphine and increases in CMI were analyzed using Logistic 
regression analysis. Age was entered as covariate. In all analyses age was 
entered as a dummy variable, i.e. < 1 month versus ≥ 1 month of age; coded 
as 1 and 0, respectively. 
 
Power analysis 
It was expected that 40% of the patients in the APAP group would need 
extra morphine versus 80% in the placebo group. For a power of 80% [α = 
0.05, (two-sided), Fisher’s exact test] 27 patients were required in each 
group.19 Seventy patients had to be included to compensate for dropouts. 
 
Assignment and blinding 
The randomization schedule, for APAP or placebo, was made prior to the 
study by random permuted blocks of four patients’ assignment, to guarantee 
equal group sizes. The schedule was kept solely by the pharmacist to ensure 
blinding until the end of the study. 
 
The study medication of patients receiving APAP consisted of APAP 
suppositories (with APAP and Witepsol H15, synthetic saturated 
triglycerides with a chain length of C12 - C18, as base). Study medication 
of patients receiving placebo consisted of placebo suppositories. As all 
children received suppositories (either APAP or placebo) manufactured in 
the department of the hospital pharmacy, patients and parents, nurses and 
investigators were blinded for the actual content of the suppositories.20  
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The composition of the placebo suppositories was equal to the composition 
of the APAP suppositories, except for the APAP. The APAP doses in the 
suppositories never deviated more than 10%. APAP was supplied by Bufa 
b.v., Uitgeest, the Netherlands. The suppositories and all ingredients met 
with the requirements in the European Pharmacopoeia. APAP suppositories 
were manufactured according to the Dutch Pharmacists Formulary. Stability 
of these preparations is tested by the laboratory of the Royal Dutch 
Association of Pharmacists. 
 
 
Results 
 
Analysis 
Median (25-75th percentile) age and weight of patients receiving APAP (16 
boys, 13 girls) and placebo (13 boys, 12 girls) as adjuvant to intravenous 
morphine were respectively: 0.0 (0.0-1.0) months, 3.1 (2.6-3.6) kg and 0.0 
(0.0-2.5) months, 3.1 (3.8-5.2) kg. 
 
Age, weight, gender, baseline heart rate (HR), baseline mean arterial 
pressure (MAP), operative procedure, peroperative blood loss, duration of 
the operative procedure, extra medication and mean duration of 
postoperative mechanical ventilation of the APAP, the placebo group and 
the group of patients excluded from analysis are shown in Table 1.  
Most frequent performed abdominal, urological and thoracic surgical 
procedures were respectively: closure of diaphragmatic hernia, intestinal 
atresia, nefrectomy and esophageal atresia repair,  
 
Pain scores 
There were no significant differences between patients receiving APAP and 
placebo as adjuvant to intravenous morphine with respect to COMFORT 
scores and VAS scores.  
VAS scores were low and showed a decline after the first 4 hours 
postoperatively (Figure 3a). In the APAP group lowest en highest median 
(25th–75th percentile) VAS scores in the first 4 hours postoperatively were 
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respectively 0.0 (0.0-0.3) and .2 (0.0-0.5). After the first 4 hours 
postoperatively lowest en highest median (25th–75th percentile) VAS 
scores were respectively 0.0 (0.0-0.1) and 0.1 (0.0-0.4). In the placebo 
group lowest en highest median (25th –75th percentile) VAS scores in the 
first 4 hours postoperatively were respectively 0.2 (0.0-1.2) and 0.3 (0.0-
2.2). After the first 4 hours postoperatively lowest en highest median (25th 
–75th percentile) VAS scores were 0.0 (0.0-0.0) and 0.2 (0.0-1.0) 
respectively. VAS scores ranged from 0.0-6.6. 
 
Although individual Comfort scores exceeded 17, cut off point for patients 
being in distress, median COMFORT scores were low (Figure 3b).22 In the 
APAP group lowest and highest median (25th –75th percentile) 
COMFORT score were respectively 9.0 (8.0-11.0) and 12.0 (9.0-13.0). In 
the placebo group lowest and highest median (25th-75th percentile) 
COMFORT score were respectively 10.0 (9.0-12.0) and 12.0 (10.0-16.0). 
COMFORT scores ranged from 6-26. 
 
Morphine consumption 
Ordinal regression analysis, using the complementary logit link function, 
showed no significant differences between the APAP and placebo group in 
median (25th -75th percentile) total morphine consumption, respectively 
7.91 (6.59-14.02) µg/kg/h and 7.19 (5.45-12.06) µg/kg/h for the APAP and 
the placebo group (p = 0.60). Age was not related to total morphine 
consumption (p = 0.38). However total morphine consumption was related 
to the amount of morphine loading dose and to additional morphine 
requirements postoperatively, being higher when infants had received a 
higher morphine loading dose (p < 0.01) or when additional morphine 
boluses or increases in CMI were needed (p < 0.01); pseudo R-square 
(Nagelkerke) was 0.66. Logistic regression showed no difference in 
additional morphine boluses, increases in CMI and decreases in CMI 
between APAP and placebo group (p = 0.36, p = 0.06 and p = 0.51 
respectively).  
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 Table 1  Patients’ characteristics 
 
Included for analysis  
(n = 54) 
Excluded for analysis 
(n = 17) 
 
Placebo (n = 25) APAP (n = 29) (n = 17) 
Age (months)* 
 
0 (0-3)
0-9
(0-1)
0-10
3 (0-7) 
0-8 
Weight (kg)* 
 
3.1 (2.8-5.2)
1.8-9.3
3.1 (2.6-3.6)
1.7-9.2
5.3 (3.5-6.5) 
2.3-8.5 
Gender  
 Male 
 Female 
13
12
16
13
 
10 
7 
Baseline heart rate  
(beats/min)* 
132 (126-152)
118-169
136 (125-152)
99-167
144 (140-147) 
138-150 
Baseline mean arterial  
pressure (mm Hg)* 
51 (49-64)
27-115
53 (46-61)
38-81
52 (45-56) 
33-75 
Operative procedures* 
 Thoracic 
 Abdominal 
 Urological 
7
18
0
7
19
3
 
2 
11 
4 
Peroperative blood loss (ml)* 
 
15 (10-30)
5-120
20 (5-40)
0-85
25 (10-70) 
5-80 
Duration of operative  
procedure (min)* 
150 (135-233)
85-365
160 (120-210)
60-300
135 (120-205) 
90-285 
Extra medication 
 Midazolam 
 Norcuron 
8
3
10
1
 
- 
- 
Mean duration of  
postoperative mechanical  
ventilation (h)* 
12.0 (0.0-25.5)
0.0-48.0
20.0 (2.0-42.0)
0.0-48.0
- 
 
*Median (25th-75th percentile); Range 
 
Regarding age, infants <1 month of age needed significantly less additional 
morphine boluses (n = 1/30) compared with infants ≥ 1 month of age (n = 
10/24; p < 0.01); pseudo R-square (Nagelkerke) was 0.44. The number of 
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children needing an increase in CMI was significantly lower in infants < 1 
month of age compared with infants ≥1 month of age (n = 3/30 versus (n = 
16/24; p < 0.01); pseudo R-square (Nagelkerke) was 0.43. There was no 
significant difference in CMI decreases in the second 24 hours 
postoperatively between infants < 1 month (n = 18/30) and ≥ 1 month of 
age (n = 10/24; p = 0.69); pseudo R-square (Nagelkerke) was 0.06.  
 
Paracetamol plasma concentrations 
APAP plasma levels increased during the first hours postoperatively and 
then reached a steady state concentration. Individual APAP plasma levels 
varied widely (0.8-59.9 mg/l) (Figure 4). 
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Figure 4 APAP plasma levels  
   Individual APAP plasma levels,  
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Discussion 
 
Despite concerns about the adverse effects of morphine in neonates and 
infants, such as respiratory depression, morphine is the standard analgesic 
after major surgical procedures in young infants.3,1 Combined analgesic 
regimens, leading to adequate analgesia with lower doses of opiods and 
subsequently reduced side effects have been proposed.4 
 
Our study assessed the potential morphine sparing effect of APAP in infants 
0-2 months of age after major thoracic or abdominal surgery. Patients 
receiving APAP and patients receiving placebo as adjuvant to intravenous 
morphine did not differ significantly with regards to additional morphine 
boluses (VAS ≥ 4), incidence of increases in CMI or incidence of CMI 
decreases in the second 24 hours postoperatively when VAS < 4. There was 
no significant difference in total morphine consumption between APAP and 
placebo group [median (25th-75th percentile) total morphine consumption 
respectively 7.91 (6.59-14.02) µg/kg/h and 7.19 (5.45-12.06) µg/kg/h]. The 
result that VAS scores were not significantly different between both groups 
supports the absence of a morphine sparing effect of APAP, since according 
to the study protocol extra morphine was administered when VAS ≥ 4. 
These findings are in line with the results of Morton, showing no morphine 
sparing effect of APAP in children 3-15 years of age following 
appendectomy.11 In contrast studies in adults have reported a decrease in 
postoperative morphine consumption when morphine was combined with 
APAP.5 Possibly the fact that the studies in adults were performed using 
self report, which was not possible in our study due to the age of our 
patients, might have been of influence on these results. Furthermore a 
placebo effect in adults can not be ruled out, reporting lower pain and using 
less morphine due to the placebo effect.  
 
Patients ≥ 45 weeks PCA (n = 18) received a loading dose of 100 µg/kg 
followed by CMI of 10 µg/kg/h, based on a study showing that morphine 
infusion at a dose of 10.9-12.3 µg/kg/h provided adequate analgesia in 
children 0 to 3 years of age after major abdominal surgery. 14 Based on the 
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study of Kart et al, advising a CMI of 7 µg/kg/h, and the results of 
Bouwmeester et al, indicating that neonates had lower morphine 
requirements, children < 45 weeks PCA (n = 36) received a loading dose of 
100 µg/kg, followed by a CMI of 5 µg/kg/h 22,23 Looking at the incidence of 
additional morphine requirements and increases in CMI we found them to 
be lower in patients < 1month of age, regardless of APAP or placebo group. 
This is consistent with the results of Bouwmeester et al, indicating that 
neonates had lower morphine requirements.23 Based on our results 5 
µg/kg/h CMI was sufficient for children < 1 month of age.  
 
Although there was no relation between age and total morphine 
consumption, we did show that children ≥ 1 month of age had a higher 
incidence of additional morphine boluses and increases in CMI. The extra 
amount of morphine administered with additional morphine boluses and 
increases in CMI did not result in a statistical significant difference in total 
morphine consumption. Also the fact that the group of children < 45 weeks 
PCA consisted of 36 children, whereas the group of children ≥ 45 weeks 
PCA consisted of only 18 children, might have affected the results. 
 
Most of the children included in this study had adequate analgesia, which 
makes it difficult to assess a dose-effect relationship. Pharmacodynamic 
variability might result from variability in distribution from the blood to the 
site of action and from variability in the sensitivity receptors. The 
contribution of variability in distribution from the blood to the site of action 
will depend largely on changes in perfusion of target tissue (5-60%). The 
sensitivity of receptors, defined in terms of affinity for binding or potency 
relative to another agent, may be an important source of variability in 
response when typical concentrations produce effects that are less than 80% 
maximal. Typical values are 5% (effect > 80% of Emax) and 50% (effect > 
20% of Emax). The imprecision and bias in the EC50 is increased if 
observed effect intensity is low compared to predicted Emax. A typical 
value for inter-individual variability in efficacy is 30%. The observed 
response may not be a direct consequence of drug-receptor binding, but 
rather through intermediate physiological mechanisms (e.g. antipyretics, 
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angiotensin converting enzyme inhibitors). A typical value for this 
variability is 30%.24 
 
Individual APAP plasma concentrations showed wide variability (range 
0.8-59.9 mg/l), despite dosing equivalence. This is well recognized by 
others and is attributable, in part, to absorption variability, size effects and 
genetic polymorphisms interfering with APAP metabolism, such as from 
CYP2E1 and CYP3A4.20,25-28  
 
Population pharmacokinetic parameter estimates are associated with 
considerable variability. Factors affecting this variability are absorption, 
tissue distribution, metabolic elimination and renal elimination. Holford and 
Peck report typical values of 30% for absorption, 10% for tissue 
distribution, 50% for metabolic elimination and 20% for renal elimination.24  
They also report a value of 50% for compliance with medication 
regimens.24 This however was not an issue in our study. These parameter 
variabilities contribute to the large concentration ranges seen after a rectal 
APAP dosing.20,25,27 The use of concentration to link dose and effect allows 
PK variability to be separated from PD variability. The reduction in total 
variability produced by the removal of the PK component has been 
estimated to be 50% or greater.  
 
Many clinical studies in which APAP is compared to another analgesic are 
destined either to fail showing a difference between the two analgesic 
treatments or to have inadequate power because pain score reporting 
methods, the pain stimulus and pharmacokinetic and pharmacodynamic 
parameters all have large variability.27  
 
 
Conclusion 
 
APAP as adjuvant to CMI does not have an additional analgesic effect and 
should not be considered as standard of care in young infants, 0-2 months 
of age, following major thoracic or abdominal surgery. 
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Abstract 
 
Introduction 
Paracetamol (APAP) is metabolized through glucuronidation, sulphation 
and oxidation. A negligible part of APAP is hydroxylated into 3’-hydroxy-
APAP. In the glucuronidation UGT1A6 and to a far lesser extend UGT1A9 
are involved in the formation of APAP-glucuronide, whereas in the 
formation of N-acetyl-p-benzoquinone-imine (NAPQI) through oxidation 
CYP2E1, CYP3A4, CYP1A2 and possibly CYP3A5 are involved. Since 
NAPQI is the APAP metabolite responsible for the toxic effects and 
CYP2E1, CYP3A4 and possibly CYP3A5 are the enzymes responsible for 
the majority of the oxidation, we conducted a pilot study to analyze the 
relation between APAP clearance and CYP3A4, CYP3A5 and CYP2E1 
genotype in children receiving APAP during participation in previously 
reported studies. Furthermore we evaluated the relation between age and 
clearance to account for developmental changes. 
 
Methods 
Children received an APAP loading dose followed by administration of 
APAP maintenance doses for postoperative analgesia. Blood samples were 
obtained for APAP plasma concentration analysis. To obtain genomic 
DNA, either a blood sample was collected or buccal swabs were used. DNA 
analysis was performed for CYP3A4, CYP3A5 and CYP2E1 genotype. 
 
Results 
115 patients were eligible for this study. Informed consent for DNA 
analysis was obtained from 106 patients. In 57 of these patients both 
genotyping was performed and a sufficient number of blood samples was 
collected to allow us to calculate APAP clearance. Therefore we were able 
to study 57 children in this study. Median (25th-75th percentile) age and 
weight of the patients were respectively 10 (1-11) months and 8.5 (3.5-
10.4) kg. The study group consisted of 32 boys and 25 girls. Median (25th-
75th percentile) APAP clearance was 1.1 (0.5-2.6) l/h. APAP plasma 
concentrations ranged from 0-59.9 mg/l.  
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We could not establish a relation between APAP clearance and CYP3A4, 
CYP3A5 and CYP2E1 genotype. APAP clearance increased with age. 
 
Conclusion 
This pilot study showed no relation between APAP clearance and CYP3A4, 
CYP3A5 and CYP2E1 genotype. APAP clearance increased with age. 
Since population allelic frequencies of the mutations are low, further 
research in a larger sample of patients is needed for complete analysis of the 
relation between APAP and CYP3A4, CYP3A5 and CYP2E1 genotype. 
 
 
Introduction 
 
A wide variability in paracetamol (APAP) plasma concentrations is 
reported after APAP administration,1,2,3 resulting from variability in 
absorption,1 size effects,1 and from variability in enzyme activity of the 
enzymes involved in APAP metabolism. Differences in enzyme activity 
might result both from developmental changes in enzyme activity as from 
genetic polymorphisms leading to an altered enzyme activity.4  
APAP is metabolized through glucuronidation, sulphation and oxidation 
(Figure 1).5 A negligible part of APAP is hydroxylated into 3’-hydroxy-
APAP.5 In the glucuronidation UGT1A6 and to a far lesser extend 
UGT1A9 are involved in the formation of APAP-glucuronide,6 whereas in 
the formation of N-acetyl-p-benzoquinone-imine (NAPQI) through 
oxidation CYP2E1, CYP3A4, CYP1A2 and possibly CYP3A5 are 
involved.4,5,7 NAPQI is the APAP metabolite responsible for the toxic 
effects and is conjugated with glutathion. When there is not enough 
glutathion present to conjugate all NAPQI, NAPQI will bind with hepato-
cellular proteins and will cause liver necrosis.5 Glucuronidation and 
sulphation are the major pathways of APAP metabolism, whereas APAP 
metabolism through oxidation will increase when high or toxic doses of 
APAP are administered and metabolism through sulphation and 
glucuronidation is rate limiting. Unchanged APAP and APAP metabolites 
are all excreted in urine. 
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Figure 1 APAP metabolism 
 
Miller studied the contribution of the different pathways of APAP 
metabolism at different ages. In neonates sulphation is the major pathway 
and contributes 50% towards total APAP metabolism, whereas 
glucuronidation and oxidation contribute respectively 18 and 28%.8 
Compared to neonates, the contribution of sulphation has slightly decreased 
to 44% in children 3-9 years of age, whereas the contribution of 
glucuronidation has increased to 30 %. The contribution of the oxidation at 
this age is 21%.8 In children 12 years of age, the contribution of sulphation 
has been further decreased to 30%, and glucuronidation has been further 
increased to 45%. The contribution of the oxidation at this age is 20%.8  In 
adults, the contribution of sulphation is still 30% and glucuronidation has 
further increased to 50%. Oxidation accounts for 16%.8 The percentage of 
APAP excreted unchanged is equal at the different ages, approximately 4-
5%. 
 
Evaluating the ratio between APAP glucuronidation and APAP sulphation, 
an increase from 0.12 in preterm infants 28 to 32 weeks gestational age9 to 
0.28 in preterm infants 32 to 36 weeks gestational age9 and 0.34 in 
newborns8 is reported. We studied infants with a mean age of 10 months 
and showed a ratio of 0.69.10 This is comparable with a ratio of 0.75 found 
in infants 3-9 years of age.8,11  In 12 year olds and adults, ratios were 
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respectively 1.69 and 1.8.8 The contribution of glucuronidation towards 
total APAP metabolism increases with age. 
 
Since NAPQI is the APAP metabolite responsible for the toxic effects and 
CYP3A4, CYP2E1 and possibly CYP3A5 are the enzymes responsible for 
the majority of the oxidation, we conducted a pilot study to analyze the 
relation between APAP clearance and CYP3A4, CYP2E1 and CYP3A5 
genotype in children receiving APAP during participation in previously 
reported studies performed at the Erasmus MC Rotterdam.10, 12, 13 
Furthermore we evaluated the relation between age and clearance to 
account for developmental changes.  
 
  
Patients and methods  
 
Following approval of the study by the Medical Ethical Committee of the 
Erasmus MC Rotterdam and after separate written informed consent for 
DNA analysis was obtained from the parents of the children participating in 
3 of our previously reported trials,10,12,13 in which APAP was administered 
and APAP plasma concentrations were measured. 
 
I. 45 children were included in a randomized controlled trial comparing 
the analgesic effect of rectal versus oral APAP following major 
craniofacial surgery (chapter 3.1). Children received a rectal loading 
dose of 40 mg/kg directly after induction of anesthesia, followed by 20 
mg/kg APAP either rectally or orally postoperatively. APAP plasma 
concentrations were measured 30, 60 and 90 minutes after loading dose 
administration, and 1 hour prior to and 2 hours after APAP maintenance 
dose administration during the first 24 hours postoperatively. Median 
(25th-75th percentile) age was 10 (9-11) months (Figure 2).10 
II. 71 children were included in a randomized controlled trial evaluating 
the potential morphine sparing effect of APAP following major 
abdominal and thoracic surgery (chapter 3.3). 37 children were eligible 
for this current study, receiving a rectal APAP loading dose of 30-40 
mg/kg directly after induction of anesthesia, followed by 20 mg/kg 6-
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Eligible n=115  
I   
n=45  
II  
n=37  
III 
n=33  
n=40   n=35  
  
n=31  
 
n=28   
  
n=19  
  
n=10  
 
hourly postoperatively. APAP plasma concentrations were sampled 30 
and 90 minutes after loading dose and just prior to and 2 hours after 
APAP maintenance dose administration for the first 48 hours 
postoperatively. Median (25th-75th percentile) age was 0 (0-2) months 
(Figure 2).12 
III. 65 children were included in a randomized controlled trial comparing 
the analgesic effect of rectal APAP versus rectal diclofenac for 
postoperative analgesia following (adeno)tonsillectomy (chapter 3.2), of 
which 33 children were eligible for this currents study, receiving APAP 
40 mg/kg 90 minutes prior to surgery. APAP plasma concentrations 
were measured directly after induction of anesthesia, at the end of the 
procedure and 1, 2 and 3 hours postoperatively. Median (25th-75th 
percentile) age was 4 (3-5) years (Figure 2).13  
 
Procedure 
Children received an APAP loading dose according to the study protocol of 
the study in which they participated, followed by administration of APAP 
maintenance doses. Blood samples were obtained for APAP plasma 
concentration analysis according to the study protocols. For DNA analysis, 
either a blood sample (1 ml) was obtained directly after induction of 
anesthesia or buccal swaps were used to obtain DNA.  
 
 
 
 
 
 
 
 
Informed consent  
n = 106 
 
Sufficient blood  
samples to calculate 
clearance n = 57 
 
Figure 2 Patients’ flowchart 
I patients undergoing major craniofacial surgery10  
II patients undergoing major abdominal or thoracic surgery12  
II patients undergoing (adeno)tonsillectomy13 
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APAP assay 
Plasma samples were stored at 4 °C until analysis. APAP plasma 
concentrations were determined using fluorescence polarization 
immunoassay (ADX systems, Abbott Laboratories, North Chicago, IL) 
(Erasmus MC Rotterdam). The APAP plasma determination limit was 1.0 
mg/l which was defined as the lowest measurable concentration which can 
be distinguished from zero with 95% confidence. Precision was measured at 
APAP plasma concentrations of 15, 35 and 150 mg/l; 55 samples of each 
concentration were assayed to determine coefficients of variation at these 
concentrations (CV = SD/mean; RSD = CV*100%). RSDs at these 
concentrations were 7.22%, 3.37% and 3.11% respectively. The APAP 
plasma concentration range in which accuracy was measured was 10-150 
mg/l. 
 
DNA analysis 
DNA analysis for was performed isolating genomic DNA from blood using 
GenomicPrep Blood DNA Isolation Kit (Amersham Pharmacia Biotech, 
Buckinghamshire, UK). DNA samples were analyzed for CYP3A4*1b, 
CYP3A5*3, CYP2E1*1d, CYP2E1*2, CYP2E1*5 and CYP2E1*7 
mutations using PCR-RFLP method developed by van Schaik et al.14 
 
Data analysis 
APAP clearances were calculated using the Area Under the Curve 
(AUC).15Analysis of the relation between clearance and genotype was 
performed using cross tabs after discretizing clearances based on the 
interquartile ranges. For CYP3A4 genotype, we compared patients being 
wild type (*1/*1) to patients being heterozygous (*1/*1b) and to patients 
being homozygous (*1b/*1b) for CYP3A4*1b. For CYP3A5 genotype, we 
compared patients being wild type (*1/*1) or heterozygous (*1/*3) to 
patients being homozygous (*3/*3), as only patients being wild type or 
being heterozygous have CYP3A5 activity.16 For CYP2E1 we compared 
patients being wild type (*1/*1) to patients being hetero- or homozygous 
for CYP2E1*1d (*1/*1d; *1d/*1d), CYP2E1*2 (*1/*; *2/*2), CYP2E1*5 
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(*1/*5; *5/*5), CYP2E1*7 (*1/*7; *7/*7) and for CYP2E1*7 and 
CYP2E1*1d (*1d/*7).  
 
 
Results  
  
Participant flow and follow up 
115 patients were eligible for this current analysis. Informed consent for 
DNA analysis was obtained for 106 patients; the parents of 9 children 
refused informed consent, as they did not see any additional value in DNA 
analysis for their children. Blood sampling was not sufficient for calculation 
of clearances in 49 patients. Therefore data of 57 children were available 
for DNA analysis and plasma concentration analysis (Figure 2).  
 
Patients’ characteristics 
Median (25th-75th percentile) age and weight of the patients were 
respectively 10 (1-11) months and 8.5 (3.5-10.4) kg. The study group 
consisted of 32 boys and 25 girls. Median (25th-75th percentile) APAP 
clearance was 1.1 (0.5-2.6) l/h (Table 1, Figure 3). 
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Figure 3 APAP clearance 
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Table 1 Patients’ characteristics  
Age (years)1 10 (1-11)
0-72
Weight (kg)1 8.5 (3.5-10.4)
1.7-31.0
Gender  Male 
  Female 
32
25
APAP clearance (l/h)1 1.1 (0.5-2.6)
0.1-12.9
 
1 median (25th-75th percentile); range 
 
APAP plasma concentrations  
I. Median (25th-75th percentile) APAP plasma concentration in the 
children undergoing major craniofacial surgery was 9.0 (5.3-13.5) mg/l, 
ranging from 0.2-26.1 mg/l (Figure 4a).10 
II. Median (25th-75th percentile) APAP plasma concentration in the 
children undergoing major abdominal or thoracic surgery was 20.8 
(12.4-29.8) mg/l, ranging from 0.0-59.9 mg/l (Figure 4b).12 
III. Median (25th-75th percentile) APAP plasma concentration in the 
children undergoing (adeno)tonsillectomy was 14.2 (11.0-18.9) mg/l, 
ranging from 4.8-29.4 mg/l (Figure 4c).13 
 
DNA analyses 
DNA analysis was performed for CYP3A4*1b, CYP3A5*3, CYP2E1*1d, 
CYP2E1*2, CYP2E1*5 and CYP2E1*7. 57 samples were available for 
analysis. Considering CYP3A4, 65% (n = 37) of the patients were wild type 
(*1/*1), 4% (n = 2) of patients were heterozygous (*1/*1b) and 4% (n = 2) 
of patients were homozygous (*1b/*1b) for CYP3A4*1b. Quality of buccal 
swaps was not sufficient to perform CYP3A4 genotyping in 28% (n = 16) 
of the patients (Figure 5a). 
Considering CYP3A5, 7% (n = 4) of the patients were wild type (*1/*1), 
7% (n = 4) of patients were heterozygous (*1/*3) and 54% (n = 31) of 
patients were homozygous (*3/*3) for CYP3A5*3. Quality of buccal swaps 
was not sufficient to perform CYP3A5 genotyping in 32% (n = 18) of the 
patients (Figure 5b). 
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Figure 4a APAP plasma concentrations in children undergoing major craniofacial 
surgery  
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Figure 4b APAP plasma concentrations in children undergoing major abdominal or 
thoracic surgery 
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Figure 4c APAP plasma concentrations in children undergoing (adeno) 
tonsillectomy  
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Analyzing CYP2E1, 55% (n = 31) of the patients were wild type (*1/*1), 
2% (n = 1) was heterozygous for CYP2E1*2 (*1/*2), 2% (n = 1) was 
heterozygous for CYP2E1*5 (*1/*5), 13% (n = 7) was heterozygous for 
CYP2E1*7 (*1/*7) and 2% (n = 1) was heterozygous for CYP2E1*7 and 
CYP2E1*1d (*1d/*7). Quality of buccal swaps was not sufficient to 
perform CYP2E1 genotyping in 26% (n = 12) of the patients (Figure 5c). 
 
Relation APAP clearance, genotyping and age 
Genotyping of the outliers in APAP clearance shows CYP3A4 and 
CYP2E1 wild type (*1/*1) and CYP3A5*3 homozygous (*3/*3) for the 
patient with an APAP clearance of 8.5 l/h; CYP3A4*1b homozygous 
(*1b/*1b), CYP3A5 wild type (*1/*1) and CYP2E1*7 heterozygous 
(*1/*7) for the patient with an APAP clearance of 9.1 l/h; CYP3A4 and 
CYP2E1 wild type (*1/*1) and CYP3A5*3 homozygous (*3/*3) for the 
patient with an APAP clearance of 9.7 l/h and CYP3A4 wild type (*1/*1), 
CYP3A5*3 homozygous (*3/*3) and CYP2E1*7 heterozygous (*1/*7) for 
the patient with an APAP clearance of 12.9 l/h (Table 2). 
 
There was no relation between APAP clearance and CYP3A4, CYP3A5 
and CYP2E1 (Figure 6a, 6b & 6c). Table 3 shows the number of patients 
being wild type, heterozygous or homozygous for CYP3A4, CYP3A5 and 
CYP2E9 genotype in the different interquartile ranges of APAP clearance 
(Table 3). APAP clearance increases with age (Figure 7). 
 
 
Table 2  Genotyping of outliers in clearances 
 
CYP3A4 CYP3A5 CYP2E1 
APAP clearance (l/h) 
8.5
9.1
9.7
12.9
*1/*1
*1b/*1b
*1/*1
*1/*1
*3/*3
*1/*1
*3/*3
*3/*3
*1/*1
*1/*7
*1/*1
*1/*7
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Cyp3A4
64%4%
4%
28%
*1/*1
*1/*1b
*1b/*1b
missing
 
Figure 5a 
 
Cyp3A5
7% 7%
57%
29%
*1/*1
*1/*3
*3/*3
missing
 
Figure 5b 
 
Cyp2E1
55%
2%2%
13%
2%
26%
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missing
 
Figure 5c 
 
The impact of pharmacogenetics on the pharmacokinetics and metabolism of APAP in children 
 
 
173
 
2237N =
Cyp3A4
*1b/*1b*1/*1b*1/*1
AP
AP
 c
le
ar
an
ce
 l/
h
20
15
10
5
0
 
Figure 6a 
 
318N =
Cyp3A5
*3/*3*1/*1 *1/*3
AP
AP
 c
le
ar
an
ce
 l/
h
20
15
10
5
0
 
Figure 6b 
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Figure 6c 
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Table 3  CYP3A4, CYP3A5 and CYP2E1 genotype and APAP clearance  
 
Interquartile ranges of APAP clearance 1st 2nd 3rd 4th
CYP3A4 *1/*1 
  *1/*1b 
  *1b/*1b 
1
2
6
1 
0 
9 
1 
2 
6 
1
0
10
CYP3A5 *1/*1 
  *1/*3 
  *3/*3 
0
1
3
0 
0 
14 
2 
0 
9 
0
1
11
CYP2E1 *1/*1 
  *1/*2 
  *1/*5 
  *1/*7 
  *1d/*7 
11
-
-
1
-
8 
- 
- 
1 
- 
6 
1 
- 
1 
- 
6
-
1
4
1
 
 
Discussion  
 
This is the first study that investigates the relationship between genotype 
and APAP clearance in children. In this pilot study we could not establish a 
relationship between CYP3A4, CYP3A5 or CYP2E1 genotype and APAP 
clearance. The number of patients in this pilot study is limited and therefore 
we can not draw definite conclusions with regards to the relationship 
between CYP3A4, CYP3A5 or CYP2E9 genotype and APAP clearance.  
 
The fact that we could not establish a relation between APAP clearance and 
CYP3A4, CYP3A5 and CYP2E1 genotype is in line with the fact that only 
21-28% of APAP is metabolized through oxidation at this age.8 The 
contribution of the oxidation to APAP metabolism is minor compared to the 
contribution of the glucuronidation and sulphation pathway, and only 
increases when glucuronidation and sulphation are rate limiting in case high 
or toxic doses of APAP are administered. Thummel et al reported that 
CYP3A4 has a higher affinity for APAP, whereas CYP2E1 has a greater 
capacity to form NAPQI.7 CYP3A4 is mainly involved in oxidation when 
APAP doses within the normal dosing range are administered, compared to 
CYP2E1 being mainly involved in the oxidation when high or toxic doses 
are administered.7 APAP doses administered in this study were within the 
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normal dosing range (90 mg/kg/day). Therefore it was to be expected that 
APAP metabolism occurred mainly through glucuronidation and 
sulphation, explaining the absence of a relation between APAP clearance 
and CYP3A4, CYP3A5 and CYP2E1 genotype.  
 
Furthermore the small number of patients and the relatively low population 
allelic frequencies (Table 4) of the mutations analyzed in this study could 
have contributed to the fact that we could not establish a relation between 
APAP clearances and CYP3A4, CYP3A5 and CYP2E1 genotype. This is in 
line with the results reported by de Wildt et al,24 showing no relationship 
between the presence or absence of CYP3A4*1b alleles and midazolam 
clearances in preterm born infants 26.0-33.6 weeks gestational age. 
Although the frequency of CYP3A4*1b in the Caucasian population is 
5.3% (van Schaik et al, 2000), the number of patients used by the Wildt et 
al was low (n = 29), making it difficult to establish a potential relationship 
between midazolam clearance and the presence or absence of CYP3A4*1b 
alleles.  
 
Table 4 Allelic frequencies of CYP3A4*1b, CYP3A5*3, CYP2E1*1d, 
CYP2E1*2, CYP2E1*5, CYP2E1*7  
 Population 
CYP3A4*1b  
 Caucasians14 
 US Caucasians17 
 African Americans18 
 
5.3% 
9.6% 
54.6% 
CYP3A5*3 
 Caucasians16 
 Japan19 
 African Americans19 
 
91% 
71% 
27% 
CYP2E1*1d  
 Caucasians20 
 China21 
 
3.5% 
23% 
CYP2E1*2  
 China22 
 
1.3% 
CYP2E1*5 - 
CYP2E1*7  
 North Europe23  
 
20% 
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When APAP is administered in high or toxic doses, metabolism through 
oxidation will increase. More NAPQI will subsequently be formed, leading 
to toxic effects if not enough glutathion is present to detoxify NAPQI. 
Patients will be more susceptible to toxic APAP effects, when either 
glutathion stores are reduced or glucuronidation pathway is compromised, 
for example in situations of acute protein-calorie malnutrition,25 or when 
enzyme activity is altered. When altered enzyme activity in the 
glucuronidation pathway leads to a decreased glucuronidation and 
sulphation is rate limiting, the contribution of the oxidation pathway 
increases, possibly leading to more toxic effects. When enzyme activity is 
altered in the oxidation pathway, this might directly lead to an increased or 
decreased NAPQI formation and thus affecting the clinical outcome of 
APAP overdoses. 
 
 
Conclusion 
 
This pilot study showed no relation between APAP clearance and CYP3A4, 
CYP3A5 and CYP2E1 genotype. APAP clearance increased with age. 
Since population allelic frequencies of the mutations are low, further 
research in a larger sample of patients is needed for complete analysis of the 
relation between APAP and CYP3A4, CYP3A5 and CYP2E1 genotype.  
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Abstract 
 
Introduction 
Data considering the pharmacokinetics of diclofenac in children are scant. 
Studies have mainly focused on measuring diclofenac plasma 
concentrations. However, one of the diclofenac metabolites, 4’-hydroxy-
diclofenac (D4OH), has activity as well. Diclofenac is metabolized into 
D4OH by CYP2C9, whereas metabolism into 5’-hydroxy-diclofenac 
(D5OH) occurs through CYP3A4 and possibly through CYP3A5. We 
conducted a pilot study to investigate the relation between diclofenac 
clearance and CYP2C9, CYP3A4 and CYP3A5 genotype, between D4OH 
formation clearance and CYP2C9 genotype and between D5OH formation 
clearance and CYP3A4 and CYP3A5 genotype. 
 
Methods 
Children (n = 32), 3 to 8 years of age, received a loading dose of 2 mg/kg 
diclofenac rectally 30 minutes before scheduled elective 
(adeno)tonsillectomy. Blood samples (1 ml) for the analysis of diclofenac, 
D4OH and D5OH plasma concentrations were obtained directly after 
induction, at the end of the procedure and 1, 2 and 3 hours after awakening. 
For DNA analysis, a blood sample (1 ml) was obtained directly after 
induction of anesthesia. Data analysis was performed using cross tabs after 
discretizing clearances based on the interquartile ranges. 
 
Results 
Blood samples were not available in 6 patients, hence data of 26 patients 
were analyzed, 14 boys and 12 girls. Median (25th-75th percentile) age and 
weight of the patients were respectively 4.0 (3.8-5.0) years and 20.0 (17.8-
22.7) kg. Diclofenac plasma concentrations ranged from 0-2.6 mg/l, D4OH 
plasma concentrations ranged from 0-0.5 mg/l and D5OH plasma 
concentrations ranged from 0-0.6 mg/l. We could not establish a relation 
between diclofenac clearance and CYP3A4, CYP3A5, CYP2C9 genotype. 
Nor could we establish a relation between D4OH formation clearance and 
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CYP2C9 or between D5OH formation clearance and CYP3A4 and 
CYP3A5.  
 
Conclusion 
This pilot study showed no relation between diclofenac clearance and 
CYP3A4, CYP3A5, CYP2C9 genotype. Nor did it show a relation between 
D4OH formation clearance and CYP2C9 or between D5OH formation 
clearance and CYP3A4 and CYP3A5.  
 
 
Introduction 
 
Data on diclofenac pharmacokinetics in children are scant. Only a few 
studies have included the analysis of diclofenac plasma concentrations. 
Rømsing reported diclofenac plasma concentrations in children 5 to 15 
years of age following administration of single oral doses (1-2 mg/kg) of 
diclofenac.1 Although diclofenac has an active metabolite, 4’-hydroxy-
diclofenac (D4OH), no data are available of clinical studies that have 
investigated diclofenac metabolite plasma concentrations. 
 
Diclofenac belongs to the Non-Steroidal Anti Inflammatory Drugs 
(NSAIDs) and is almost completely metabolized and eliminated in bile (30-
35%) and urine (50-70%). Only a small part (0.5%) is eliminated 
unchanged in urine. Ten percent of diclofenac is glucuronidated as an intact 
molecule and eliminated in urine (5-10%) and in bile (< 5%). The largest 
part of diclofenac is hydroxylated first, after which it is conjugated with 
glucuronic acid, sulphic acid, taurine or other ligands.2 
 
The main metabolite of diclofenac is D4OH, which is formed through 
hydroxylation by CYP2C9. This hydroxylation can be inhibited by 
sulfaphenazol, phenytoin and warfarin. After hydroxylation into D4OH, 
D4OH is glucuronidated and eliminated in urine (20-30%) and in bile (10-
20%).2  
After hydroxylation of diclofenac into 3’-hydroxy-diclofenac (D3OH), 
D3OH is conjugated with glucuronic acid, whereas hydroxylation of 
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diclofenac into 5’-hydroxy-diclofenac (D5OH) and into 4’,5’-dihydroxy-
diclofenac can also be followed by conjugation with the amino acid taurine 
or with sulphic acid. After conjugation, these metabolites are eliminated in 
urine (10-20%) and bile (5-6%).2 The enzymes responsible for 
hydroxylation into D5OH are CYP3A4 and possibly CYP3A5.3 CYP3A4 
activity is influenced by age, medication, disease state, nutrition and, 
potentially, genotypic expression.3-6  
 
The 3’-hydroxy-4’methoxydiclofenac metabolite (t ½ 80 h) of diclofenac is 
eliminated only in small amounts in urine (1.4%) and accumulates, 
resulting in high concentrations after 6-10 months in case of prolonged 
use.2  
Diclofenac has 2 active metabolites, D4OH AND D3OH. D4OH has an 
anti-inflammatory effect (30% of the activity of diclofenac), whereas 
D3OH has a weak anti-inflammatory effect as well. Other diclofenac 
metabolites are pharmacologically inactive.2 Figure 1 represents diclofenac 
metabolism schematically. 
 
There are no studies in the literature evaluating the effect of CYP3A4, 
CYP3A5 and CYP2C9 genotype on diclofenac clearance, D4OH formation 
clearance and D5OH formation clearance. Genotype might be linked to an 
increased or decreased enzyme activity in individuals hetero- or 
homozygous for certain mutations in specific enzymes. Therefore we 
conducted a pilot study in children receiving rectal diclofenac for 
postoperative analgesia and determined diclofenac, D4OH and D5OH 
plasma concentrations and analyzed DNA for CYP3A4*1b, CYP3A5*3, 
CYP2C9*2 and CYP2C9*3, to evaluate the effect of CYP3A4, CYP3A5 
and CYP2C9 genotype on diclofenac clearance, D4OH formation clearance 
and D5OH formation clearance. 
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Figure 1 Diclofenac metabolism 
 
Patients and methods  
 
Following approval of the study by the Medical Ethical Committee of the 
Erasmus MC Rotterdam and after written informed consent was obtained 
from the parents, 65 children were included in a randomized controlled trial 
comparing the analgesic effect of rectal paracetamol (APAP) versus rectal 
diclofenac for postoperative analgesia following (adeno)tonsillectomy.7  
Inclusion criteria were: age between 3 and 12 years, elective (A)TE and 
ASA status 1 or 2. Exclusion criteria were: coagulopathy, diclofenac or 
APAP < 24 hours prior to surgery, known allergy for diclofenac or APAP, 
hepatic diseases interfering with drug metabolism and abnormal renal 
function. 
Patients receiving diclofenac (n = 32) were eligible for this current analysis, 
identifying the relation between genotype and diclofenac clearance, D4OH 
formation clearance and D5OH formation clearance. Separate informed 
consent was obtained for DNA analysis. No patients received drugs known 
to alter the activity of CYP3A4 or CYP2C9. 
 
Procedure 
Children received a loading dose of 2 mg/kg diclofenac rectally 30 minutes 
before scheduled (A)TE. Blood samples (1 ml) for the analysis of 
diclofenac, D4OH and D5OH plasma concentrations were obtained through 
a peripheral venous catheter directly after induction of anesthesia, at the end 
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of the procedure and 1, 2 and 3 hours after awakening. For DNA analysis, a 
blood sample (1 ml) was obtained directly after induction of anesthesia.  
 
Diclofenac, D4OH and D5OH assay 
Diclofenac sodium and naproxen were purchased from SIGMA ALDRICH 
(Saint Quentin Falavier, France), D4OH and D5OH were provided by 
Novartis, USA. All solvents used were analytical grade. 
The HPLC system consisted of a Quaternary P 1000 XR pump 
(ThermoQuest-TQ, Florida, USA), a TQ auto sampler, a TQ UV 6000 
detector (280nm) linked to TQ Spectranet for recording and storing 
throughout analysis. We used a LC8 5 µm particle size Supelcosil column 
(150 x 4.6 nm, Supelco Bellafonte, USA). The mobile phase was a mixture 
of acetonitrile/ sodium acetate 50 mV (70/30, v/v) adjusted to pH 5 by 
phosphoric acid and the flow rate 1.2 ml/min. 
 
Stock solutions of diclofenac (1000 mg/l) , D4OH and D5OH (500 mg/l) 
and naproxen (1000 mg/l) were prepared in methanol and stored at –20°C. 
Calibration standards (0.01-1 mg/l) and plasma controls (0.04, 0.2, 0.750 
mg/l) were prepared by appropriate dilutions of the stock solutions in drug-
free plasma. Naproxen (10 mg/l) was used as internal standard. Briefly, 500 
µl of plasma sample, 100 µl of internal standard and 1500 µl H3PO4 (1M) 
were extracted in 8 ml of diethylether. After centrifugation, the organic 
layer was evaporated to dryness at 40°C under nitrogen. The residue is 
dissolved in a mixture of 50 mM sodium acetate and –methanol (50/50, 
v/v). 
 
Under the chromatographic conditions used, the retention times were 18.5, 
6.9, 6.1 and 7.9 min for respectively diclofenac, D4OH, D5OH and 
naproxen. Recovery from extraction was over 90% for the three 
compounds. Calibration curves were linear over the range of 0.01 to 1 mg/l 
and coefficients of variation of the slope were between 2.8 and 5.8% (n = 
5). The limit of quantification was 5 µg/l for the three compounds. The intra 
and inter-assay coefficients of variation, determined from three quality 
controls (0.04, 0.2, 0.750 mg/l) were lower than 7%. 
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DNA analysis 
DNA analysis for CYP3A4*1b, CYP3A5*3, CYP2C9*2 and CYP2C9*3 
mutations was performed isolating genomic DNA from blood using 
GenomicPrep Blood DNA Isolation Kit (Amersham Pharmacia Biotech, 
Buckinghamshire, UK). DNA samples were examined for CYP3A4*1b, 
CYP3A5*3, CYP2C9*2 and CYP2C9*3 mutations using PCR-RFLP 
method developed by van Schaik et al.8 
 
Data analysis 
Diclofenac clearance, D4OH formation clearance and D5OH formation 
clearance were estimated using non-linear mixed effects models. A single 
compartment, first order absorption and first order elimination model was 
used to describe diclofenac pharmacokinetics.9 Analysis of the relation 
between clearances and genotype was performed using cross tabs after 
discretizing clearances based on the interquartile ranges. For CYP3A4 
genotype, we compared patients being wild type (*1/*1) to patients being 
hetero- or homozygous for CYP3A4*1b (*1/*1b; *1b/*1b). For CYP3A5 
genotype, we compared patients being wild type (*1/*1) or heterozygous 
(*1/*3) to patients being homozygous (*3/*3), as only patients being wild 
type or being heterozygous have CYP3A5 activity.10 For CYP2C9 we 
compared patients being wild type (*1/*1) to patients being hetero- or 
homozygous for CYP2C9*2 or CYP2C9*3 (*1/*2; *1/*3; *2/*2; *3/*3), as 
the latter enzymes are associated with decreased enzyme activity.10  
 
 
Results  
  
Participant flow and follow up 
32 patients received diclofenac and were eligible for this current analysis. 
Blood samples were not available in 6 patients. Therefore data of 26 
children were available for DNA analysis and plasma concentration 
analysis.  
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Patients’ characteristics 
Median (25th-75th percentile) age and weight of the patients were 
respectively 4.0 (3.8-5.0) years and 20.0 (17.8-22.7) kg. The study group 
consisted of 14 boys and 12 girls. (Table 1) 
 
Diclofenac and metabolite plasma concentrations  
Diclofenac plasma concentrations ranged from 0-2.6 mg/l, being highest at 
the start of surgery, approximately 30 minutes after loading dose, and 
decreasing slowly postoperatively (Figure 2a). D4OH concentrations 
varied, ranging from 0-0.5 mg/l. Highest plasma concentrations were 
measured at the start of surgery, but there was only a slight decrease during 
the postoperative period (Figure 2b). D5OH concentrations were often not 
detectable. Therefore it was not possible to plot all concentrations. They 
ranged from 0-0.6 mg/l (Figure 2c).  
 
Diclofenac clearance and D4OH and D5OH formation  
Median (25th-75th percentile; range) diclofenac clearance, D4OH 
formation clearance and D5OH formation clearance were respectively 18.1 
(15.6-20.2; 11.2-66.9), 3.3 (2.8-3.9; 2.0-4.7) and 1.1 (0.7-1.6; 0.5-9.0) l/h. 
Clearances are represented in Figure 3, showing 2 outliers for diclofenac, 
respectively with a clearance of 30.8 l/h and 66.8 l/h, and 4 outliers for 
D5OH formation clearance with a D5OH formation clearance of 5.1 l/h, 5.7 
l/h, 9.0 l/h and 15.3 l/h.  
 
Table 1  Patients’ characteristics  
Age (years)1 4.0 (3.8-5.0)
2-8
Weight (kg)1 20.0 (17.8-22.7)
14.0-30.0
Gender  Male 
         Female 
12 (46.2%)
14 (53.8%)
 
1 median (25th-75th percentile); range 
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Figure 2a Diclofenac plasma concentrations 
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Figure 2b D4OH plasma concentrations 
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Figure 2c D5OH plasma concentrations 
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DNA analysis 
DNA analysis was performed for CYP3A4*1b, CYP3A5*3, CYP2C9*2 
and CYP2C9*3. 25 samples were available for analysis. 1 sample was 
missing due to logistical problems. Considering CYP3A4, 88% (n = 23) of 
the patients were wild type (*1/*1) and 8% (n = 2) of patients were 
heterozygous for CYP3A4*1b (*1/*1b). There were no homozygous 
patients for CYP3A4*1b (Figure 4a). 
 
Considering CYP3A5 8% (n = 2) of the patients were wild type (*1/*1), 
15% (n = 4) were heterozygous for CYP3A5*3 (*1/*3) and 73% (n=19) of 
the patients were homozygous for CYP3A5*3 (*3/*3) (Figure 4b). 
Analyzing CYP2C9 69% (n = 18) of the patients were wild type (*1/*1), 
15% (n = 4) of the patients were heterozygous for CYP2C9*2 (*1/*2), 12% 
(n = 3) of the patients were heterozygous for CYP2C9*3 (*1/*3) No 
patients were homozygous for CYP2C9*2 (*2/*2) or CYP2C9*3 (*3/*3) or 
heterozygous for both CYP2C9*2 and CYP2C9*3 (*2/*3) (Figure 4c). 
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Table 2  Genotyping of outliers in clearances 
 
 CYP3A4 CYP3A5 CYP2C9 
Diclofenac clearance (l/h) 
30.8
66.8
*1/*1
-
1/*3
-
*1/*1
-
D5OH formation clearance (l/h) 
9.0
5.3
5.1
5.7
*1/*1
*1/*1
*1/*1
*1/*1b
*3/*3
*1/*3
*3/*3
*1/*3
*1/*1
*1/*1
*1/*2
*1/*1
 
Relation between clearances and genotyping 
Genotyping of the outliers in diclofenac clearance shows CYP3A4 wild 
type (*1/*1), Cyp3A5 heterozygous (*1/*3) and CYP2C9 wild type (*1/*1) 
for the patient with a diclofenac clearance of 30.8 l/h. Genotyping for the 
patient with a diclofenac clearance of 66.8 l/h is missing (Table 2). 
Genotyping of the outliers in D5OH formation clearance shows Cyp3A5 
homozygous (*3/*3) and CYP3A4 and CYP2C9 wild type (*1/*1) for the 
patient with a D5OH formation clearance of 9.0 l/h; Cyp3A5 heterozygous 
(*1/*3) and CYP3A4 and CYP2C9 wild type (*1/*1) for the patient with a 
D5OH formation clearance of 5.3 l/h; Cyp3A5 homozygous (*3/*3), 
CYP3A4 wild type (*1/*1) and CYP2C9 heterozygous (*1/*2) for the 
patient with a D5OH formation clearance of 5.1 l/h; Cyp3A5 heterozygous 
(*1/*3), CYP3A4 heterozygous (*1/*1b) and CYP2C9 wild type (*1/*1) 
for the patient with a D5OH formation clearance of 5.7 l/h (Table 2). 
There was no relation between diclofenac clearance and CYP3A4, CYP3A5 
or CYP2C9 genotype (Figure 5a, 5b, 5c). There was also no relation 
between D4OH formation clearance and CYP2C9 (Figure 6) or between 
D5OH formation clearance and CYP3A4 and CYP3A5 (Figure 7a, 7b). 
Table 3 shows the number of patients being wild type, heterozygous or 
homozygous for CYP3A4, CYP3A5 and CYP2C9 genotype in the different 
interquartile ranges of the diclofenac clearance (Table 3a), D4OH formation 
clearance (Table 3b) and D5OH formation clearance (Table 3c).  
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Table 3a  CYP3A4, CYP3A5 and CYP2C9 genotype and diclofenac clearance   
Interquartile ranges of diclofenac clearance 1st 2nd 3rd 4th
CYP3A4     *1/*1 
             *1/*1b 
4
2
6
0
7 
0 
6
1
CYP3A5     *1/*1 
             *1/*3 
             *3/*3 
1
1
4
0
1
5
0 
1 
6 
0
2
4
CYP2C9     *1/*1 
            *1/*2 
             *1/*3 
4
0
2
7
0
0
3 
3 
1 
4
1
0
 
 
Table 3b  CYP2C9 genotype and D4OH formation clearance   
Interquartile range of D4OH formation clearance 1st 2nd 3rd 4th
CYP2C9 1/1 
  1/2 
  1/3 
5
0
0
2 
0 
3 
6 
3 
1 
5
1
0
 
 
Table 3c  CYP3A4 and CYP3A5 genotype and D5OH formation clearance  
Interquartile range of D5OH formation clearance 1st 2nd 3rd 4th
CYP3A4     *1/*1 
            *1/*1b 
6
0
-
5 
2 
- 
6 
0 
- 
5
1
-
CYP3A5     *1/*1 
             *1/*3 
             *3/*3 
0
1
5
1 
3 
3 
0 
0 
6 
0
1
5
 
Discussion  
 
This is the first study that investigates the relationship between genotype 
and diclofenac clearance and genotype and D4OH formation clearance and 
D5OH in children. In this pilot study we could not establish a relationship 
between CYP3A4, CYP3A5 or CYP2C9 genotype and diclofenac 
clearance, between D4OH formation clearance and CYP2C9 genotype or 
between D5OH formation clearance and CYP3A4 and CYP3A5 genotype. 
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The number of patients in this pilot study is limited and therefore we can 
not draw definite conclusions with regards to the relationship between 
CYP3A4, CYP3A5 or CYP2C9 genotype and diclofenac clearance and 
D4OH and D5OH formation clearance. Aithal et al described patients 
having CYP2C9*2 or CYP2C9*3 alleles to require lower doses of warfarin 
to achieve an anticoagulant effect similar to that in patients being wild type 
and to be more likely to have an excessive anticoagulant response.10 
Furthermore, bleeding episodes tend to be more common in persons having 
CYP2C9*2 or CYP2C9*3 alleles.10 
 
Looking at the metabolism of diclofenac, a potential effect of decreased 
CYP2C9 activity in patients being homozygous for CYP2C9*2 or 
CYP2C9*3, the effect would be higher on diclofenac clearance compared to 
its influence on D4OH formation clearance, since only 20% of diclofenac is 
metabolized into D4OH and therefore the amount of D4OH is low, which is 
shown in Figure 2b.9 
Table 4 shows the population allelic frequencies of the mutations analyzed 
in this study.  
 
Table 4 Allelic frequencies of CYP3A4*1b, CYP3A5*3, CYP2C9*2 and 
CYP2C9*3   
 Population frequency
CYP3A4*1b  
 Caucasians8 
 US Caucasians11 
 African Americans12 
5.3%
9.6%
54.6%
CYP3A5*3 
 Caucasians13 
 Japan14 
 African Americans14 
91%
71%
27%
CYP2C9*2 
 African Americans15 
 Sweden16 
3.6%
10.7%
CYP2C9*3 
 African Americans17 
 Korea18 
1.2%
1.1%
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Frequencies of the mutations analyzed in this study were comparable 
between the children included in our study and the normal population. 
Since population frequencies are relatively low, except for CYP3A5*3, and 
samples of only 25 patients were available in this study, the number of 
patients in this study was not sufficient to establish a relationship between 
clearances and genotype. De Wildt et al showed no relationship between 
CYP3A4 genotype and midazolam clearances in preterm born infants 26.0-
33.6 weeks gestational age.19 Although the frequency of CYP3A4*1b in the 
Caucasian population is 5.3%,8 the number of patients used by the Wildt et 
al was low (n = 29), making it difficult to establish a potential relationship 
between midazolam clearance and CYP3A4 genotype. 
 
Furthermore the developmental changes in enzyme activity have an effect 
on clearance other than that of altered enzyme activity due to differences in 
genotype. CYP3A4 activity changes with age.3 Before birth CYP3A4 
activity is low, but activity increases rapidly after birth and reaches adult 
levels of activity at the age of 6 to 12 months.3 During infancy CYP3A4 
activity appears to be increased.3 Developmental changes of CYP3A5 and 
CYP2C9 have not been described so far.  
Since children included in this study were approximately of the same age, 
the influence of developmental changes on enzyme activity probably will 
not have influenced our results. 
Besides the influence of developmental changes on enzyme activity, there 
might also be an influence of expression on the enzyme activity. We do not 
know to what extent certain mutations are expressed and subsequently to 
what extent certain mutations lead to altered enzyme activity. Therefore we 
do not know what the actual influence of these mutations is on enzyme 
activity. All these factors might have had an effect on our results. 
 
 
Conclusion 
 
This pilot study showed no relation between diclofenac clearance and 
CYP3A4, CYP3A5 or CYP2C9 genotype. There was also no relation 
between D4OH formation clearance and CYP2C9 or between D5OH 
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formation clearance and CYP3A4 and CYP3A5. Further research in a larger 
sample of patients is needed to fully analyze the relation between diclofenac 
clearance, D4OH and D5OH formation clearances and CYP3A4, CYP3A5 
and CYP2C9 genotype. 
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Pharmacokinetic studies 
 
The pharmacokinetics of paracetamol (APAP) in children have received 
limited attention in the literature. Most studies have aimed at the differences 
in APAP pharmacokinetics following oral versus rectal administration. 
Delayed and erratic absorption, leading to unpredictable APAP plasma 
concentrations following rectal administration and higher peak plasma 
concentrations following oral administration have been reported.1-4 Relative 
bioavailability of suppositories compared to oral administered APAP varies 
from 54-80%.2,5 Alternative routes of administration, such as intravenous 
administration of propacetamol, have not been investigated in neonates 
until recently (chapter 2.3).6 
 
Pharmacokinetic studies have reported APAP plasma concentrations, time 
to achieve maximum plasma concentrations (Tmax) and maximum APAP 
plasma concentration (Cmax). Linking APAP plasma concentrations to 
analgesic effect shows the absence of a relation between analgesic effect 
and APAP plasma concentrations (chapter 3.1, 3.2).7,8 A delay in 
maximum analgesic effect and peak plasma concentrations is reported,9,10 
suggesting that the plasma compartment is not the effect compartment. 
Piletta et al have suggested that APAP-induced analgesia might be centrally 
mediated,11 in which the time-course of APAP in CSF may parallel that of 
analgesic effect.12 Anderson et al suggest that cerebrospinal fluid (CSF) 
kinetics approximate more closely the effect compartment than plasma.13 
Based on these reports we measured APAP CSF concentrations and 
compared these with APAP plasma concentrations (chapter 2.1), resulting 
in a equilibration half life (Teq) of 1.93 (CV 43%) h. Taking into account 
the effect compartment Teq estimated for analgesia (53 min, CV 217%) and 
for anti-pyresis (71 min, CV 10%) in children, our results suggest that the 
CSF compartment is not the effect compartment responsible for these 
actions since analgesic and anti-pyretic effects occur earlier than APAP 
concentration changes in the CSF.14,15  
APAP plasma concentrations are not related to analgesic effect (chapter 
3.1, 3.2).7,8 However APAP plasma concentrations are related to APAP 
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concentrations in the effect compartment and provide information on the 
amount of APAP absorbed and the amount of APAP available for the effect 
compartment.  
Moreover, measuring APAP plasma concentrations reveals information on 
APAP metabolism, enabling us to determine APAP clearance. When 
combined with measurement of APAP metabolites, i.e. APAP-glucuronide, 
APAP-sulphate and mercapturine and cysteine metabolites, in urine, APAP 
clearances to APAP-glucuronide, APAP-sulphate and N-acetyl-p-
benzoquinone-imine (NAPQI) can be determined. These data provide 
information about the relative contributions of the different pathways 
involved in APAP metabolism. This enables us to study potential toxic 
effects and developmental changes both in clearance and in enzyme activity 
of the enzymes involved in APAP metabolism. 
 
An increase in mean (SE) APAP-glucuronide to APAP-sulphate ratio from 
0.12 (0.09) in preterm neonates 28-32 weeks gestational age,16 to 0.28 
(0.35) in preterm neonates 32-36 weeks gestational age,16 0.34 (0.08) in 
newborns,17 0.75 (0.10) in 3-9 year old children17,18 and 1.61 (0.21) in 12 
year old children,17 with an adult ratio of 1.80 (0.32)17 has been reported. 
Our results studying the APAP-glucuronide to APAP-sulphate ratio in 
infants shows a ratio of 0.69 at the age of 12 months (chapter 2.2). The 
contribution of glucuronidation to total APAP clearance appeared to be 
similar in infants compared to children, whereas the contribution of the 
glucuronidation is increased in adults. The fact that we were not able to 
detect oxidative pathways in our study supports the minor importance of 
this pathway in the normal dosing range. Furthermore infants and children 
have a relative enhanced capacity for sulphation.  
As glucuronide formation clearance increases with age, a developmental 
effect of enzyme activity in glucuronidation (UGT1A6 and UGT1A9) 
might be involved. Developmental changes in glucuronidation have been 
reviewed recently by the Wildt et al.19  
 
As an alternative route of APAP administration we investigated 
pharmacokinetic and pharmacodynamic actions of propacetamol in preterm 
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and term neonates (chapter 2.3).6 Intravenous administration of 
propacetamol enables us to more precise dosing, since bioavailabilty is not 
compromised by first pass effects. Furthermore APAP peak plasma 
concentrations are achieved more rapidly. Considering the clearance and 
half life in preterm and term neonates we found a maturational trend, which 
was in line with propacetamol pharmacokinetic data reported beyond the 
neonatal period. However pharmacokinetic data of APAP following 
administration of propacetamol in children are limited.  
 
 
Pharmacodynamic studies 
 
Evaluating the pharmacodynamic effects of APAP, all three studies showed 
no difference in effect between both treatment groups (chapter 3.1 
comparing analgesic effect of oral versus rectal APAP following major 
craniofacial surgery: 40 patients with a mean (SD) age of 10.3 (2.3) 
months;7 chapter 3.2 comparing analgesic effect of APAP versus 
diclofenac: 60 children with a median (25th-75th percentile) age of 4 (3-5) 
years; chapter 3.3 evaluating the potential morphine sparing effect of 
APAP: 54 patients with a median (25th-75th percentile) age of 0 (0-2) 
months). The number of patients requiring extra analgesia was low, 
indicating that overall analgesia was adequate, making it hard to assess a 
dose-effect relation. Distribution of patients between both groups was too 
uniform to determine any differences in analgesic regimens. Furthermore 
following the concept of pre-emptive analgesia, we administered loading 
doses prior to or during the operative procedure in order to achieve 
maximum analgesic effect at the time of awakening, which enhances 
adequate postoperative analgesia. Most important in performing these 
studies, is the fact that medical ethical aspects make it impossible to 
perform studies in which part of the children do not receive adequate 
analgesia.  
 
Furthermore when assessing pharmacodynamics a large variability in 
effects is reported, resulting from distribution of the blood to the site of 
action and from variability in the sensitivity of the receptors.20 The 
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contribution of the variability in distribution from the blood to the site of 
action will depend largely on changes in perfusion of the target tissue (5-
60%). The sensitivity of the receptors, which is defined in terms of affinity 
for binding or potency relative to another agent, might also be an important 
source of variability in effects.20  
 
The primary outcome parameter in these studies is the absence or presence 
of pain. In our study population we used COMFORT scale and VAS scores 
to assess the analgesic effects.21-23 The age of the children in our study 
population made self-report, which is generally considered as the “gold 
standard”, impossible. Therefore both nurses and investigators were trained 
to perform COMFORT scale scores to objectively assessing patients’ 
specific pain behavior. However the COMFORT scale not exclusively 
represents pain, but also distress, which might originate both from pain as 
well as from other forms of distress, for example the absence of the parents 
and the ICU environment.  
 
VAS scores represent pain experienced by the patients, but can not be 
considered as the “gold standard”, due to inter-individually varying patterns 
of pain response, which can not be accounted for in the VAS score. 
Furthermore there is inter-observer variability.22,24 Overall the effect on 
amount of pain as determined by validated pain scores as a “surrogate 
golden standard” is daily clinical practice and remains the primary outcome 
parameter. 
 
 
Pharmacogenetic studies 
 
Studying pharmacogenetics, we investigated the effect of DNA mutations 
encoding for enzymes involved in diclofenac and APAP metabolism. DNA 
mutations might lead to an altered enzyme activity or an altered expression 
of the enzyme involved, subsequently leading to an altered drug 
metabolism. If there’s only one pathway involved in drug metabolism, 
effects of altered enzyme activity may be extensive. Patients may be slow 
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or fast metabolizers due to altered enzyme activity and therefore requiring a 
different drug dosing regimen. However large samples of patients are 
needed to fully investigate the effect of DNA mutations on drug 
metabolism, since population allelic frequencies of most mutations are low 
(for example CYP3A4*1b 5.3-9.6% in Caucasians25,26 and CYP2E1*1d 
3.5% in Caucasians27 and 23% in Chinese28). 
 
Evaluating the effect of DNA mutations in enzymes involved in the 
oxidative pathway of APAP metabolism, we were not able to detect a 
relation between genotype and APAP clearance (chapter 4.1). This was in 
line with the fact that the contribution of the oxidative pathway to APAP 
metabolism is minor within the normal dosing range. However these 
mutations might have significant relevance when toxic APAP doses are 
administered and sulphation and glucuronidation are rate limiting, leading 
to an increased or decreased formation of NAPQI and therefore to increased 
or decreased toxic effects. This may indeed partly explain the inter 
individual differences in propensity to APAP toxicity.  
 
When we evaluated the effect of DNA mutations of enzymes involved in 
diclofenac metabolism on diclofenac and diclofenac metabolite formation 
clearances in a pilot study (chapter 4.2), we could not establish a relation 
between clearances and genotype.  
 
The relevance of this kind of studies is underlined by Aithal et al, who 
described patients having CYP2C9*2 or CYP2C9*3 alleles to require lower 
doses of warfarin to achieve an anticoagulant effect similar to that in 
patients being wild type and to be more likely to have an excessive 
anticoagulant response.29 Furthermore, bleeding episodes tend to be more 
common in persons having CYP2C9*2 or CYP2C9*3 alleles,29 outlining 
the importance of certain mutations on both adverse effects and toxic 
effects.  
 
Looking at the metabolism of diclofenac, a potential effect of decreased 
CYP2C9 activity in patients having CYP2C9*2 and/or CYP2C9*3 alleles 
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would be higher on diclofenac clearance compared to its influence on 
D4OH formation clearance, since only 20% of diclofenac is metabolized 
into D4OH and therefore the amount of D4OH is low (chapter 2.4). 
 
 
Future directions 
 
Pharmacokinetics 
Most of the pharmacokinetic studies report APAP plasma concentrations, 
both as a measure for analgesic effect as well as an indicator for potential 
toxicity. However, the plasma compartment is not the effect compartment 
and maximum analgesic effect is delayed after peak plasma concentrations. 
To circumvent this problem an alternative approach is warranted, for 
example population modeling. When using population modeling, smaller 
numbers of samples are needed, times on which samples are collected are 
less strict and pharmacokinetic parameters can be estimated based on 
smaller numbers of samples. 
 
The use of APAP plasma concentrations as an indicator for potential APAP 
toxicity may not be the right choice, since there is no direct relation 
between APAP plasma concentrations and the formation of the oxidative 
metabolite NAPQI, which is responsible for APAP’s toxic effects. It would 
be better to focus on the clearance through oxidation, i.e. the NAPQI 
formation clearance, and on the availability of glutathion stores, as 
glutathion detoxifies NAPQI. Glutathion stores may be compromised in 
critically ill children with low protein-calorie intake.30 In addition to the 
low glutathion stores, resulting from this low protein-calorie intake, the 
capacity for glucuronidation in these critically ill children might be 
decreased,30 leading to an increased oxidation and subsequently to an 
increased NAPQI formation clearance. On the other hand, Carcillo et al 
report that cytochrome P450 mediated drug metabolism is reduced in 
critically ill children with sepsis induced multiple organ failure.31 This 
might lead to a decreased potential APAP toxicity, since metabolism 
through oxidation will then be decreased. 
Chapter 5 
 
208 
 
Measuring APAP plasma concentrations following oral or rectal 
administration in order to determine clearance, one should realize that both 
volume of distribution as well as clearance are obscured by bioavailabilty. 
We used relative bioavailability of the rectal compared to the oral 
formulation to correct for differences in bioavailability between oral and 
rectal formulations. However, only by comparing APAP plasma 
concentrations after rectal or oral administration with APAP plasma 
concentrations following intravenous administration of APAP, in which 
bioavailability is 100%, we will be able to determine bioavailability in an 
adequate way. 
 
Furthermore we need to explore developmental changes in APAP 
clearances, which might partly be due to developmental changes in enzyme 
activity. This way we will be able to predict the risk of APAP toxicity for 
children in different age groups, since children experience less toxicity after 
high APAP doses compared to adults,32-34 which makes it important to 
investigate toxicity changes with age.  
 
Pharmacodynamics 
The main problem in studying pharmacodynamics is objectively assessing 
the effects of APAP. Antipyretic effects can be measured objectively. The 
analgesic effects in neonates, infants and children however are more 
difficult to assess objectively. In determining the analgesic effect of APAP 
the most important question that remains is how to assess the analgesic 
effect of APAP in children. As the majority of the children in our studies 
was below the age of 1 year, we could not use self-report pain measurement 
instruments, which are considered to be the “gold standard”. Even in our 
study comparing the analgesic effect of APAP and diclofenac, in which 
children were 2-7 years of age, children at the age of 5 years were not 
always able to report their pain adequately and consistently following 
(adeno)tonsillectomy in hospital setting.  
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Using the COMFORT scale and the VAS score, an attempt is made to 
objectively assess pain and thus analgesic effect. Although both nurses and 
investigators were trained to perform the COMFORT scale scores, this 
should not be considered as a surrogate gold standard. Non-invasive 
methods in combination with validated pain assessment instruments open 
new possibilities to explore the relation between neurophysiological 
changes and observed behavior during painful moments. Several methods 
may reveal the integrity of the pain conducting system (fMRI, PET scan, 
laser Evoked Potentials).35 However methods that objectively assess and 
quantify the reaction to pain are restricted to studies in adult volunteers up 
till now. Therefore we conducted the study described in chapter 6, to 
assess the value of Electroencephalography (EEG) and Sympathic Skin 
Response (SSR) for postoperative pain assessment.36 In this study the 
clinical role of the SSR could not be unambiguously assessed, most likely 
because of the homogeneity of the group of children included in this study 
with respect to adequate and equal pain control. However SSR monitoring 
is an interesting new variable in future pain studies. 
 
Pharmacogenetics 
As we demonstrated in chapter 4, evaluating the relation between 
clearances and genotype, the largest problem in pharmacogenetic studies is 
the limited number of patients. As population allelic frequencies of most 
mutations are low, large samples of patients are needed in order to fully 
investigate the effect of DNA mutations on enzyme activity or expression. 
 
When linking genetic blueprint to toxic APAP effects, developmental 
changes in enzyme activity and the impact of specific mutations on enzyme 
activity should be further investigated. However only by administering 
different doses of APAP to children of different ages and measuring 
NAPQI formation clearance or mercapturine or cysteine metabolites, one 
can fully investigate the contribution of the oxidative pathway under 
different circumstances in different age groups and thus predict potential 
toxic effects of APAP. Although potentially very important, medical ethical 
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reasons will prevent the conduction of this kind of studies in the pediatric 
age group. 
 
 
Conclusion 
 
Against the background of the increasing knowledge of genetics, these 
pharmacokinetic and pharmacodynamic studies together with new, non-
invasive methods to visualize pain within the central nervous system can be 
considered as a model for future research of drugs, in particular analgesic 
drugs.  
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Abstract 
 
Background 
Although the concept of nociception and the presence of specific pain tracts 
in the central nervous system have been known for many years, very little 
clinical research has been done with regards to the central conduction of 
pain in young infants. Non-invasive methods in combination with validated 
pain assessment instruments are potential powerful tools to determine a 
relationship between neurophysiological changes and the observed behavior 
during painful moments. 
 
Methods 
Following major thoracic or abdominal surgery a simultaneous Electro 
Encephalogram (EEG) and Sympathic Skin Response (SSR) registration of 
30 minutes was made on the first and on the second day postoperatively in 
31 patients in the age of 0-12 months. These children participated in a 
randomized clinical trial evaluating morphine and morphine in combination 
with paracetamol for postoperative pain management. Simultaneous 
standardized video registrations were made in 15 patients. During the 30-
minute registration a painful stimulus, consisting of standardized pressure 
on 1 of the patient’s fingernails, was applied to the patients after 15 and 
after 20 minutes. Postoperative pain assessment using the validated 
COMFORT scale and Visual Analogue Scale (VAS) was performed every 
2 or 3 hours and during SSR and EEG registration.  
 
Results 
Analysis of the frequencies and the amplitudes of the SSRs during the SSR 
registration showed no relation between age and SSR frequency or between 
age and SSR amplitude. SSR amplitudes in awake situation were highest 
compared to drowsy situation and sleep. In addition SSR amplitudes were 
higher on the second day postoperatively, compared to the first day 
postoperatively. Analysis of the video registrations showed no correlation 
between SSR frequency and VAS or COMFORT scale scores. An increase 
in spontaneous SSR frequency was observed during the 2 minutes 
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preceding the painful stimulus. Spontaneous SSR frequency decreased 
during the interval between the first and the second painful stimulus. Visual 
assessment of the EEG registrations showed that the number of unchanged 
EEGs expressed as a percentage of the total number of unchanged EEGs 
and EEGs showing arousal, in sleep, awake and drowsy situation after 
spontaneous SSRs was respectively 71%, 23% and 62% compared to a 
percentage of 22% after induced SSRs. 
 
Conclusion 
This study describes a method for continuous Sympathic Skin Response 
monitoring as an objective neurophysiological variable. The clinical role 
could not be unambiguous assessed in this study, most likely because of the 
homogeneity of the group of children included in this study with respect to 
adequate and equal pain control. Also, the ICU environment might 
encounter non-painful distress, resulting in spontaneous SSRs. However 
SSR monitoring is an interesting new variable in future pain studies. 
 
 
Introduction 
 
One of the key issues in pain assessment is the response and conduction of 
the painful (nociceptive) stimulus in the central nervous system. Very little 
clinical research has been done with regards to the central conduction of 
pain, even though the concept of nociception and the neuroanatomy of pain 
tracts have been known for many years. Non-invasive methods in 
combination with validated pain assessment instruments open new 
possibilities to determine a relation between the neurophysiological changes 
and the observed behavior during painful moments.1 
 
Although several methods may reveal the integrity of the pain conducting 
system (fMRI, PET scan, laser Evoked Potential),2 methods that objectively 
assess and quantify the reaction to pain as a normal function are sparse. 
Also, most methods require a standardized stimulus-response procedure 
and/ or a co-operative patient to (subjectively) respond to given stimuli and 
have only been tested in an experimental setting.3  
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Electroencephalography (EEG) and the Sympathic Skin Response (SSR) 
are neurophysiological methods that have the potential to objectively 
measure and quantify the reaction to pain. Andersson observed EEG 
changes to painful stimuli in 28 out of 31 premature babies less than 33 
weeks gestational age. Visual assessment of the EEGs showed that the EEG 
reaction was either a generalized desynchronisation or sudden, generalized, 
increase in amplitude.4 
 
The Sympathic Skin Response (SSR) is a reflection of the activation of the 
autonomic nervous system in response to a stimulus like pain.5 The main 
pathways involved in the SSR are nociceptive afferent pathways, and 
efferent from the hypothalamus, ventrolateral brainstem reticular formation, 
down to the spinal cord in the lateral column to sympathic ganglia and 
finally C-fibers that innervate the sweat glands. Changes in sweat gland 
production are responsible for the SSR in combination with local changes in 
the epidermis.5 Although the SSR is usually studied as a response to a 
standardized stimulus, it is expected that the response can also be measured 
as a result of an ‘in vivo’ pain stimulus. 
 
The use of behavioral pain assessment scores has become standard of care 
in our ICU.6,7 The aim of the present study was to assess the value of EEG 
and SSR registration for postoperative pain assessment. We included 
neonates and infants at the age of 0 – 12 months for 48 hours following 
major abdominal or thoracic surgery as part of a randomized clinical trial 
evaluating the effect of additional paracetamol (APAP) on morphine 
consumption, using the COMFORT scale6,8 and the Visual Analogue Scale9 
to assess the effect of the analgesic regimen.  
 
 
Methods 
 
Patients 
Following approval of the study by the Medical Ethical Committee of the 
Erasmus MC Rotterdam and The Central Committee on Research Involving 
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Human Subjects and after written informed consent was obtained from the 
parents, a simultaneous EEG and SSR registration of 30 minutes was made 
on the first and the second day following major thoracic or abdominal 
surgery. 
 
Patients included were between 0 and 12 months of age, ≥ 36 weeks 
gestational age and body weight ≥ 1800 grams. Based on the magnitude of 
the surgical procedure all patients received morphine postoperatively. After 
a loading dose of 100 µg/kg morphine at the end of the operative procedure, 
children < 45 weeks postconceptional age received 5 µg/kg/h and children 
≥ 45 weeks postconceptional age received 10 µg/kg/h morphine, based on a 
randomized clinical trial performed before in our ICU.7 According to the 
study protocol patients received either APAP (80-100 mg/kg/24 hours) or 
placebo in addition to continuous intravenous morphine. 
 
Procedure 
Patients were included as part of a study protocol investigating the 
morphine sparing effect of APAP in neonates and infants. Postoperatively 
patients were admitted to the Pediatric Surgical Intensive care Unit 
(PSICU) for at least 48 hours. Patients received either morphine or 
morphine in combination with APAP for postoperative analgesia. Pain 
assessment using the COMFORT scale6,8 and the Visual Analogue Scale 
(VAS)9 was performed every 2 hours during the first 24 hours 
postoperatively and every 3 hours during the second 24 hours 
postoperatively. Thirty-minute EEG and SSR registrations were made at the 
ICU during the first and the second day after surgery, preferably between 
9.00 and 12.00 am. In order to record a neonatal derivation of the EEG, 14 
Ag-AgCl surface electrodes were placed on the patient’s head according to 
the international 10-20 system. To record the SSR, we placed 2 surface 
electrodes on one of the patient’s hands (one on the palm and one on the 
dorsum as a reference) and 2 surface electrodes on one of the patient’s feet 
(one on the palm and one on the dorsum as a reference). During the 30-
minute registration spontaneous occurring SSRs were recorded. In addition 
SSRs were recorded after a painful stimulus, which was given to the 
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patients after 15 minutes and after 20 minutes. This stimulus consisted of 
applied pressure on one of the patient’s fingernails performed as standard 
procedure in the evaluation of the level of consciousness using the pediatric 
Glasgow Coma Scale in children less than 4 years of age.10 The exact time 
of the stimuli was recorded on the computer during EEG and SSR 
registration. In 15 patients simultaneous video registrations of the patients 
during the time of EEG and SSR registration were made as well, enabling 
off line reassessment of clinical signs of pain. These video registrations 
were used by the investigators to determine the VAS and COMFORT scale. 
The total number of SSRs recorded during the 30 minute registration, the 
total number of spontaneous SSRs and the number of induced SSRs after 
painful stimuli were assessed. In addition the amplitude of the SSR in sleep, 
drowsy and awake situation was measured. 
 
Statistical analysis 
Mann-Whitney U test was used to analyze the relation between age and the 
total number of SSRs, the number of spontaneous SSRs and the number of 
induced SSRs; Spearman’s rho for the correlation between age and SSR 
amplitude in sleep, drowsy and awake situation; one-way Anova for the 
difference in SSR amplitude in sleep, drowsy and awake situation; 
Friedman test for the difference in SSR frequency in sleep, drowsy and 
awake situation; Wilcoxon signed ranks test for the difference between SSR 
frequency (total, induced and spontaneous) on day 1 and day 2 
postoperatively and for the difference in amplitude in sleep, drowsy and 
awake situation on day 1 and day 2 postoperatively. 
 
 
Results 
 
In the period from January till September 2001 we included 31 patients, of 
which we made a total of 57 EEG and SSR registrations. EEG and SSR 
registrations at the second day after surgery were missing in 5 patients: 1 
due to logistic problems, 1 due to early discharge from the ICU and 3 due to 
withdrawal of the parental informed consent for the second EEG and SSR 
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registration. Median age (25th-75th percentile) was 48 (38-54) weeks 
postconceptional age. The analgesic regimen, assessed by trained nurses 
using the COMFORT scale and the VAS, was adequate in all patients at the 
moment of EEG and SSR registration (VAS < 4cm, COMFORT scale < 
17), in which patients received a higher total dose of morphine on the first 
day postoperatively compared to the second day postoperatively (mean 
(SD) respectively 325 (104) and 206 (87) µg/kg). 
 
EEG registration 
For EEG analysis we focused on the EEG during periods of painful stimuli 
and periods where spontaneous SSRs were recorded. In a subgroup of 24 
consecutive EEGs, the number of unchanged EEGs after spontaneous SSRs, 
expressed as a percentage of the total number of unchanged EEGs and 
EEGs showing arousal in sleep, awake and drowsy situation after 
spontaneous SSRs was respectively 71%, 23% and 62% compared to a 
percentage of 22% after induced SSRs (Table 1). 
 
Visual assessment of these 24 EEGs revealed 4 different patterns of 
changes at the same moment of the SSR responses, either spontaneous 
occurring or provoked after a painful stimulus. Of the EEGs that were not 
artefact obscured, 27% showed EEG changes during spontaneous SSRs and 
77% during induced SSRs. Within the same patient the patterns of EEG 
reactivity could differ between the various SSR periods. These EEG 
patterns were an increase in fast activity (Figure 1a), a decrease in the 
amount of faster activity, a more general slowing of the background activity 
or a general attenuation in background amplitude (Figure 1b & 1c, Table 1).  
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Table 1  
 Spontaneous SSRs Induced SSRs 
 Total Awake Drowsy Sleep  
Total number of SSRs  
 
334 205 38 91 42 
With unchanged EEG 
 
187 110 18 59 8 
With EEG changes 
 
 Increase of fast activity 
 Decrease of fast activity 
 General slowing 
 Attenuation 
 
68 
 
8 
14 
12 
34 
33 
 
3 
7 
1 
22 
11 
 
1 
2 
4 
4 
24 
 
4 
5 
7 
8 
27 
 
5 
4 
8 
10 
EEG artefact obscured  79 62 9 8 7 
 
EEG changes after spontaneous and induced SSRs in a subgroup of 24 EEG registrations 
 
 
 
  
Figure 1a EEG increase in fast activity acceleration after a spontaneous SSR
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Figure 1b EEG attenuation in background amplitude deceleration after an  
induced SSR 
Figure 1c EEG attenuation in background amplitude deceleration after a 
spontaneous SSR 
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SSR registration 
Age was not significantly related to the total number of SSRs, the number 
of spontaneous SSRs and the number of induced SSRs. Neither was age 
related to the SSR amplitude in sleep, drowsy and awake situation. 
However there was a significant difference in SSR amplitude (spontaneous 
and induced) in sleep, drowsy and awake situation. SSR amplitude was 
highest in awake situation (Table 2a). 
 
When we compared the SSR registrations made on the first day 
postoperatively to the SSR registrations made on the second day 
postoperatively, there were no significant differences in total number of 
SSRs, number of spontaneous SSRs and number of induced SSRs (Table 
2b). The SSR amplitude in sleep, drowsy and awake situation however 
differed significantly between day 1 and day 2 postoperatively, being higher 
on the second day postoperatively (Table 2b). 
SSR frequency showed an increase in spontaneous SSR frequency during 
the 2 minutes preceding the painful stimulus. Spontaneous SSR frequency 
in the interval between the first and the second painful stimuli was 
decreased compared to spontaneous SSR frequency before the first painful 
stimulus.    
 
Video registrations 
Analysis of the video registrations showed no correlation between SSR 
frequency and VAS or COMFORT scale score.  
 
 
Discussion 
 
To our knowledge this is the first study in children, admitted to an ICU, 
using SSR monitoring for the assessment of pain. Up until now there was 
no experience with the use of SSR registration other than in an 
experimental setting. 3  
In this study we were able to continuously monitor the occurrence of SSRs 
in neonates and infants in the age range of 0-12 months. Other recently 
developed “pain visualising” methods (PET scan, fMRI) 2 can not be 
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applied in a daily clinical setting of the ICU and, moreover, these latter 
methods can not be used for neuromonitoring purposes.  
 
Our data showed no relation between age and SSR frequency or between 
age and SSR amplitude, which might indicate that sympathic activity 
resulting in a SSR is comparable for all subjects within this age range. 
However there was a significant difference in SSR amplitude between 
sleep, drowsy and awake situation, being highest in awake situations. This 
might be explained by a higher responsiveness in awake situation. 
The number of spontaneous SSRs increased during the 2 minutes preceding 
the painful stimulus, which might be due to the fact that preparations were 
made to apply pressure on one of the patient’s fingernails by touching the 
patient’s finger and to register the exact time of the painful stimulus.  
The SSR amplitude in sleep, drowsy and awake situation however was 
higher on the second day postoperatively, which could be explained by a 
more sedated condition on the first day postoperatively as a consequence of 
the effects of anesthesia or to the higher doses of morphine patients were 
receiving on the first day postoperatively (mean (SD) morphine 
consumption on day 1 and 2 respectively 325 (104) µg/kg and 206 (87) 
µg/kg). 
 
The SSR response is the result of sympathic activity.5 A stimulus that can 
provoke a SSR is non specific and includes various stimuli, for example 
noise stimuli or painful stimuli.5 
Therefore, for interpretation of SSRs one should keep in mind that not 
every SSR is provoked by pain and one should be very careful in 
controlling the circumstances under which SSR registration takes place, 
before it can be used as an additional tool for pain assessment in non verbal 
patients. Especially when SSR registrations of different patients are 
compared, it is very difficult to control these circumstances. Although SSRs 
were seen after painful stimuli in our study, the presence of SSRs was not 
always clearly related to the moment of painful stimuli or distress. The 
tentative question is whether these spontaneous occurring SSRs without 
visible pain or distress are indicative of internal pain or distress. 
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Table 2a  
 awake drowsy sleep 
SSR total 1 
 
11.0 
27.5 ; 0-139 
3.5 
7.6 ; 0-33 
4.2 
5.0 ; 0-15 
Amplitude SSR 1 
 
846 
938 ; 400-6200 
670 
890 ; 300-4000 
744 
769 ; 300-5300 
    
SSR total 2 
 
14.2 
12.8 ; 0-39 
3.6 
6.5 ; 0-29 
6.5 
12.0 ; 0-49 
Amplitude SSR 2 
 
1311 
892 ; 300-5000 
830 
966 ; 400-4400 
550 
893 ; 200-4600 
  
Mean (SD; range) SSR number during 30-minute registration  and amplitudes (µV) in 
sleep, drowsy and awake situation on day 1 and day 2 postoperatively 
 
 
Table 2b   
 day 1 day 2 
SSR total  
 
20.8 
5.4 ; 0-139 
27.4 
4.1 ; 2-72 
SSR spontaneous 
 
18.7 
5.3 ; 0-130 
24.3 
3.7 ; 2-62 
SSR induced 
 
2.2 
0.4 ; 0-9 
3.1 
0.6 ; 0-10 
 
Mean (SD; range) SSR number (total, spontaneous and induced) during 30-minute 
registration on day 1 and day 2 postoperatively 
 
 
The fact that we could not establish a correlation between SSR frequency 
and VAS or COMFORT scale score might be explained by the fact that the 
group of patients included in this study was to homogenous. The absence of 
high VAS scores and COMFORT scale scores indicates that the analgesic 
regimen was adequate in all patients, which makes it more difficult to test 
the EEG and SSR as suitable instruments for objective assessment of pain. 
Another explanation could be that in this clinical setting patients might be 
distressed for other reasons than pain, for example the noisy environment 
on the ICU and the absence of their parents. Distress other than originating 
from pain, might provoke SSRs as well. This makes it more difficult to 
SSR’s and EEG’s contribution to postoperative pain assessment in neonates and infants 
 
 
227
 
distinguish the SSRs resulting from the actual painful stimuli, than induced 
by other reasons. 
Visual assessment of the EEG registrations showed EEG changes both after 
spontaneous and after induced SSRs. However the number of unchanged 
EEGs expressed as a percentage of the total number of unchanged EEGs 
and EEGs showing arousal was higher after induced SSRs. This indicates 
that, although visible signs of pain are absent, the registration of SSRs 
could well be a measure for activity within the central nervous system 
resulting from pain or more generally from arousal. 
 
 
Conclusion 
 
This study describes a method for continuous SSR monitoring as an 
objective neurophysiological variable. The clinical role could not be 
unambiguously assessed in this study, most likely because of the 
homogeneity of the group of children included in this study with respect to 
adequate and equal pain control. Also, the ICU environment might 
encounter non-painful distress, resulting in spontaneous SSRs. However 
SSR monitoring is an interesting new variable in future pain studies. 
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Summary 
 
Paracetamol (APAP), known as acetaminophen in the USA, is widely used 
both in hospital settings and at home for antipyresis and mild 
(postoperative) pain. Even though APAP is available over the counter and 
is the third most prescribed drug in our Pediatric Surgical Intensive Care 
Unit (PSICU), following nystatin and cisapride, there are still surprisingly 
few data available concerning the pharmacokinetics and pharmacodynamics 
of APAP in children.  
To further elucidate APAP’s pharmacokinetics (i.e. the absorption, 
distribution, metabolism and elimination of APAP), pharmacodynamics 
(i.e. the effects encountered by APAP) and pharmacogenetics (i.e. the 
influence of DNA on APAP metabolism) in children, we conducted the 
studies summarized below.  
 
 
Pharmacokinetic studies 
  
APAP-induced analgesia might be centrally mediated, with the time-course 
of APAP in CSF paralleling that of analgesic effect. There are few studies, 
however, describing APAP cerebrospinal fluid (CSF) concentrations in 
children. To investigate age-related changes in the plasma to CSF 
equilibration half-time (Teq) of APAP, we studied 41 children undergoing 
(semi) elective surgery for placement or revision of a ventriculo-peritoneal 
shunt or insertion of a temporary external ventricular drain, and receiving a 
loading dose of 30-40 mg/kg APAP 1 hour before scheduled surgery.  
Median (25th-75th percentile) age and weight of the children were 12 (3-
62) months and 10.0 (5.8-20.0) kg. Median (25th-75th percentile) time 
between APAP loading dose administration and collection of blood samples 
and median time (25th-75th percentile) between APAP loading dose and 
collection of CSF were 125 (95-210) and 133 (33-202) minutes, 
respectively. The population mean Teq, standardized to a 70 kg person, was 
1.93 (CV 43%) h, an estimate similar to that described in adults (2.1 h). 
There was no relationship between age and Teq other than that predicted by 
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size. APAP plasma concentrations ranged from 0.0 – 33.0 mg/l, APAP CSF 
concentrations ranged from 0.0 – 21.0 mg/l.  
Size rather than blood-brain-barrier maturation determines Teq changes 
with age in children. Based on these results we predict a neonate (3.5 kg), a 
1-year-old child (10 kg), a 5-year-old child (20 kg), a 10-year-old child (30 
kg) and an adult (70 kg) to have a Teq of 0.9, 1, 1.4, 1.6 and 1.93 h, 
respectively (chapter 2.1) 
 
Data concerning APAP metabolism in infants are scant. Previous studies 
have examined urinary metabolite recovery rates after a single dose of 
APAP either in neonates (<6 weeks) or in children (3-9 years). There are no 
such studies in infants. Therefore we studied 47 infants undergoing major 
craniofacial surgery receiving APAP 19-45 mg/kg 6-, 8-, or 12 hourly as 
either elixir or suppository formulation for postoperative analgesia, after a 
loading dose of 33–59 mg/kg rectally during the operative procedure. 
Mean (SD) age and weight of the patients were 11.8 (2.5) months and 9.1 
(1.9) kg. Clearance of APAP to APAP-glucuronide (%CV) and to APAP-
sulphate were 6.6 (11.5) and 7.5 (11.5) l/h, respectively, standardized to a 
70 kg person using allometric ‘¼ power’ models. Glucuronide formation 
clearance, but not sulphate formation clearance, was related to age and 
increased with age from a predicted value in a neonate of 2.73 l/h/70kg to a 
mature value of 6.6 l/h/70kg with a maturation half-life of 8.09 months. 
Urine clearance of APAP-glucuronide, APAP-sulphate and unchanged 
APAP (%CV) were 2.65, 3.03 and 0.55 (28) l/h/70kg, respectively. The 
urine clearance of unchanged APAP and metabolites was related to urine 
volume flow rate. Clearance attributable to pathways other than these 
measured in urine was not identifiable. The glucuronide/sulphate formation 
clearance ratio was 0.69 at 12 months age. Sulphate metabolism contributed 
50% towards APAP clearance. Glucuronide formation clearance increases 
with age in the infant age range but sulphate formation does not. Renal 
clearance of APAP and its metabolites increases with urine flow rate.  
This and other studies show that APAP metabolism to glucuronide appears 
to be similar in infants and children, but is higher in adults in comparison to 
children. Oxidative pathways were undetectable in this infant study and 
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may explain, in part, the reduced incidence of hepatotoxicity in infants 
(chapter 2.2). 
 
In order to investigate pharmacokinetic and pharmacodynamic actions of 
APAP after intravenous administration of a single dose of propacetamol in 
preterm and term infants on the first day of life, we studied 20 preterm and 
10 term infants.  
Mean (SD) serum half lifes (t ½) in preterm and term infants were 277 (143) 
min and 172 (59) min (p<0.05), respectively; mean (SD) clearances (CL) 
were 0.116 (0.08) l/kg/h and 0.170 (0.06) l/kg/h (p<0.05), respectively. A 
correlation between gestational age and t ½ was established (r = -0.46). We 
could not show an effect of gender or administration of prenatal steroids on 
the pharmacokinetics of APAP. The level of analgesia seemed to be 
associated with a therapeutic (> 5 mg/l) level in neonates receiving no 
medication other than propacetamol (n=15). The maturational trend of CL 
and t ½ in preterm and term neonates was in accordance with propacetamol 
pharmacokinetic data reported beyond the neonatal period (chapter 2.3). 
 
The metabolism of diclofenac in children has only been studied after 
intravenous administration and with the use of enteric-coated oral 
formulations. There are no data on diclofenac or its hydroxyl metabolite 
pharmacokinetics after rectal administration in children. Therefore we 
studied 26 infants undergoing (adeno) tonsillectomy receiving diclofenac 2 
mg/kg loading dose followed by 1 mg/kg 8-hourly as a suppository for 
postoperative analgesia. 
Mean (SD) age and weight of the patients were 4.5 (1.5) years and 20.5 
(4.1) kg. The formation clearance to 4’-hydroxy-diclofenac (D4OH) (%CV) 
and to 5’-hydroxy-diclofenac (D5OH) were 8.41 (8.1) and 3.41 (113) l/h, 
respectively, standardized to a 70 kg person using allometric ‘¼ power’ 
models. Clearance by other routes contributed 33.0 (64) l/h/70kg. 
Elimination clearance of hydroxyl metabolites was fixed at 27.5 l/h/70kg. 
The volumes of distribution of parent diclofenac and its hydroxyl 
metabolite were 22.8 (19.0) and 45.3 l/70kg, respectively. Suppositories 
had an absorption half-life of 0.613 (33.2) h with a lag time of 0.188 (24.9) 
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h. Inter-occasion variabilities of formation clearance to D4OH, diclofenac 
volume of distribution, absorption half-time and lag time for the 
suppository were 36%, 55%, 14% and 119%, respectively. The relative 
bioavailability of the suppositories compared to the enteric-coated tablets 
was 1.26. 
The formation clearance of the active metabolite D4OH contributed 19% to 
total clearance (44.82 l/h/70kg). The rectum is a suitable route for 
administration of diclofenac in children 2-8 years of age and is associated 
with a higher relative bioavailability than enteric-coated tablets and an 
earlier maximum concentration (50 vs. 108 min). This pharmacokinetic 
profile renders diclofenac suppositories a suitable formulation for short 
duration surgery (chapter 2.4). 
 
 
Pharmacodynamic studies 
 
Analgesic APAP plasma concentrations after major surgery in neonates and 
infants have not yet been established in the literature. We therefore studied 
40 children with a mean (SD) age of 10.3 (2.3) months, receiving 20 mg/kg 
APAP either orally (N=20) or rectally (N=20) 6-hourly after a rectal 
loading dose (40 mg/kg) during elective craniofacial surgery. 
APAP plasma concentrations and AUC were higher in patients receiving 
rectal APAP (mean AUC: 171.2 mg.hour/l) than in patients receiving oral 
APAP (mean AUC: 111.9 mg.hour/l). Pain scores were higher in patients 
receiving oral APAP. However, after exclusion of the patients who vomited 
after oral APAP administration, APAP plasma concentrations and pain 
scores did not differ between both groups. There was no relation between 
APAP plasma concentrations and pain scores.  
Although 9 of all 40 patients (22.5 %) did not reach the expected analgesic 
APAP plasma concentrations of 10- 20 mg/l, less than 7.5 % of the VAS 
pain scores exceeded the 4 cm cut-off score. This shows that analgesic 
APAP plasma concentrations after major surgery in this age group do not 
always reach the 10-20 mg/l level. Comparing rectal and oral 
administration, our findings also demonstrate that after craniofacial surgery 
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the rectal route is  the best way of administering APAP , after a rectal 
loading dose of 40 mg/kg during surgery (chapter 3.1). 
 
APAP is commonly prescribed for pain relief after (adeno)tonsillectomy 
[(A)TE] but reports of effectiveness are inconsistent. Diclofenac has been 
suggested as an alternative, although concerns about possible postoperative 
bleeding have tempered the use of diclofenac following (A)TE. We 
designed and conducted a study to compare the analgesic effect of rectally 
administered APAP and diclofenac in children undergoing (A)TE during 
ambulatory surgery and to assess the relations between APAP, diclofenac 
and D4OH plasma concentrations and postoperative pain scores. 
Furthermore we assessed the safety of diclofenac by monitoring 
postoperative bleeding and by registering the use of bipolar diathermy at the 
end of the procedure to arrest further bleeding. 
Data of 60 patients were analyzed. Median (25th-75th percentile) age was 4 
(3 – 5) years. Both groups consisted of 30 patients. There was no difference 
in analgesic effect between APAP and diclofenac and there was no 
relationship between plasma concentrations and pain scores. Two children 
from the APAP group had primary bleeding. Bipolar diathermy had been 
performed in 14 patients, 8 in the APAP group versus 6 in the diclofenac 
group. 
These findings indicate that rectal diclofenac (2 mg/kg loading dose, 1 
mg/kg 8 hourly) does not provide better pain relief than rectal APAP (40 
mg/kg loading dose, 30 mg/kg 8-hourly) following (A)TE. No relationship 
was shown between plasma concentrations and pain scores, and no increase 
was shown in incidence of primary or secondary bleeding due to the 
administration of diclofenac, despite its effect on platelet aggregation 
(chapter 3.2).  
 
The use of APAP in addition to continuous morphine infusion (CMI) has 
increased in recent years, despite the fact that safety and additional value of 
this combined treatment have never been studied in newborns and young 
infants. We therefore investigated if addition of APAP would decrease 
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postoperative morphine consumption in newborns and infants after major 
thoracic or abdominal surgery. 
We studied 54 patients with a median (25th -75th percentile) age of 0 (0-2) 
months. APAP was administered to 29 patients and 25 received placebo. 
Additional morphine bolus requirements and increases in CMI did not 
differ between the groups, and nor did total morphine consumption. 
COMFORT and VAS scores as well did not differ between the groups. 
Postoperative total morphine consumption was not related to age, although 
children < 45 weeks PCA needed less additional morphine boluses (p<0.01) 
and needed less increases in CMI (p<0.01). Mean APAP plasma 
concentrations ranged from 9.5 to 27.6 mg/l. 
Our findings show that APAP as adjuvant to CMI does not have an 
additional analgesic effect following major thoracic or abdominal surgery 
and should not be considered as standard of care in young infants, 0-2 
months of age, undergoing such surgery (chapter 3.3). 
 
 
Pharmacogenetic studies 
 
Given that the toxic effects of APAP result from the oxidative metabolite 
N-acetyl-p-benzoquinone-imine (NAPQI), we conducted a pilot study to 
analyze the relation between APAP clearance and the genotype of the 
enzymes involved in the oxidative pathway, CYP3A4, CYP2E1 and 
possibly CYP3A5, in children receiving APAP during participation in 
previously reported studies. Furthermore we evaluated the relation between 
age and clearance to account for developmental changes. 
Children received an APAP loading dose followed by APAP maintenance 
doses. Blood samples were obtained for APAP plasma concentration 
analysis. DNA was obtained from either a blood sample or a buccal swap. 
DNA analysis was performed for CYP3A4*1b, CYP3A5*3, CYP2E1*1d, 
CYP2E1*2, CYP2E1*5 and CYP2E1*7 genotype.  
Data of 57 children (32 boys and 25 girls) were available for analysis. 
Median (25th-75th percentile) age and weight of the patients were 10 (1-11) 
months and 8.5 (3.5-10.4) kg, respectively. Median (25th-75th percentile) 
Chapter 7.1 
 
238 
APAP clearance was 1.1 (0.5-2.6) l/h. APAP plasma concentrations ranged 
from 0.0-59.9 mg/l.  
This pilot study showed no relation between APAP clearance and CYP3A4, 
CYP3A5 and CYP2E1genotype. APAP clearance increased with age. 
Further research in a larger sample of patients is needed for complete 
analysis of the relation between APAP and CYP3A4, CYP3A5 and 
CYP2E1 genotype (chapter 4.1). 
 
Data on the pharmacokinetics of diclofenac in children are scant. Studies 
mainly concentrated on measuring diclofenac plasma concentrations, 
notwithstanding the fact that the diclofenac metabolite D4OH has activity 
as well. Diclofenac is metabolized into D4OH by CYP2C9, whereas 
metabolism into D5OH occurs through CYP3A4 and possibly through 
CYP3A5. We conducted a pilot study in 32 children receiving 2 mg/kg 
diclofenac, analyzing the relations between diclofenac clearance and 
CYP2C9, CYP3A4 and CYP3A5 genotype, between D4OH formation 
clearance and CYP2C9 genotype and between D5OH formation clearance 
and CYP3A4 and CYP3A5 genotype.  
As blood samples were not available in 6 patients, we analyzed  the data of 
26 patients only, 14 boys and 12 girls. Median (25th-75th percentile) age 
and weight of the patients were 4.0 (3.8-5.0) years and 20.0 (17.8-22.7) kg, 
respectively. Diclofenac plasma concentrations ranged from 0-2.6 mg/l, 
D4OH plasma concentrations ranged from 0-0.5 mg/l and D5OH plasma 
concentrations ranged from 0-0.6 mg/l. DNA was analyzed for 
CYP3A4*1b, CYP3A5*3, CYP2C9*2 AND CYP2C9*3.  
This pilot study showed no relation between diclofenac clearance and 
CYP3A4, CYP3A5, CYP2C9 genotype. Nor did it show a relation between 
formation clearance to D4OH and CYP2C9 or between formation clearance 
to D5OH and CYP3A4 and CYP3A5. Further research in a larger sample of 
patients is needed for complete analysis of the relation between diclofenac 
clearance, formation clearances to D4OH and D5OH and CYP3A4, 
CYP3A5 and CYP2C9 genotype (chapter 4.2). 
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General discussion 
 
Considering APAP pharmacokinetics, one should keep in mind that the 
plasma compartment is not the effect compartment and that the maximum 
analgesic effect is delayed after peak plasma concentrations. Measuring 
APAP plasma concentrations as an indicator for potential APAP toxicity or 
to determine clearance, one should realize that the oxidative metabolite 
NAPQI is responsible for APAP’s toxic effects and that both volume of 
distribution as well as clearance are obscured by the variability in 
bioavailabilty after oral or rectal administration. Furthermore we need to 
explore developmental changes in APAP clearances, which might partly be 
due to developmental changes in enzyme activity. Thus we will be able to 
predict the risk of APAP toxicity for children in different age groups.  
The main problem in studying pharmacodynamics in the very young is to 
objectively assess the analgesic effect of APAP, because self-report is not 
possible in these patients. Using the COMFORT scale and the Visual 
Analogue Scale (VAS) scores – as assigned by the nurses who take care of 
the children – as the basis for an analgesic algorithm, an attempt is made to 
objectively assess pain and hence the analgesic effect. Non-invasive 
methods in combination with validated pain assessment instruments open 
new ways to explore the relation between neurophysiological changes and 
observed behavior during painful moments. Several methods – fMRI, PET 
scan, laser Evoked Potentials – may serve to reveal the integrity of the pain 
conducting system). The value of Electroencephalography (EEG) and 
Sympathic Skin Response (SSR) for postoperative pain assessment is 
described in chapter 6. 
Evaluating the relation between clearances and genotype, the main problem 
in pharmacogenetic studies is the number of patients needed to draw 
conclusions. As population allelic frequencies of most mutations are low, 
large samples of patients are needed in order to fully investigate the effect 
of DNA mutations on enzyme activity or expression. When linking genetic 
blueprint to toxic APAP effects, developmental changes in enzyme activity 
and the impact of specific mutations on enzyme activity should be further 
investigated. However, only the administration of different APAP doses to 
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children of different ages and the measuring of NAPQI formation clearance 
or mercapturine or cysteine metabolites, will enable to fully investigate the 
contribution of the oxidative pathway under different circumstances in 
different age groups, and thus to predict potential toxic effects of APAP. 
From a health care perspective this is the most important issue (chapter 5). 
 
 
Future perspectives 
 
Although the concept of nociception and the presence of specific pain tracts 
in the central nervous system have been known for many years, very little 
clinical research has been performed on the central conduction of pain in 
young infants. Non-invasive methods in combination with validated pain 
assessment instruments are potentially powerful tools to determine a 
relationship between neurophysiological changes and the observed behavior 
during painful moments. Following major thoracic or abdominal surgery a 
30-minutes simultaneous EEG and SSR registration of was made on the 
first and second days postoperatively in 31 patients  aged  0-12 months. 
During registration a painful stimulus, consisting of standardized pressure 
on a fingernail, was applied after 15 and after 20 minutes. Postoperative 
pain assessment using the validated COMFORT scale and the Visual 
Analogue Scale (VAS) was performed every 2 or 3 hours and during SSR 
and EEG registration.  
Analysis of the frequencies and the amplitudes of the SSRs during the SSR 
registration showed no relation between age and SSR frequency or between 
age and SSR amplitude. The SSR amplitudes in awake situation were 
highest compared to drowsy situation and sleep. In addition, SSR 
amplitudes on the second day postoperatively were higher than those on the 
first day postoperatively. Analysis of the video registrations showed no 
correlation between SSR frequency and VAS or COMFORT scale scores. 
An increase in spontaneous SSR frequency was observed during the 2 
minutes preceding the painful stimulus. Spontaneous SSR frequency 
decreased over the interval between the first and the second painful 
stimulus. Visual assessment of the EEG registrations showed that the 
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number of unchanged EEGs expressed as a percentage of the total number 
of unchanged EEGs and EEGs showing arousal, in sleep, awake and 
drowsy situation after spontaneous SSRs was 71%, 23% and 62%, 
respectively, compared to a percentage of 22% after induced SSRs. 
The clinical role of the SSR could not be assessed unambiguously in this 
study, most likely because of the homogeneity of the group of children 
included in this study with respect to adequate and equal pain control. Also, 
the ICU environment might induce non-painful distress, resulting in 
spontaneous SSRs. Nevertheless, SSR monitoring promises to be an 
interesting new variable in future pain studies (chapter 6). 
 
 
Conclusion 
 
Against the background of the increasing knowledge of genetics, these 
pharmacokinetic and pharmacodynamic studies together with new, non-
invasive methods to visualize pain within the central nervous system can be 
considered as a model for future research of drugs, in particular analgesic 
drugs.  
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Samenvatting 
 
Paracetamol (APAP), in de Verenigde Staten bekend als acetaminophen, 
wordt zowel in ziekenhuizen als thuis, gebruikt als middel tegen koorts en 
lichte en postoperatieve pijn. Alhoewel APAP zonder recept verkrijgbaar is, 
en na nystatine en cisapride het meest gebruikte geneesmiddel is in onze 
kinderchirurgische intensive care unit, is er verrassend weinig bekend over 
de farmacokinetische en farmacodynamische eigenschappen van APAP bij 
kinderen.  
Om in deze lacune te voorzien hebben we onderzoek verricht bij jonge 
kinderen naar de farmacokinetiek (d.w.z. de absorptie, distributie, het 
metabolisme en de eliminatie) van APAP, de farmacodynamiek (d.w.z. het 
veroorzaakte effect) door APAP en de farmacogenetische eigenschapen 
(d.w.z. de invloed van DNA op het metabolisme) van APAP. De 
verschillende onderzoeken zijn onderstaand samengevat.  
 
 
Farmacokinetisch onderzoek  
 
De door APAP geïnduceerde analgesie wordt wellicht centraal tot stand 
gebracht, met het tijdsverloop van APAP in de liquor parallel aan dat van 
het pijnstillende effect. Er zijn echter maar enkele onderzoeken 
gepubliceerd naar de concentraties van APAP in liquor bij kinderen. Wij 
onderzochten leeftijdsafhankelijke veranderingen in de plasma-tot-liquor 
evenwichtshalfwaardetijd (Teq) van APAP bij 41 kinderen, die een  
(semi-)electieve ingreep ondergingen – het aanbrengen of vernieuwen van 
een ventriculo-peritoneale shunt of het inbrengen van een tijdelijke externe 
drain – en die een uur voor de ingreep een oplaaddosis van 30-40 mg/kg 
APAP kregen toegediend.  
De mediane (25e-75e percentiel) leeftijd en het gewicht van de kinderen 
waren respectievelijk 12 (3-62) maanden en 10,0 (5,8-20,0) kg. De mediane 
(25e-75e percentiel) tijd tussen het toedienen van de oplaaddosis en het 
afnemen van bloed bedroeg 125 (95-210) minuten, die tussen het toedienen 
van de oplaaddosis en het afnemen van liquor 133 (33-202) minuten. De 
mediane Teq in de groep, gestandaardiseerd naar een persoon van 70 kg, 
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was 1,93 (CV 43%) uur, een schatting die overeenkomt met die beschreven 
in volwassenen (2,1 uur). Afgezien van het verband voorspeld door 
lichaamsgrootte werd geen verband aangetoond tussen leeftijd en Teq. De 
APAP plasmaconcentraties liepen uiteen van 0,0-33,0 mg/l, de APAP 
liquorconcentraties van 0,0-21,0 mg/l.  
Het is bij kinderen eerder de lichaamsgrootte dan de ontwikkeling van de 
bloed-hersenen-barriere die de veranderingen in Teq met de leeftijd bepaalt. 
Op grond van deze bevindingen voorspellen we dat bij een neonaat (3,5 
kg), een eenjarig kind (10 kg), een vijfjarig kind (20 kg), een tienjarig kind 
(30 kg) en een volwassene (70 kg) de Teq respectievelijk 0,9, 1, 1,4, 1,6 en 
1,93 uur bedraagt (hoofdstuk 2.1) 
 
Er is ook weinig bekend over het metabolisme van APAP bij jonge 
kinderen. Eerder is onderzoek gedaan naar de urinemetaboliet terugwin-
ratio’s na een eenmalige dosis APAP aan neonaten (< 6 weken) en oudere 
kinderen (3-9 jaar). Er is nog geen onderzoek gedaan bij jonge kinderen. 
Om in deze lacune te voorzien hebben we onderzoek gedaan bij 47 jonge 
kinderen die een grote craniofaciale ingreep moesten ondergaan. Als 
postoperatieve pijnstilling kregen ze om de zes, acht of twaalf uur 19-45 
mg/kg APAP toegediend in de vorm van een elixir of een zetpil. Tijdens de 
operatie hadden ze rectaal een oplaaddosis van 33–59 mg/kg gekregen. 
De mediane (SD) leeftijd en het gewicht van de patiënten waren 
respectievelijk 11,8 (2,5) maanden en 9,1 (1,9) kg. De klaring van APAP 
naar APAP-glucuronide (%CV) en naar APAP-sulfaat bedroeg 
respectievelijk 6,6 (11,5) en 7,5 (11,5) l/h, gestandaardiseerd naar een 
persoon van 70 kg met behulp van allometrische ‘¼ power’ modellen. De 
klaring naar glucuronide, maar echter niet die naar sulfaat, bleek 
leeftijdsafhankelijk te zijn, en nam toe van een voorspelde waarde van 2,73 
l/h/70kg voor een neonaat, tot een waarde van 6,6 l/h/70kg voor een 
volwassene, met een ontwikkelingshalfwaardetijd van 8,09 maanden. De 
urineklaring van APAP-glucuronide, APAP-sulfaat en onveranderde APAP 
(%CV) bedroeg respectievelijk 2,65, 3,03 en 0,55 (28) l/h/70kg. De 
urineklaring van onveranderde APAP en zijn metabolieten was gerelateerd 
aan de geproduceerde hoeveelheid urine. Klaring toe te schrijven aan 
Chapter 7.2 
 
 
246 
 
andere routes dan deze gemeten in urine kon niet worden geïdentificeerd. 
De glucuronide/sulfaat ratio bedroeg 0,69 op de leeftijd van 12 maanden. 
Sulfaat metabolisme droeg 50% bij aan de APAP-klaring. Klaring naar 
glucuronide neemt bij jonge kinderen toe met de leeftijd, in tegenstelling tot 
de klaring naar sulfaat. De renale klaring van APAP en zijn metabolieten 
neemt toe met de hoeveelheid geproduceerde urine.  
Uit zowel dit onderzoek als uit andere publicaties blijkt dat het metabolisme 
van APAP via de glucuronidering hetzelfde is bij jonge en oudere kinderen, 
maar bij volwassenen hoger is in vergelijking met kinderen. Oxidatieve 
routes kwamen niet naar voren uit dit onderzoek bij jonge kinderen en dit 
zou gedeeltelijk de lagere incidentie van hepatotoxiciteit bij jonge kinderen 
kunnen verklaren (hoofdstuk 2.2). 
 
We hebben ook onderzoek gedaan naar de farmacokinetische en 
farmacodynamische werking van APAP na intraveneuze toediening van een 
enkele dosis propacetamol aan twintig prematuur geborenen en tien ‘a 
terme’ geborenen op hun eerste levensdag.  
De gemiddelde (SD) serum halfwaardetijd (t ½) in de prematuur geborenen 
en de ‘a terme’ geborenen bedroeg respectievelijk 277 (143) min en 172 
(59) min (p < 0,05), en de gemiddelde (SD) klaringen (CL) waren 
respectievelijk 0,116 (0,08) l/kg/h en 0,170 (0,06) l/kg/h (p < 0,05). Er 
bleek een correlatie te bestaan tussen duur van de zwangerschap en t ½  
(r = -0,46). Invloed van geslacht of prenatale toediening van steroïden op de 
farmacokinetische werking van APAP, was niet aantoonbaar. De mate van 
pijnstilling bij vijftien andere neonaten die geen andere medicatie kregen 
dan propacetamol leek op een therapeutisch niveau te liggen (> 5 mg/l). De 
ontwikkelingstrend van CL en t ½ bij zowel de prematuur geborenen als de 
‘a terme’ geborenen  kwam overeen met de eerder gerapporteerde 
farmacokinetische gegevens van propacetamol voor een periode later dan 
de neonatale periode (hoofdstuk 2.3). 
 
Het metabolisme van diclofenac in kinderen is alleen nog maar onderzocht 
na intraveneuze toediening en na het gebruik van tabletten met een coating. 
Er zijn geen gegevens bekend over de farmacokinetiek van diclofenac of 
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zijn hydroxyl-metaboliet na rectale toediening bij kinderen. Daarom deden 
we onderzoek bij 26 jonge kinderen van wie de amandelen werden geknipt 
en die een oplaaddosis diclofenac van 2 mg/kg kregen toegediend, gevolgd 
door 1 mg/kg om de acht uur als zetpil voor postoperatieve pijnstilling. 
De gemiddelde (SD) leeftijd en het gewicht van de patiënten waren 
respectievelijk 4,5 (1,5) jaar en 20,5 (4,1) kg. De klaring naar 4’-hydroxy-
diclofenac (D4OH) (%CV) en naar 5’-hydroxy-diclofenac (D5OH) bedroeg 
respectievelijk 8,41 (8,1) en 3,41 (113) l/h, gestandaardiseerd naar een 
persoon van 70 kg m.b.v. allometrische ‘¼ power’ modellen. Klaring langs 
andere routes droeg 33,0 (64) l/h/70kg bij. De eliminatieklaring van 
hydroxyl-metabolieten werd vastgesteld op 27,5 l/h/70kg. Het 
verdelingsvolume van diclofenac en zijn hydroxyl-metaboliet bedroeg 
respectievelijk 22,8 (19,0) en 45,3 l/70kg. De zetpillen hadden een 
absorptie halfwaardetijd van 0.613 (33.2) uur met een vertragingstijd (lag 
time) van 0,188 (24,9) uur. De inter-occasion variabiliteit van klaring naar 
D4OH, diclofenac verdelingsvolume, absorptie-halfwaardetijd en lag time 
voor de zetpillen was respectievelijk 36%, 55%, 14% en 119%. De relatieve 
biologische beschikbaarheid van de zetpillen in vergelijking met de 
tabletten met coating bedroeg 1,26. 
De klaring naar de actieve metaboliet D4OH droeg 19% bij aan de totale 
klaring (44,82 l/h/70kg). De rectale route is een geschikte route voor de 
toediening van diclofenac bij kinderen van 2-8 jaar, en geeft een hogere 
relatieve biologische beschikbaarheid dan tabletten met een coating en een 
eerder-optredende maximale concentratie (50 vs. 108 min). Dit 
farmacokinetische profiel maakt diclofenac zetpillen geschikt bij 
kortdurende ingrepen (hoofdstuk 2.4). 
 
 
Farmacodynamisch onderzoek 
 
Er zijn nog geen publicaties verschenen waarin pijnstillende APAP-
concentraties in plasma, na grote ingrepen bij neonaten en jonge kinderen 
werden gepresenteerd. Wij deden daarom onderzoek bij 40 kinderen met 
een gemiddelde (SD) leeftijd van 10,3 (2,3) maanden, die na een electieve 
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craniofaciale operatie, om de zes uur 20 mg/kg APAP kregen toegediend, 
hetzij oraal (n = 20) hetzij rectaal (n = 20), allen na een rectale oplaaddosis 
van 40 mg/kg tijdens de operatie. 
De APAP-concentraties in plasma en AUC bleken bij de patiënten die 
rectaal APAP kregen toegediend hoger te zijn (gemiddelde AUC: 171,2 
mg.uur/l) dan bij degenen die APAP oraal kregen toegediend (gemiddelde 
AUC: 111,9 mg.uur/l). Bij de laatste groep waren de pijnscores hoger. Er 
was geen verschil in APAP-concentraties en pijnscores in beide groepen als 
de patiënten uit de orale groep die moesten overgeven na toediening van 
APAP niet werden meegeteld. Er werd geen verband aangetoond tussen de 
APAP-concentraties en de pijnscores.  
Alhoewel bij 9 van de 40 patiënten (22,5 %) de verwachte pijnstillende 
APAP-concentraties in plasma van 10-20 mg/l niet werden bereikt, waren 
slechts 7,5 % van de VAS pijnscores hoger dan het afkappunt van 4 cm. Na 
zware ingrepen worden bij kinderen van deze leeftijd dus niet altijd de 
veronderstelde pijnstillende APAP-concentraties in plasma van 10-20 mg/l 
bereikt. Tevens blijkt dat na een craniofaciale operatie, waarbij een rectale 
oplaaddosis van 40 mg/kg is toegediend, de rectale route voor APAP de 
voorkeur geniet boven de orale route (hoofdstuk 3.1). 
 
Algemeen wordt APAP voorgeschreven als pijnbestrijding na het knippen 
van de amandelen, maar de publicaties over de effectiviteit daarvan zijn niet 
consistent. Een alternatief is diclofenac, maar het gebruik hiervan wordt 
geremd door angst voor postoperatieve bloedingen. We hebben een 
onderzoek opgezet, waarin we de pijnstillende werking van rectaal 
toegediende APAP en diclofenac konden vergelijken bij kinderen waarbij in 
dagbehandeling de amandelen werden geknipt, en tevens de relaties konden 
vaststellen tussen APAP, diclofenac, D4OH-concentraties in plasma, en 
postoperatieve pijnscores. De veiligheid van diclofenac en het gebruik van 
bipolaire diathermie aan het eind van de ingreep, beoordeelden wij door het 
registreren van postoperatieve bloedingen. De gegevens van 60 patiënten, 
met een mediane (25e-75e percentiel) leeftijd van 4 (3-5) jaar, werden 
geanalyseerd. De helft daarvan kreeg APAP toegediend, de andere helft 
diclofenac. We vonden geen verschil in pijnstillende werking tussen APAP 
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en diclofenac, en ook geen relatie tussen concentraties in plasma en 
pijnscores. Bij twee kinderen, die beiden APAP hadden gekregen, 
ontstonden primaire bloedingen. Bipolaire diathermie werd bij 14 patiënten 
toegepast, en wel bij 8 die APAP, en 6 die diclofenac hadden gekregen. 
Uit onze bevindingen leiden we af dat rectaal toegediende diclofenac (2 
mg/kg oplaaddosis, 1 mg/kg om de acht uur) na het knippen van de 
amandelen geen betere pijnbestrijding geeft dan rectaal toegediende APAP 
(40 mg/kg oplaaddosis, 30 mg/kg om de acht uur). Er werd geen relatie 
aangetoond tussen concentraties in plasma en pijnscores, noch een toename 
van primaire of secundaire bloedingen als gevolg van de toediening van 
diclofenac, dat bekend staat om de verstoring van de aggregatie van 
bloedplaatjes (hoofdstuk 3.2).  
 
In de afgelopen jaren kan er een toename worden gezien van het gebruik 
van APAP in aanvulling op continue morfine infusie (CMI), ondanks het 
feit dat de veiligheid en de toegevoegde waarde van deze 
combinatiebehandeling nog niet is onderzocht bij pasgeborenen en jonge 
kinderen. Daarom onderzochten we of bij pasgeborenen en jonge kinderen 
die extra APAP kregen na een grote thorax- of buikoperatie, de behoefte 
aan morfine daalde. 
Van een totaal van 54 patiënten met een mediane (25e-75e percentiel) 
leeftijd van 0 (0-2) maanden kregen er 29 APAP, en 25 placebo. De 
behoefte aan aanvullende morfine in de vorm van bolussen en de toenamen 
in CMI verschilden niet in beide groepen. Er bleek ook geen significant 
verschil in het totale morfineverbruik te zijn. De COMFORT en VAS 
scores verschilden niet tussen beide groepen. Het postoperatieve totale 
morfineverbruik was niet gerelateerd aan de leeftijd, alhoewel kinderen 
jonger dan 45 weken post conceptie minder aanvullende morfinebolussen 
nodig hadden (p < 0.01) en konden volstaan met geringere toenamen in 
CMI (p < 0.01). De gemiddelde APAP-concentraties in plasma liepen 
uiteen van 9,5 tot 27,6 mg/l. 
Onze bevindingen geven aan dat APAP ter ondersteuning van CMI geen 
extra pijnstillende uitwerking heeft, en dat deze combinatie niet als 
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standaardbehandeling moet worden beschouwd voor jonge kinderen van 0-
2 maanden oud na een grote thorax- of buikoperatie (hoofdstuk 3.3). 
 
 
Farmacogenetisch onderzoek 
 
Aangezien de toxische werking van APAP wordt veroorzaakt door de 
oxidatieve metaboliet N-acetyl-p-benzoquinone-imine (NAPQI), deden we 
een pilot studie om de relatie te analyseren tussen APAP-klaring en het 
genotype van de enzymen die betrokken zijn bij de oxidatieve route, 
CYP3A4, CYP2E1 en mogelijk CYP3A5. De studiegroep bestond uit 
kinderen die APAP kregen toegediend in het kader van eerdere 
onderzoeken. Tevens hebben we de relatie tussen leeftijd en klaring 
geanalyseerd om een verklaring te vinden voor veranderingen tijdens de 
ontwikkeling. 
De kinderen kregen een oplaaddosis APAP gevolgd door ‘onderhouds’-
doseringen APAP. Er werd bloed afgenomen voor de bepaling van de 
APAP-concentratie in plasma. DNA werd verkregen hetzij uit het bloed 
hetzij uit het wangslijmvlies, en gescreend op de CYP3A4*1b, CYP3A5*3, 
CYP2E1*1d, CYP2E1*2, CYP2E1*5 en CYP2E1*7.  
Uiteindelijk waren de gegevens van 57 kinderen, 32 jongetjes en 25 
meisjes, beschikbaar voor analyse. Hun mediane (25e-75e percentiel) 
leeftijd en gewicht waren respectievelijk 10 (1-11) maanden en 8,5 (3,5-
10,4) kg. De mediane (25e-75e percentiel) APAP-klaring bedroeg 1,1 (0,5-
2,6) l/h, en de APAP-concentraties in plasma liepen uiteen van 0.0-59.9 
mg/l.  
Deze pilot studie toonde geen verband aan tussen APAP-klaring en de 
CYP3A4, CYP3A5 en CYP2E1 genotypen. De APAP-klaring nam toe met 
de leeftijd. Aanvullend onderzoek in een grotere groep patiënten is 
noodzakelijk om de relaties tussen APAP en de CYP3A4, CYP3A5 en 
CYP2E1 genotypen volledig te kunnen analyseren (hoofdstuk 4.1). 
 
Er is weinig bekend over de farmacokinetische eigenschappen van 
diclofenac bij kinderen; eerder onderzoek richtte zich vooral op het meten 
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van de concentraties diclofenac in plasma. Diclofenac heeft echter ook een 
werkzame metaboliet, D4OH. Diclofenac wordt gemetaboliseerd tot D4OH 
door CYP2C9, of tot D5OH door CYP3A4 en wellicht CYP3A5. We 
hebben een pilot studie verricht bij 32 kinderen die 2 mg/kg diclofenac 
kregen toegediend, en analyseerden de relaties tussen diclofenac-klaring 
van en de CYP2C9, CYP3A4 en CYP3A5 genotypen, tussen de klaring 
naar D4OH en het CYP2C9 genotype, en tussen de klaring naar D5OH en 
de CYP3A4 en CYP3A5 genotypen.  
Doordat van 6 patiënten geen bloed beschikbaar was, werden uiteindelijk de 
gegevens van 26 patiënten geanalyseerd, 14 jongens en 12 meisjes. De 
mediane (25e-75e percentiel) leeftijd en het gewicht waren respectievelijk 
4,0 (3,8-5,0) jaar en 20,0 (17,8-22,7) kg. De concentraties diclofenac in 
plasma liepen uiteen van 0-2,6 mg/l, die van D4OH van 0-0,5 mg/l, en die 
van D5OH van 0-0,6 mg/l. Het DNA van de kinderen werd gescreend op 
CYP3A4*1b, CYP3A5*3, CYP2C9*2 en CYP2C9*3.  
We vonden geen relatie tussen diclofenac-klaring en de CYP3A4, CYP3A5, 
en CYP2C9 genotypen, en evenmin tussen de klaring naar D4OH en 
CYP2C9, of de klaring naar D5OH en CYP3A4 en CYP3A5. 
Vervolgonderzoek in een grotere groep patiënten is nodig om de relaties 
tussen de klaring van diclofenac, de klaring naar D4OH en naar D5OH, en 
de CYP3A4, CYP3A5 en CYP2C9 genotypen volledig te kunnen 
analyseren (hoofdstuk 4.2). 
 
 
Algemene beschouwing 
 
Wat betreft de farmacokinetische eigenschappen van APAP is van belang 
dat het plasma-compartment niet het effect-compartment is, en dat de 
maximale pijnstillende werking vertraagd volgt na piekconcentraties in 
plasma. Als men de APAP-concentratie in plasma wil gebruiken als 
indicator voor een mogelijke toxische werking van APAP of om de klaring 
te bepalen, dient men zich te realiseren dat de oxidatieve metaboliet NAPQI 
verantwoordelijk is voor de toxische werking van APAP, en dat zowel het 
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distributievolume als de klaring worden gemaskeerd door de variabiliteit in 
biologische beschikbaarheid na orale of rectale toediening.  
Voorts dienen we nader inzicht te krijgen in de ontwikkelingsveranderingen 
in APAP-klaring, die wellicht gedeeltelijk samenhangen met 
ontwikkelingsveranderingen in de activiteit van enzymen. Dit zal het 
mogelijk maken het risico van een toxische werking van APAP voor 
kinderen in verschillende leeftijdsgroepen te bepalen.  
Het grootste probleem bij het bestuderen van de farmacodynamiek is het 
objectief vaststellen van de pijnstillende werking van APAP, aangezien de 
kinderen van de leeftijd die we in onze onderzoeken hebben betrokken niet 
zelf hun pijngevoel kunnen rapporteren. Het toepassen van de COMFORT 
schaal en de Visuele Analoge Schaal (VAS) door de verpleegkundigen die 
de kinderen verzorgen, als basis voor een analgetica algoritme, is een stap 
in de goede richting om pijn – en daarmee de pijnstillende werking van het 
middel – objectief vast te stellen. Niet-invasieve methoden in combinatie 
met gevalideerde pijnmeetinstrumenten bieden nieuwe mogelijkheden om 
de relatie tussen neurofysiologische veranderingen en geobserveerd gedrag 
tijdens pijnmomenten te onderzoeken. Met verschillende methoden – fMRI, 
PET scan, laser Evoked Potentials – zou de integriteit van het 
pijngeleidingssysteem kunnen worden achterhaald. De bruikbaarheid van 
Electro-Encefalo-Grafie (EEG) en Sympathic Skin Response (SSR) voor 
postoperatieve pijnbeoordeling wordt beschreven in hoofdstuk 6. 
Het probleem bij farmacogenetisch onderzoek is het grote aantal patiënten 
dat nodig is om verbanden te kunnen leggen tussen klaring en genotype, 
zodat de juiste conclusies kunnen worden getrokken. Omdat de allelen van 
de meeste mutaties weinig voorkomen in de bevolking, zijn grote cohorten 
patiënten nodig om de effecten van DNA-mutaties op de activiteit of 
expressie van enzymen volledig te kunnen onderzoeken. Teneinde de 
genetische blauwdruk in verband te kunnen brengen met de toxische 
werking van APAP, dienen de ontwikkelingsveranderingen in 
enzymactiviteit en de impact van specifieke mutaties op de activiteit van 
enzymen nader onderzocht te worden. Echter, slechts door het toedienen 
van verschillende doseringen APAP aan kinderen van verschillende leeftijd 
en door het meten van de klaring van NAPQI-vorming of mercapturine of 
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cysteine metabolieten, kan men de bijdrage van de oxidatieve route onder 
verschillende omstandigheden in verschillende leeftijdsgroepen volledig 
vaststellen, en daarmee de mogelijke toxische uitwerking van APAP 
voorspellen. Gezien vanuit het gezichtspunt van de gezondheidszorg is dit 
het allerbelangrijkste thema (hoofdstuk 5). 
 
 
Toekomstperspectieven 
 
Alhoewel het begrip nociceptie en het bestaan van specifieke pijnkanalen in 
het centrale zenuwstelsel al vele jaren bekend zijn, is er nog maar weinig 
klinisch onderzoek gedaan naar de centrale geleiding van pijn bij jonge 
kinderen. Niet-invasieve methoden in combinatie met gevalideerde 
pijnmeetinstrumenten zijn in aanleg krachtige middelen om verbanden te 
leggen tussen neurofysiologische veranderingen en het waargenomen 
gedrag tijdens pijnmomenten. Bij 31 patiënten van 0-12 maanden oud 
werden gedurende 30 minuten simultaan een EEG- en een SSR- registratie 
gedaan op de eerste en de tweede dag na een grote thorax- of buikoperatie. 
Tijdens die registratie kregen de patiënten na 15 en na 20 minuten een 
pijnprikkel in de vorm van gestandaardiseerde druk, uitgeoefend op een van 
de vingernagels. Om de twee of drie uur en tijdens de EEG- en SSR-
registraties werd de postoperatieve pijn gemeten m.b.v. de gevalideerde 
COMFORT schaal en de Visuele Analoge Schaal (VAS).  
Bij analyse van de frequenties en de amplitudes van de SSR’s bleek er geen 
verband te zijn tussen leeftijd en SSR-frequentie of tussen leeftijd en SSR-
amplitude. De SSR-amplituden in wakkere toestand bleken hoger te zijn 
dan die bij slaperigheid of slaap. Voorts waren de SSR-amplitudes gemeten 
op de tweede dag hoger dan die op de eerste dag na de operatie. De analyse 
van de videoregistraties toonde geen verband aan tussen SSR-frequentie en 
scores op de VAS of COMFORT schaal. Een toename in spontane SSR-
frequentie werd waargenomen gedurende de 2 minuten voorafgaand aan de 
pijnprikkel. De spontane SSR-frequentie nam af gedurende het interval 
tussen de eerste en tweede pijnprikkel. De visuele beoordeling van de EEG-
registraties gaf als uitkomst dat het aantal ongewijzigde EEG’s uitgedrukt 
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als percentage van het totale aantal ongewijzigde EEG’s en de EEG’s die 
‘in slaap’, ‘in wakkere toestand’ en ‘in slaperige toestand’ lieten zien na 
spontane SSR’s, respectievelijk 71%, 23% en 62% bedroeg, in vergelijking 
met een percentage van 22% na geïnduceerde SSR’s. 
De klinische rol van de SSR kon bij dit onderzoek niet ondubbelzinnig 
worden vastgesteld, hoogstwaarschijnlijk vanwege de homogeniteit van de 
onderzochte groep kinderen wat betreft adequate en gelijke mate van 
pijnbestrijding. Het verblijf op de intensive care unit zou een kind “zonder 
pijn” ook overstuur kunnen maken, met spontane SSR’s als gevolg. 
Niettemin is SSR-monitoring een interessante nieuwe optie bij toekomstig 
pijnonderzoek (hoofdstuk 6). 
 
 
Conclusie 
 
Tegen de achtergrond van onze groeiende kennis van de genetica, kunnen 
deze farmacokinetische en farmacodynamische onderzoeken in combinatie 
met nieuwe methoden om pijn in het centrale zenuwstelsel op een niet-
invasieve wijze te visualiseren, worden beschouwd als een model voor 
nader onderzoek naar geneesmiddelen, en pijnstillende middelen in het 
bijzonder.  
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